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ABSTRACT 
 APOBEC enzymes are a family of innate antiviral enzymes that form an 
important barrier against DNA-based pathogens. Encoding and expressing these 
DNA mutating enzymes, however, is an inherently risky endeavor for the stability 
of the host genome if not regulated appropriately. These risks have been 
demonstrated in numerous cancers where APOBEC3B is overexpressed and the 
APOBEC-associated mutation signature is enriched. Emphasizing the 
importance of this observation, elevated expression of APOBEC3B and presence 
of APOBEC-associated mutations has now been consistently linked to 
aggressive phenotypes and worse outcome in cancer patients. Here I present 
data demonstrating overlapping functions of APOBEC3 enzymes in antiviral 
immunity and cancer. In both of these models, APOBEC3 enzymes contribute 
potentially deleterious and beneficial mutations potentially impacting the survival 
of tumors and viruses. Additionally, the functions of these enzymes can be 
modulated by heritable germline mutations in the APOBEC3 locus and viral 
infections. DNA viruses can also act as valuable molecular probes into the 
regulation of APOBEC3 enzymes in tumors leading to the development of better 
therapies.  
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 Mutation and genome evolution 
 Mutations are a byproduct of DNA damage minus correct repair. Even in 
ideal cellular environments, DNA is subject to many sources of damage both 
endogenous and exogenous. Without appropriate recognition of the DNA lesions 
resulting from damage, deleterious mutations can accumulate. Many of these 
mutational processes in cancer have come to be directly tied to mutation 
signatures observed in cancer, which are mainly defined by single nucleotide 
substitutions and the trinucleotide contexts in which they occur (1–4). Exogenous 
sources of DNA damage include UV-induced lesions and bulky DNA adducts 
from chemical carcinogens, such as from tobacco, aflatoxin and aristolochic acid 
(Fig 1.1) (4–7). These carcinogens typically affect DNA guanines and during 
DNA replication these adducts are incorrectly base-paired typically resulting in G-
to-T mutations. UV irradiation, however, typically seeds mutations at cytosine 
bases by crosslinking adjacent pyrimidines (4, 8–10). During DNA replication 
these pyrimidine dimers are bypassed by trans-lesion polymerases such as 
POLH, which inserts two adjacent alanines regardless of the cross-linked bases 
(4, 8–12). After another round of replication these are base-paired with thymines 
and in tumors this is most frequently observed as CC-to-TT dinucleotide 
substitutions. Reactive oxygen species (ROS) are abundantly generated by 
metabolism and immune responses and cause abundant damage to both protein 
and DNA within cells. ROS can cause mutation through oxidation of DNA 
guanines and subsequent repair of these oxidized bases by nucleotide excision 
repair (NER) into nearly any other base (13, 14).  
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 An additional factor used in defining signatures is whether these mutations 
occur with either a transcriptional or replicative strand bias. Transcriptional strand 
biases can occur through biased repair of DNA lesions, as is observed in the 
repair of UV-induced damage and previously mentioned guanine modifications, 
where highly transcribed genes are more frequently repaired due to the 
recruitment of XP-family ATPases/helicases by RNA polymerase II (RNAPII) 
stalled at the lesion (4, 15–17). XP-family enzymes preferentially excise from the 
transcribed stand or template strand resulting in the mutation bias (17). 
Alternatively, transcriptionally biased mutations can preferentially occur on one 
strand, which has come to be known as transcription-coupled damage (TCD) 
(15). TCD is observed with the generally distributed T-to-C mutations associated 
with a mutation signature found in most types of cancer, but the exact 
mechanism is still unknown (4, 15). 
The other type of mutation bias is based on the replication direction of 
genomic DNA from various replication origins. Replication timing has been 
identified as remarkably consistent across cell types in humans. This information 
has been paramount in identifying any biases when mutations occur during 
genome replication. Inherently, the polymerases of DNA-based organisms have 
very low mutation rates because of the presence of proof-reading domains (18, 
19). Not surprisingly, error-prone DNA polymerases are also a key source of 
replication biased mutations in many tumor types (4, 18, 19). These polymerases 
also provide a mechanism for viral diversity in DNA viruses, yet most have 
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exceptionally low mutation rates compared to their RNA-based counterparts due 
to hijacking host high-fidelity DNA polymerases or encode their own (20). 
The most abundant source of DNA damage that occurs within virtually 
every tumor type is the spontaneous deamination of methylcytosines into 
thymines catalyzed by water molecules. These types of mutations continuously 
accumulate over the lifespan of an individual. Lastly, a major endogenous source 
of mutations in both cancer and viral genomes is seeded by an evolutionarily 
conserved family of innate immune defense proteins known as apolipoprotein B 
mRNA-editing enzyme catalytic polypeptide-like enzymes (APOBECs). This 
family of enzymes will be expanded upon in the following sections. 
 
The APOBEC family of DNA cytosine deaminases 
The apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 
(APOBEC) family of enzymes is highly evolutionarily conserved immune-related 
single-stranded DNA cytosine deaminases that has gained a substantial amount 
of diversity through gene duplications and rearrangements over time (21, 22). In 
higher primates and humans, there are 11 APOBEC enzymes that are involved 
at various stages of the immune response (22–26). These enzymes are 
activation induced deaminase (AID), APOBEC1, APOBEC2, APOBEC3A-H, and 
APOBEC4 (26–28). AID and APOBEC2 are the most evolutionarily conserved 
APOBEC family members, with homologs existing in all vertebrates from present 
day bony fish to higher primates (22, 28). In mammals, AID is primarily 
expressed in B-cells and through precise regulation is responsible for somatic 
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hypermutation and class switch recombination of the immunoglobulin locus that 
results in antibody maturation. The next most evolutionarily conserved member 
and the namesake of the family is APOBEC1, which primarily exhibits RNA-
editing function, initially discovered at the 6666 position of the APOB mRNA in 
the liver (29–31). The exact functions of APOBEC2 and APOBEC4 are still 
currently unknown and they have yet to elicit enzymatic activity (27, 28, 32). 
The APOBEC3 subfamily of enzymes have gone through a series of 
duplications and rearrangements during the evolution of primates and in humans 
there are 7 family members encoded in tandem on chromosome 22 (21, 23, 24, 
26). These enzymes are composed of one or two catalytic domains that fall into 
one of three evolutionarily conserved categories, Z1, Z2 or Z3 (23) (Fig 1.2A). 
These enzymes are unified in their function to target and deaminate cytosines to 
uracils in single-stranded (ss)DNA, found commonly during many DNA 
transactions including transcription and replication of host and viral genomes (Fig 
1.2B). These enzymes are widely expressed in tissues, however, APOBEC3D, F, 
G and H are most highly expressed in T cells and have all been widely studied in 
their ability to restrict retroviruses in primates and humans through hypermutation 
of their ssDNA genome intermediates (33, 34). Overexpression of APOBEC3B, 
C, F and G have all demonstrated some capacity to restrict retrotransposons via 
enzymatic and non-enzymatic means (35–43). The effects of these enzymes on 
retrotransposons has seemingly had strong effects on shaping the evolution of 
primate genomes with approximately 20% of inherited variants at TCW sites 
likely originating from APOBEC-mediated deamination (44, 45).  
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Although many APOBEC3 proteins have overlapping functions, these 
enzymes are differentially regulated and localized in various stages of the cell 
cycle (1, 33, 34, 46). The predominantly cytoplasmic enzymes are APOBEC3D, 
F, G and H and endogenously expressed APOBEC3A in myeloid lineage cells. 
APOBEC3A and C are expressed cell wide when overexpressed, while 
APOBEC3B is the only family member that is predominantly nuclear even though 
it is too large to passively pass through nuclear pores (47–49). APOBEC3B 
transits into the nucleus through a similar mechanism to how AID is imported and 
is dependent on a valine at position 54 (49). 
The common ability of APOBECs to target cytosine-containing ssDNA 
makes any pathogen with a DNA stage in its lifecycle a potential target and 
research supports a working model in which many viruses and endogenous 
elements are inhibited by APOBEC-mediated deamination. When these enzymes 
are dysregulated, they can begin to erroneously target the human genome and 
cause cancer. Primarily, inherited germline mutations, somatic alterations in 
cancer, and viral proteins form the three primary axes that promote APOBEC3 
dysregulation and aberrant function (Fig 1.3). 
 
APOBEC mechanism of mutagenesis and dysregulation in cancer 
Through specific gene knockdown and over-expression studies, as well as 
somatic mutation signature analysis, APOBEC3B was discovered to be a 
dominant mutator in breast cancer (1). Through bioinformatic and biochemical 
studies, the preferred targets of APOBEC3 deamination were determined to be 
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enriched at cytosines preceded by a 5’ thymine and followed by a 3’ adenosine, 
guanine, or thymine (50–53). The deamination events at these sites result in a 
genomic DNA uracil that most commonly will result in a cytosine to thymine 
transition mutation if allowed to persist through DNA replication. Next most 
common, excision of this uracil by uracil DNA glycosylase (UDG) and repair of 
the resulting abasic site by REV1, frequently results in a cytosine to guanine 
transition mutations because of the propensity for REV1 to insert a cytosine 
opposite of an abasic site (54–58). Subsequently, APOBEC3B-mediated 
mutations and elevated expression have been found in many types of cancer, but 
most prominently in human papillomavirus (HPV)-associated cancers (34, 59, 60) 
and bladder cancer, which may be also be influenced by DNA viruses (34, 61–
65). 
APOBEC-signature mutations are enriched on the lagging strand of 
replicating DNA in bacterial and eukaryotic cell based assays (44, 66–68). 
Additionally, APOBEC-mediated mutations are enriched in the early replicating 
portions of the human genome occurring in strand-coordinated clusters (69). 
These APOBEC-mediated mutations are in part initiated by stalled replication 
forks, which can be caused by various types of DNA damage (67, 68). Elevated 
expression of APOBEC3B is associated with more aggressive phenotypes and 
recurrence in breast cancer, lung cancer and bladder cancers (1, 70–72). 
Additionally, elevated expression of APOBEC3B associates with greater 
resistance to the estrogen receptor agonist, tamoxifen, in mouse models and is 
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supported by human clinical data likely through increased tumor diversity through 
APOBEC-mediated mutagenesis (73). 
Because of the ability of APOBEC3B to augment tumor survival and 
evolution, APOBEC3B regulation has now become an important in therapeutic 
target in regards to limiting the effects of the enzyme on tumor survival. 
APOBEC3B is uniquely upregulated compared to other APOBEC family 
members in cancer as has been determined via numerous studies using 
RTqPCR, microarray, and RNAseq transcriptome analyses. The non-canonical 
PKC/NFκB pathway has been identified as a significant axis to manipulate 
APOBEC3B expression in normal-like breast epithelial cells and cancer cell lines 
(74). This pathway can be activated by phorbol-myristate acetate or by agonists 
of the lymphotoxin beta receptor, which both feed into the non-canonical NF-B 
signal transduction pathway (75).  
 
Germline variants in the APOBEC3 locus and effects on susceptibility to 
cancer and viral infections 
APOBEC3A and APOBEC3B 
APOBEC3A and the carboxyl half of APOBEC3B share some of the 
highest homology of any APOBEC3 enzymes (92% identical) (22–24). The 
primary differences between these enzymes have mapped to loops 1 and 3 (with 
most other loops being 100% identical) (22–24). Specifically, loop 1 has been 
demonstrated to impact the structure of the active site of these enzymes with 
APOBEC3B having a longer, flexible loop 1 leading to a more closed 
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conformation compared to APOBEC3A (76–79). In fact, swapping loop 1 from 
APOBEC3A into APOBEC3B increases the enzymatic activity of APOBEC3B 5-
50 fold (77, 79). It is now known that both APOBEC3A and APOBEC3B interact 
with ssDNA in a U-shaped hairpin formation (Fig 1.2C) (78, 80). While it is well 
understood that APOBEC3A and APOBEC3B prefer to deaminate TCA context 
cytosines, it has yet to be fully realized if there is a true difference in the preferred 
context between these enzymes (78, 80, 81).  
There is a geographically distributed APOBEC3B-deletion that fuses the 
coding region of APOBEC3A with the 3’UTR of APOBEC3B (82). The junctions 
of this rearrangement occur within a 350 bp region of 100% homology between 
these genes (82). This variant has been widely studied for potential effects on the 
replication of pathogens and the development of cancer. This germline variant 
has paradoxically associated with increased ovarian and breast cancer 
susceptibility in several populations (83–88). This has been partially attributed to 
increased stability of the fusion transcript due to the absence of an Alu element in 
the APOBEC3B 3’ UTR compared to the APOBEC3A 3’ UTR (89). This Alu 
element may be targeted by miRNAs leading to its degradation. More recently 
the observed APOBEC deaminase activity in the absence of APOBEC3B has 
been attributed to APOBEC3H-I (90), which is expanded more in a later section. 
As previously mentioned, the APOBEC3B deletion allele has been studied widely 
in its potential effect on host-pathogen interactions. From these studies it has 
been revealed most commonly an increased susceptibility to chronic HBV 
infection (91–94), which supports the role of APOBEC3B as an innate-immune 
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restriction factor against HBV (75, 95, 96). Additionally the deletion allele has 
been found to be associated with increased incidence and co-infection with HBV 
of a diverse subset of DNA and RNA viruses including hepatitis C virus (HCV), 
Torque Teno virus (TTV) and GB virus C (GBV-C). Lastly this allele has even 
been associated with increased incidence of parasitic infections from Falciparum 
malaria and Toxoplasma gondii (92, 97). 
Independently of the APOBEC3B deletion allele, a cluster of genetically 
linked risk variants has been identified that correspond to increased expression 
of APOBEC3B in bladder cancer (98). These variants occur within a 2kb region 
that is 20kb upstream of APOBEC3A. This region is likely a long-distance 
enhancer for APOBEC3B as cell lines with the risk allele demonstrated an ~8-
fold increased responsiveness to exogenous stressors such as viral infection and 
treatment with bleomycin (98). Additionally, patients with the high-expression 
allele showed increased APOBEC-signature mutations in their tumors which in 
turn proved to be the best metric for survival in this cohort (98). 
APOBEC3C 
 APOBEC3C is the most highly and widely expressed APOBEC family 
member in humans (33, 34, 46). However, despite this near ubiquity, the exact 
function of APOBEC3C is not known. APOBEC3C demonstrates some of the 
lowest deaminase activity in the APOBEC3 family in cell-based overexpression 
assays. However, when overexpressed, APOBEC3C is able to prevent 
retrotransposition of endogenous elements in a deamination-independent 
mechanism that is at least partially explained through the direct interaction with 
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the ORF1 protein of LINE1 elements (36). Investigation into a rare SNP that 
converts a serine to an isoleucine at position 188 in APOBEC3C has shown a 2-
fold increase in the ability of this enzyme to restrict HIV (99).  
APOBEC3G 
 Being the most potent restriction factor against HIV-1 in the APOBEC3 
family, variants in APOBEC3G have been importantly studied in regards to elite 
control and resistance to HIV-1. The vast majority of APOBEC3G variants occur 
within the 5’ UTR and introns and either have no or very weak effects on disease 
susceptibility and outcome (100). The primary variant in APOBEC3G identified to 
influence HIV-1 disease progression is H186R. R186 results in more rapid CD4+ 
T cell loss and disease progression to AIDS (101, 102). This variant is more 
common in African populations (37%) compared to Caucasian populations (5%), 
yet no significant difference has been observed for APOBEC3G-signature 
mutations in HIV-1 proviruses in these populations or tied to any other 
APOBEC3G variant (103, 104). These observations indicate that this 
APOBEC3G variant is still fully functional in hypermutating the HIV-1 genome, 
but may have other deficiencies, such as packaging or expression later in 
disease. Although this variant has had no observable effect on HIV-1 
susceptibility, a recent study showed that it may have significant effects in 
individuals with specific genetic backgrounds indicating that in conjunction with 
other genetic characteristics it may be a risk factor for infection (105). 
APOBEC3H 
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 In humans, APOBEC3H is the most polymorphic family member (48, 106–
109).  APOBEC3H amino acid changes have been used to create groups of 
variants or “haplotypes” for functional characterization. To date, seven 
APOBEC3H haplotypes have been defined with varying degrees of stability and 
enzymatic activity. Stable, well-expressed, and enzymatically active haplotypes 
are II, V and VII. In comparison, haplotype I is expressed at intermediate levels 
but this variant still elicits full activity in biochemical comparisons (90). In 
contrast, haplotypes III, IV, and VI are not expressed at the protein level nor 
active due to a deletion of asparagine 15, which is situated in the middle of an 
essential alpha helix.  
An attenuation of A3H function against retroviruses and retroelements 
most likely occurred twice during human evolution (108). As alluded to above, a 
deletion of an asparagine at position 15 results in complete destabilization of the 
enzyme through the interruption of a critical alpha helix in the structure (48, 106–
108). This variant is evenly distributed throughout the globe with an approximate 
allele frequency of 20-30% (90, 103). A glycine at position 105 results in a protein 
with intermediate stability as judged by immunoblots, approximately 5-fold lower 
than variants with N15 intact and an arginine at position 105 (48, 106–108). 
G015 greatly diminishes the ability of this enzyme to restrict HIV, however, when 
expressed at equal protein amounts to stable, active forms like haplotype II, it is 
an equally effective deaminase (90). Haplotypes I and II are inversely distributed 
around the globe with haplotype I being abundant in Caucasians and East Asians 
and haplotype II being most abundant in individuals of African descent (90, 103). 
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In the absence of APOBEC3B, we have identified APOBEC3H-I as a genomic 
DNA mutating enzyme in breast and lung cancers (90).  Supporting of these 
findings, a study in Han Chinese cohort revealed that there is a variant in 
APOBEC3H genetically linked with haplotype I that results in increased 
susceptibility to the development of lung cancer (110). 
 
APOBEC enzymes and tumor-associated viruses 
Retroviruses 
APOBEC enzymes are best understood in their ability to restrict 
retroviruses such as HIV-1 (25, 111, 112). Although there is little direct evidence 
that HIV-1 mediates the development of cancer, it is well documented that the 
associated immunosuppression leads to the development of cancers such as 
Kaposi’s sarcoma, which were a hallmark of AIDS early in the HIV epidemic 
(113–115). APOBEC enzymes package into newly forming virions in infected 
host cells. After these virions are released from the productively infected cell and 
infect a new cell, the viral genome and packaged APOBEC3 enzymes reside 
together in the viral core. During reverse transcription of the HIV genome, the 
nascent ssDNA strand is subject to enzymatic targeting by APOBEC3 enzymes. 
This frequently results in hypermutation, when the ssDNA strand accumulates 
multiple C-to-U lesions, which can be deleterious to the virus and prevent the 
production of future infectious progeny. When the results are not lethal, these 
APOBEC-mediated mutations may also contribute to HIV-1 evolution, although 
this point has been contested. Most studies over the past decade have indicated 
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that APOBEC3 enzymes contribute to diversity in the HIV-1 genome (112, 116–
118). However, two papers have recently shown that APOBEC3 preferred motifs 
are not significantly depleted in the viral genome, and when replicating the virus 
in the presence or absence of APOBEC3s that reverse transcriptase is 
responsible for most of the mutations (119, 120). 
Another human retrovirus, human T-lymphotropic virus type 1 (HTLV-1), 
directly associates with the development of adult T-cell leukemia/lymphoma 
(ATLL) (121). HTLV-1 is a deltaretrovirus with a much longer evolutionary history 
in the order of thousands of years rather than the decades that HIV-1 has been in 
the human population. HTLV-1 is transmitted sexually, blood-to-blood (e.g. 
intravenous drug use), and mother-to-child through breast milk and is endemic in 
various regions around the world, including Southern Japan, sub-Saharan Africa, 
South America and the Caribbean (121). Similar to HIV, HTLV-1 primarily infects 
CD4+ T cells. APOBEC3A, APOBEC3B, and APOBEC3H-II have all been shown 
to be able to restrict HTLV in over-expression cell culture studies through editing 
of the HTLV-1 genome (122). While APOBEC3G appears incapable of packaging 
into HTLV-1 particles and restricting virus infectivity, it does show evidence of 
being able to actively edit the viral genome (123–125).  
Endogenous retroviruses (ERVs) comprise a large proportion of 
mammalian genomes including the human genome. Retrotransposition of these 
DNA pathogens has the potential to interrupt genes and seed deleterious events 
that can lead to cancer (126, 127). In many ways, host cells respond to these 
endogenous elements like exogenous retroviruses and most appear to be 
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susceptible to restriction by several APOBEC family members (35, 36, 38, 39, 
41, 43, 128–130).  
Papillomaviruses 
Virtually all cervical cancers and a growing proportion of head and neck 
cancers have integrated high risk HPV types 16 or 18 (131–133). Human 
papillomaviruses are a highly diverse family of small dsDNA non-enveloped 
viruses now containing over 250 subtypes. These viruses have small circular 
genomes that can be divided into three general regions, early ORFs, late ORFs, 
and the long control region (Fig 1.4A). High risk HPVs differ from their low risk 
counterparts by the enhanced function of their oncoproteins, E6 and E7, and 
ability to promote the integration of foreign DNA into the host genome (133, 134). 
The primary function of HPV E6 is to bind and inhibit p53 and that of HPV E7 is 
to bind and degrade Rb (135, 136). Both of these functions enhance the ability of 
the infected cells to survive and produce progeny while having the unintended 
consequence of increasing chances of surviving cells accumulating APOBEC-
mediated chromosomal damage. High-risk HPV E6 has been shown to 
specifically upregulate APOBEC3B expression in normal immortalized 
keratinocytes (NIK), hTERT-immortalized keratinocytes, and primary foreskin 
keratinocytes (59). This mechanism has been explained by both the direct 
transcriptional activation of A3B by HPV E6 and by the induction of the TEAD 
family of transcription factors (137, 138). 
Although expressed at low levels, increased fold expression of 
APOBEC3A has been observed in cervical invasive neoplasms (139). This may 
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be part of the normal response to papillomavirus infection as it has been shown 
that overexpression of APOBEC3A can mutate and restrict HPV (140, 141). 
Additionally, overexpression of APOBEC3C has shown the ability to restrict HPV 
in a deaminase-independent mechanism (141). In support of APOBEC3-
mediated mutagenesis of HPV, only alpha-papillomavirus, to which high-risk HPV 
16 and 16 belong, genomes generally show evidence of being shaped by 
APOBEC3 enzymatic activity through the depletion of TC target motifs and the 
enrichment of TT product motifs throughout the viral genome (142, 143). One of 
the consequences of using a DNA damaging enzyme like APOBEC3s is 
increasing the likelihood that DSBs will occur in both the host and viral genomes 
greatly increasing the chance that these breaks will be repaired to each other 
using non-homologous end-joining resulting in viral genome integration and 
partially explaining why high-risk HPVs cause cancer. 
Polyomaviruses 
Papillomaviruses and polyomaviruses were previously classified together 
in the papovaviridae family due to the similarity that these small dsDNA viruses 
utilize their compact genome to hijack cellular processes for the production of 
progeny. It is understandable that these viruses may also have similarities in 
regards to their relationship with the APOBEC family of enzymes. These viruses 
are ubiquitous in humans with some populations having nearly 100% 
seropositivity. The highly related, BK and JC polyomaviruses infect early on in 
human lifespans and establish latent, subclinical infections in urothelial tissues. 
Both viruses can reactivate in immunosuppressed individuals leading to fatal 
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diseases. JCPyV has emerged as the causative agent of progressive multifocal 
leukoencephalopathy (PML) (144–146); whereas, BKPyV reactivation is the 
leading cause of kidney rejection in transplant recipients and can cause 
hemorrhagic cystitis and polyomavirus-associated nephropathy (147, 148). 
The polyomavirus genome is approximately 5kb and can be divided into 
early and late transcription regions (Fig 1.4B). The late region contains the 
structural genes for major capsid protein, VP1, and minor capsid proteins, VP2 
and VP3. The early region contains the tumor antigen gene and its splice 
variants, large T antigen, truncated T antigen, and small T antigen. Small t 
antigen contains a J-domain that binds to HSC70 and activates its ATPase 
activity. Together, they as a molecular chaperone that remodels other cellular 
complexes and regulates their function (149, 150). Large T antigen has several 
domains that allow the protein to interact with numerous host factors. Similar to 
E6 and E7, large T antigen inhibits both p53 and pRb through the binding of its 
DNA-binding domain and LXCXE motif, respectively (135, 151, 152). Truncated 
T antigen shares much of the sequence of LTAg but lacks the DNA-binding 
domain (153). 
Non-human polyomaviruses have been well understood for their ability to 
transform normal cells in culture and cause cancer in animal models such as 
SV40 and murine polyomavirus. While human polyomaviruses can transform cell 
in culture, they have generally been considered to be non-pathogenic. However, 
the advent of high-throughput sequencing has dramatically expanded the number 
of known human polyomaviruses and our understanding of their role in disease 
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(154–158). Most notably, in 2008, Merkel cell polyomavirus was discovered to be 
the primary causative agent in about 80% of Merkel cell carcinomas (MCC), a 
rare, aggressive form of skin cancer (155, 157).  Risk factors for MCC not only 
include viral infection, but also old age and sun exposure. 
The large T antigen of BKPyV, JCPyV and MCPyV has been 
demonstrated to upregulate the cancer-associated enzyme, APOBEC3B. The 
genome of BK polyomavirus, like alpha-papillomaviruses, shows strong evidence 
for APOBEC-mediated TC depletion. The growing association of BKPyV 
seropositivity with bladder cancer, which is an APOBEC-signature high cancer, 
may be due to chronic infection and reactivation of BKPyV (61, 62). Surprisingly, 
virus-associated Merkel cell carcinoma shows no evidence of elevated 
APOBEC3B expression or APOBEC-mediated mutation signatures (159–161). 
Additional studies into these polyomavirus-associated tumors will help to clarify 
the complexities of APOBEC regulation and activity in tumor development. 
HBV 
Hepatitis B virus is a small enveloped DNA virus that replicates through an 
RNA intermediate belonging to the hepadnaviridae family. The viral genome is 
encapsidated as relaxed circular DNA (rsDNA). After infection of host 
hepatocytes, the viral genome is converted to covalently closed circular DNA 
(cccDNA) in the nucleus where transcription of viral genes occurs and 
persistence is established. Over 350 million people are chronically infected with 
HBV worldwide and approximately 600,000 die every year from HBV-associated 
diseases such as liver cirrhosis and hepatocellular carcinoma (162).  
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APOBEC involvement in the restriction of HBV has become convoluted 
over the years with several conflicting reports. APOBEC3B, APOBEC3C, 
APOBEC3F, APOBEC3G, and APOBEC3H are all significantly upregulated by 
HBV-infected liver cirrhosis (95). Additionally, APOBEC3G preferred motifs are 
the most frequently mutated in virus isolated from liver cirrhosis and sera from 
chronically infected patients (95, 163–165). In overexpression studies, the HBV 
genome is susceptible to targeted deamination by APOBEC3B, APOBEC3C, 
APOBEC3F and APOBEC3G (95, 96, 163, 164). Together, this evidence points 
toward APOBEC3G being the primary APOBEC involved in HBV infection. 
However, more recent studies have shown that APOBEC3B can be 
induced by lymphotoxin beta receptor crosslinking and this leads to degradation 
of the cccDNA genome in HBV-infected hepatocellular carcinoma cell lines (75). 
Further supporting the involvement of APOBEC3B, the primary HBV oncoprotein 
HBx can upregulate the ligase MSL2 and target APOBEC3B for 
polyubiquitination and degradation protecting HBV cccDNA (166). Lending to 
even more complexity, initially the APOBEC3B deletion has was not associated 
with HBV infection, but several recent studies have shown that the APOBEC3B 
deletion does associate with chronic HBV infection in several cohorts (91–93). 
Lastly, there has been a report that APOBEC3D may act as a molecular sponge, 
dimerizing with APOBEC3F and APOBEC3G during HBV infection and 
preventing their ability to restrict the virus (167) 
Herpesviruses 
 20 
Herpesviruses are large dsDNA viruses that are ubiquitous in vertebrates. 
Much like their small DNA virus cousins, herpesvirus infections are 
predominantly established early in life with herpes simplex virus (HSV) 2 being 
the primary exception being transmitted through sexual contact. Also like small 
dsDNA viruses, herpesviruses should be susceptible to deamination by 
APOBEC3 enzymes. Specifically, Epstein-Barr virus (EBV), HSV1, and murine 
gammaherpesvirus 68 genomes are able to be targeted by human APOBEC3-
mediated DNA-editing (168, 169). Additionally, it has been shown that AID can 
restrict Kaposi’s sarcoma-associated herpesvirus (KSHV) in the absence of 
UNG2 and KSHV encoded miRNAs are able to target AID transcripts for 
degradation (170). 
EBV is understood to cause diverse malignancies, such as Hodgkin’s 
lymphoma, Burkitt’s lymphoma, gastric cancer, and nasopharyngeal carcinoma. 
Compared to primary effusion lymphoma, Burkitt’s lymphoma has generally 
decreased proportion of APOBEC-signature mutations and expression of most 
APOBECs indicating a potential inverse correlation with EBV and APOBEC 
mutagenesis in B cell lymphomas (171). Generally, about 9% of gastric cancers 
are EBV positive and 14.4% of gastric cancers have significant proportion of 
APOBEC signature mutations and these groups do not seem to have significant 
overlap (4, 172, 173). Contrastingly, many nasopharyngeal carcinomas appear to 
be dominated by APOBEC-signature mutations, but in depth analysis of EBV 
involvement has not been conducted (174). Together, this may indicate that the 
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cell type of origin is important for APOBEC involvement in HBV-associated 
tumors.  
Concluding Introductory Remarks and Chapter Prelude 
 The APOBEC3 family of DNA cytosine deaminases is important for 
mutagenesis in cancer and viral evolution (with restriction being an outcome of 
viruses that have yet to adapt to the host APOBECs). For all of these enzymes, 
their expression and function can be impacted by inherited germline mutations, 
novel somatic mutations in tumors, and the exogenous effects of viral proteins. 
To address the aforementioned paradox caused by the APOBEC3B germline 
deletion, I investigated germline mutations in the polymorphic antiviral gene, 
APOBEC3H, and identify their association with APOBEC mutagenesis in cancer 
(Chapter 2).  
Building off of previous work demonstrating that the E6 oncoprotein from 
high-risk HPV upregulates APOBEC3B, I tested whether human polyomaviruses 
are able to modulate the expression of APOBEC3B (Chapter 3). This study 
revealed that the large T antigen of human polyomaviruses share the ability to 
significantly and specifically upregulate APOBEC3B. To then test if APOBEC3B 
upregulation by polymaviruses impacts the mutation profiles of MCPyV-
associated tumors, we performed RNA and whole genome sequencing (Chapter 
4). This did not reveal any APOBEC-mediated mutations in the tumors, rather 
that viral integration events result in focal amplifications of the host genome. 
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Figure 1.1. Previously established exogenous and endogenous sources of 
mutation and their outcomes. Examples of established exogenous and 
endogenous sources are listed on the left. The primary mutation context and 
base substitutions of each source are contained within the colored arrows. Red 
arrows are for signatures with a replication-based strand bias, blue arrows are for 
a transcription-based strand bias and grey arrows do not have a strand bias. 
Examples of cancers that are molded by these processes are on the right. 
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Figure 1.2. The APOBEC family of polynucleotide cytosine deaminases. (A) 
Diagram of the 11 APOBEC family members. Colored arrows represent the 
evolutionary conservation of the deaminase domain; green is Z1, orange is Z2, 
blue is Z3. All other colors are unique to that enzyme (B) Schematic of APOBEC-
catalyzed deamination in ssDNA. (C) U-shaped ssDNA is shown as a ball and 
stick model with the target cytosine embedded in the active site of APOBEC3B 
(green ribbon structure) (PDB: 5TD5). 
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Figure 1.3. Model for three axes of APOBEC3 regulation. Normal, healthy 
cells are in yellow. Cells in the beginning stages of APOBEC3B dysregulation are 
in light orange. Cells undergoing high APOBEC3B expression and mutagenesis 
are in dark orange and red. 
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Figure 1.4. Schematic of the genomes of papillomavirus and polyomavirus.  
(A) Genome organization of human papillomavirus 16 (HPV16). (B) Genome 
organization of BK polyomavirus (BKPyV). Abbreviations: Long control region 
(LCR), non-coding control region (NCCR), small T antigen (sTAg), Large T 
antigen (LTAg), truncated T antigen (truncTAg). Approximate genome size is 
shown underneath the virus name in the inner circle. Starting position of the 
reference genome (i.e. position 1) is marked with a tick on the inner circle. Early 
and late expressing regions of the genome are marked appropriately with black 
lines. 
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SUMMARY 
 
Cytosine mutations within TCA/T motifs are common in cancer. A likely 
cause is the DNA cytosine deaminase APOBEC3B (A3B). However, A3B-null 
breast tumors still have this mutational bias. Here we show that APOBEC3H 
haplotype-I (A3H-I) provides a likely solution to this paradox. A3B-null tumors 
with this mutational bias have at least one copy of A3H-I despite little genetic 
linkage between these genes. Although deemed inactive previously, A3H-I has 
robust activity in biochemical and cellular assays, similar to A3H-II after 
compensation for lower protein expression levels. Gly105 in A3H-I (vs. Arg105 in 
A3H-II) results in lower protein expression levels and increased nuclear 
localization, providing a mechanism for accessing genomic DNA. A3H-I also 
associates with clonal TCA/T-biased mutations in lung adenocarcinoma 
suggesting this enzyme makes broader contributions to cancer mutagenesis. 
These studies combine to suggest that A3B and A3H-I, together, explain the bulk 
of “APOBEC signature” mutations in cancer.   
 
INTRODUCTION 
Tumor genome sequencing studies have identified a number of mutation 
patterns, or signatures, in cancer that directly reflect the source of the original 
DNA damage [reviewed by refs. (175–178)]. Prominent established sources 
include UV-induced C-to-T transition mutations in dipyrimidine motifs in 
melanoma (UV signature), and spontaneous, water-mediated methyl-C-to-T 
transition mutations in CG motifs in many tumor types (ageing signature), as well 
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as a number of other known signatures. However, the most abundant previously 
unknown mutation signature to emerge from sequencing tumors is “APOBEC”. 
The signature of APOBEC mutagenesis is C-to-T transition and C-to-G 
transversion mutations within TCA and TCT trinucleotide motifs (hereafter TCW; 
TCG motifs may also be targeted by this process but are difficult to distinguish 
from the ageing signature and therefore discounted in most analyses). APOBEC 
signature mutations are mostly dispersed throughout the genome, but a fraction 
occurs in clusters called kataegis (179). APOBEC signature mutations are 
prevalent in over half of human cancers and often account for the majority of 
mutations within a single tumor (1, 2, 4, 34, 179–182). For instance, the 
APOBEC signature often dominates the overall mutation landscapes of breast, 
lung, head/neck, bladder, and cervical cancers. 
Although commonly referred to as a single entity, APOBEC is in fact a 
family of 11 distinct proteins in humans, and 9 have demonstrated DNA cytosine 
deaminase activity in a variety of assays with 7 eliciting intrinsic preferences for 
TC motifs in single-stranded DNA [reviewed by refs.(24, 183, 184)]. Leading 
candidates to account for the overall APOBEC mutation signature in cancer are 
APOBEC3A (A3A) and APOBEC3B (A3B). A3A has been attractive because it is 
arguably the most potent human DNA deaminase that, upon overexpression in 
heterologous systems, causes genomic DNA damage that results in cell death 
(1, 81, 89, 185–188). A comparison of the A3A and A3B mutation signatures 
derived from yeast overexpression experiments and the actual APOBEC 
signature from tumor genomes suggested that A3A provides the most 
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parsimonious explanation (81). However, endogenous A3A expression is largely 
specific to myeloid lineage cell types and, upon natural induction by interferon-α, 
it localizes to the cytoplasmic compartment and is not cytotoxic (118, 189–191). 
Consistent with strict developmental regulation and dedicated innate immune 
function, A3A has yet to be detected at the protein level in cancer cell lines or 
tumors. Moreover, much of the reported RNA level expression may be due to 
A3B sequence mis-mapping due to >90% nucleotide identity with A3A, a 
likelihood strongly supported by positive linear correlations between A3A and 
A3B expression in non-myeloid cancer data sets (Supplementary Fig. S2.1) and 
clear differences in the transcriptional regulatory programs for each of these 
genes (59, 74, 118, 189–192). 
A3B was first implicated as an endogenous mutagen in breast cancer (1). 
A3B is overexpressed in approximately 50% of breast tumors and the majority of 
breast cancer cell lines (1). A3B is constitutively nuclear (47, 49, 193), and the 
only detectable DNA deaminase activity in breast cancer cell extracts (1). A3B 
overexpression also induces DNA damage and cytotoxicity, but timing is delayed 
in comparison to A3A overexpression and more cells become multinucleated 
before dying (1). A3B expression levels correlate positively with overall cytosine 
mutation loads in breast cancer (1). A3B overexpression has also been 
documented in many other tumor types, although overexpression alone is not the 
sole factor determining whether or not a tumor will have a visible APOBEC 
mutation signature (1, 2, 34, 60, 180, 194). High A3B expression levels have 
been associated with poor clinical outcomes for estrogen receptor-positive breast 
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cancer, lung cancer, multiple myeloma, and renal cell carcinoma (70–72, 195–
198). Altogether, these data are consistent with a model in which A3B causes 
mutations that fuel the evolution of multiple different tumor types and negatively 
influences clinical outcomes (199–201). 
However, the importance of A3B in cancer has been questioned with the 
observation that APOBEC signature mutations are still clearly evident in A3B-null 
breast tumors (202). A 29.5 kbp deletion that removes the entire A3B coding 
sequence and fuses the 3’ untranslated regions (UTR) of A3A and A3B occurs at 
different frequencies in different populations around the world ranging from <5% 
in Caucasian and African populations to >30% in many Southeast Asian and 
Polynesian populations (82). Here, we extend this result to the largest available 
breast tumor data sets, and test the hypothesis that stably expressed variants of 
the only other functionally dimorphic DNA deaminase family member, 
APOBEC3H (A3H), are responsible for APOBEC signature mutations in the 
absence of A3B.  
A3H is the most polymorphic APOBEC3 protein in humans with 7 reported 
haplotypes (107, 108). Haplotypes II, V, and VII are stable, highly active 
enzymes with potent retrovirus restriction and hypermutation activities (48, 107, 
108, 122, 203). Haplotypes III, IV, and VI are unstable proteins with no reported 
function, most likely due to a structure-corrupting deletion of Asn15 in the 
conserved α1-helix (48, 107, 108, 203). Haplotype I is poorly expressed at the 
protein level due to Gly105 (versus Arg105 in stable haplotypes) and, until now, 
has failed to show reproducible activity (48, 107, 108, 203, 204). This functional 
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dimorphism is apparent in immunoblots comparing overexpressed A3H 
constructs in 293 cells (107) or endogenous A3H proteins in primary T 
lymphocytes (203), in which the stable haplotypes show robust expression and 
unstable haplotypes have no detectable expression. An exception to these 
phenotypes is the A3H-I protein, which is expressed at steady state levels 
approximately 10-fold lower than stable variants and is difficult to detect by 
immunoblotting. 
Surprisingly, during the course of testing the hypothesis that stable A3H 
haplotypes contribute to cancer mutagenesis, we found that the poorly expressed 
haplotype, A3H-I, associates with the APOBEC mutation signature in breast 
tumors lacking A3B. Linkage studies showed that the responsible SNP encoding 
Gly105, as well as surrounding genetic variations in A3H, are genetically 
unlinked to most of the remaining APOBEC3 locus including A3A and A3B, 
indicating that other APOBEC3 genes are unlikely to be responsible. Enzyme 
activity assays and HIV-1 restriction and mutation experiments demonstrated that 
A3H-I has strong DNA cytosine deaminase activity with a clear preference for TC 
dinucleotide substrates. Moreover, after compensation for lower protein 
expression levels, A3H-I and A3H-II showed similar enzymatic activities and local 
motif preferences. Subcellular localization images demonstrated that A3H-I has a 
significantly greater tendency to localize to the nuclear compartment in 
comparison to A3H-II, suggesting that Gly105 may disrupt an interaction with a 
cytoplasmic retaining factor and thereby provide a plausible mechanism for 
somatic mutation in cancer. The potential generality of this mechanism was 
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indicated by an additional, statistically significant, correlation between A3H-I and 
early-arising, clonal mutations in lung adenocarcinoma. Overall, together with 
prior studies on A3B, we propose that the combination of A3B and A3H-I 
explains the full APOBEC signature in breast and lung cancer, with a strong 
likelihood of extending more broadly to somatic mutation in other tumor types 
given the ~50% global frequency of A3H-I, the general nature of the underlying 
molecular mechanism, and the fact that global searches have failed to identify an 
APOBEC-hypermutated tumor data set without at least one copy of either A3B or 
A3H-I. 
 
RESULTS 
A3H-I associates with APOBEC signature mutations 
To test the hypothesis that stable forms of A3H (haplotypes II, V, and VII) 
contribute to breast cancer mutagenesis in the absence of A3B, we 
computationally screened and manually confirmed all available breast tumor data 
sets from TCGA to identify specimens with two copies of the A3B deletion allele, 
deduce A3H haplotypes, and assess association with APOBEC signature 
mutations (gene schematics in Fig. 2.1a, b). A total of 17 A3B-null tumors were 
identified and, as reported previously from analyses of 13 null-tumors (202), the 
overall APOBEC signature in these tumors is visibly more pronounced than the 
composite cytosine mutation spectrum from 577 breast tumors with 2 confirmed 
intact copies of A3B (boxed in Fig. 2.1c).  
The 17 independent A3B-null tumors could be divided into 4 distinct A3H 
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haplotype groupings for additional analyses. Contrary to our initial hypothesis, 
A3B-null tumors with an A3H-II/III haplotype combination, one active allele and 
one inactive allele, showed the lowest (not the highest) proportion of TC-biased 
cytosine mutations (Fig. 2.1d). This result indicated that A3H-II is unlikely to be 
contributing to the APOBEC mutation signature in breast cancer. We were 
additionally surprised to find that A3B-null tumors with one copy of A3H-I (A3H-
I/II or I/III) or two copies of A3H-I showed remarkably strong APOBEC signatures 
(boxed in Fig. 2.1d with statistical significance for non-A3H-I versus A3H-I 
mutation proportion comparisons in Supplementary Table S2.1). This 
relationship was especially strong and statistically significant for C-to-T 
transitions and C-to-G transversion mutations in TCA trinucleotide contexts, 
which represent the largest proportion of APOBEC signature mutations in cancer. 
These results suggested that the previously classified “unstable” and “inactive” 
A3H-I protein could be the source of APOBEC signature mutations in breast 
tumors lacking A3B.  
 
A3H linkage analysis 
We next performed a genetic linkage analysis using all available 1000 
genomes SNP data within the 7-gene human APOBEC3 locus, arranged 
tandemly A3A through A3H in ~120 kbp segment of chromosome 22, to assess 
the simple possibility that the A3B deletion and A3H-I allele may be linked 
genetically and, therefore, that one of the other family members in the same 
linkage group may be responsible for the observed APOBEC signature mutations 
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in A3B-null, A3H-I breast tumors. SNP data from the 1000 genomes project (103) 
were used to determine linkage disequilibrium (r2) between all A3H SNPs and all 
SNPs for the six other APOBEC3 genes. The r2 values for linkage disequilibrium 
between two SNPs range from 0 for no correlation to 1 for a perfect correlation. 
An r2 of 0.9 indicates that knowledge of one allele will correctly predict the 
second allele 90% of the time.  
Interestingly, we found that the A3H gene is only linked strongly to itself 
and to the immediate upstream gene, A3G. Linkage is weaker with genes further 
upstream, A3D and A3F, and completely absent with A3A, A3B, and A3C (Fig. 
2.2a). Although A3G is linked to A3H, it is very unlikely to be involved in cancer 
mutagenesis because the encoded enzyme has an intrinsic preference for the 3’ 
cytosine in CC and CCC motifs (205, 206), which are rarely mutated in cancer 
(e.g., Fig. 2.1 for cytosine mutations in breast cancer). Importantly, this linkage 
analysis shows that the A3H gene is unlinked to A3A (or the A3A-B chimeric 
gene resulting from the A3B deletion), suggesting that the significant association 
with A3H-I and APOBEC signature mutations in A3B-null tumors may be due 
directly to A3H-I enzymatic activity and not to A3A [as favored by recent studies 
(1, 89, 185–188, 207)] nor to any other TC-preferring enzyme encoded by the 
locus. 
Our analyses of the 1000 genomes project data also revealed an 
interesting inverse correlation between the presence of A3B and A3H-I in 
different human populations around the world (-0.76, Spearman’s rho; p=0.0015; 
Fig. 2.2b). In areas such as Africa where A3B dominates (>95%), A3H-I occurs 
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at a very low frequency (<10%). In other parts of the world, such as Southeast 
Asia where the A3B deletion allele is found at higher frequencies (>30%), A3H-I 
is found at higher frequencies (~65%). In other words, if A3B is present then 
A3H-I is rare, and if A3B is absent then A3H-I is more common. This correlation 
implies that A3B and A3H-I may have a redundant physiological function, 
possibly in antiviral immunity, or that the two genes together may incur a fitness 
penalty. In addition, when A3H-I is common then A3H-II is rare (Southeast Asia), 
whereas when A3H-I is rare then A3H-II is common (Africa). The null A3H 
haplotypes (III/IV/VI) occur at similar frequencies regardless of population 
implying the existence of an as yet unknown balancing selective pressure.  
 
A3H-I is an active DNA cytosine deaminase.  
Prior studies comparing the DNA deamination activity of A3H-I and A3H-II 
have reported that the former protein is inactive (107, 108, 204) or weakly active 
(203). Obviously, an inactive enzyme cannot contribute to cancer mutagenesis. 
We therefore interrogated the activity of this enzyme using multiple independent 
approaches.  
 A3H-I, A3H-II, and catalytic mutant derivatives (E56A) were purified from 
human 293T cells, normalized to be equimolar, and assayed for DNA cytosine 
deaminase activity using a gel-based single-stranded DNA deamination assay (1, 
51, 59, 77, 194) (schematic in Fig. 2.3a). In agreement with prior studies (48, 
107, 108, 203, 204), A3H-I showed lower overall protein expression levels in 
cellular lysates in comparison to A3H-II (Fig. 2.3b). However, similar 
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concentrations of each protein could be achieved by concentrating A3H-I, as 
evidenced by near-equivalent A3H band intensities upon direct visualization of 
SDS-PAGE fractionated proteins (Fig. 4.3c). A head-to-head comparison of 
A3H-I and A3H-II using a ssDNA with a single TCA target motif indicated near-
equivalent enzymatic activities (Fig. 4.3d). Importantly, the E56A catalytic mutant 
derivatives purified and analyzed in parallel had no detectable catalytic activity, 
which demonstrates that all of the observed activity is due to active A3H-I or 
A3H-II (and not, for instance, to a co-purifying factor from 293T cells). In 
independent experiments, recombinant A3H-I from Sf9 insect cells also elicited 
single-stranded DNA C-to-U editing activity indicating no other human factors are 
required (Fig. 4.3e). 
 Next, HIV-1 restriction and mutation assays were used as biological read-
outs for A3H-I activity (schematic in Fig. 4.4a). Vif-deficient HIV-1 particles were 
produced in 293T cells with a range of untagged A3H concentrations up to 
maximally tolerated amounts. As expected (24, 183), A3H-II and A3G-HA caused 
strong dose-responsive decreases in virus infectivity (Fig. 4.4b). In comparison, 
overexpression of A3H-I caused more modest, but still significant, drops in virus 
infectivity (200 ng, p=0.055; 400 ng, p=0.0059, Welch’s t-test). These virus 
restriction phenotypes correlated with the overall amounts of A3H and A3G-HA 
proteins expressed in cells and packaged into nascent viral particles (Fig. 4.4b). 
It is notable that the highest quantity of A3H-I yielded an HIV-1 restriction 
phenotype similar to the lowest amount of A3H-II, and that these transfected 
amounts produced similar steady-state protein levels by immunoblotting (red 
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boxed data in Fig. 4.4b). These HIV-1 restriction phenotypes lend further support 
to the in vitro biochemical results above and to the surprising finding that A3H-I 
elicits a level of catalytic activity similar to the better-expressed A3H-II enzyme.  
To extend these results, DNA was purified from infected target cells (400 
ng condition), and high-fidelity PCR was used to amplify proviral sequences for 
mutation analyses. A3H-I and A3H-II inflicted an average of 3.4 and 18 C-to-T 
mutations per kilobase, respectively (>32 independent 276 bp sequences per 
condition). Interestingly, although A3H-I has lower virus restriction activity per 
unit of transfected expression plasmid, its intrinsic DNA cytosine deamination 
preferences strongly resemble those of A3H-II with clear biases for TC 
dinucleotides (Fig. 4.4c). As expected, A3G caused high levels of mutation within 
CC dinucleotide contexts, which are rarely mutated in cancer. It is noteworthy 
that the APOBEC3-catalyzed viral cDNA uracils in this system are not subject to 
normal cellular DNA repair processes because DNA deamination and reverse 
transcription occur within the physical confines of the capsid-encased viral core, 
and reverse transcription effectively immortalizes these uracil lesions as viral 
genomic strand G-to-A mutations prior to integration into the genomic DNA of a 
susceptible host cell [mechanism reviewed by refs. (24, 183, 184)].  
  
A3H-I has increased nuclear localization 
We next asked if A3H-I is capable of accessing the nuclear compartment, 
which is another property likely to be essential for cancer mutagenesis. Prior 
studies have lacked consensus with epitope-tagged A3H-I showing variable 
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subcellular localization (48, 108, 109, 204). However, one study proposed that 
A3H-II (Arg105) is retained in the cytoplasm by interacting with a specific host 
factor, and that the Gly105 amino acid characteristic of A3H-I dislodges this 
mechanism and enables entry into the nuclear compartment by passive diffusion 
(48). 
To clarify and advance this important point, we used immunofluorescent 
microscopy to quantify the localization of untagged A3H-I versus A3H-II in cell 
lines with varying endogenous A3B levels (null, SK-BR-3; low, HeLa; high, 
U2OS) (1). A3B-HA and A3G-HA were used as controls for predominantly 
nuclear and cytoplasmic localization, respectively (Fig. 2.5). We found the overall 
subcellular distributions of A3H-I and A3H-II to be consistent in all cell types, 
regardless of endogenous A3B levels, with the former enzyme invariably 
appearing more nuclear than the latter (representative images, Fig. 2.5a; 
quantification, Fig. 2.5b). These data show that A3H-I is proficient at entering the 
nuclear compartment, and advance the general model in which Gly105 disrupts a 
cytoplasmic retention mechanism and enables the A3H-I enzyme to breach the 
nuclear compartment and mutagenize genomic DNA. 
 
A3H-I explains many clonal mutations in lung adenocarcinoma  
Given the results detailed above, particularly the potent enzymatic activity 
of A3H-I with an intrinsic preference for cytosines in a TC context, the capacity of 
A3H-I to mutate a variety of substrates, and the ability of A3H-I to breach the 
nuclear compartment, we next performed a comprehensive analysis of all 
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available TCGA tumor data sets with n-values >400 exomes to begin to assess 
whether A3H-I is a general source of mutation in cancer or a unique mechanism 
that compensates for the loss of A3B in a limited subset of breast cancers. To 
distinguish between these possibilities, we determined whether A3H-I associates 
with common mutation signatures including APOBEC, smoking, and ageing 
(respectively, C-to-T in TCW motifs, C-to-A in any motif, and C-to-T in CG 
motifs). We predicted an association of A3H-I with APOBEC signature in some 
tumor types, but not with smoking or ageing in any tumor type because these 
signatures are clearly due to independent mechanisms. Mutations with the 
highest frequency of occurrence in a given tumor normalized by copy number 
and tumor purity are considered early-arising and clonal, whereas any mutation 
occurring at a lower frequency is considered later-arising and subclonal (Fig. 
2.6a). Such temporal relationships are critical because different mutational 
processes have been shown to promote different stages of tumor evolution (177).  
Three distinct scenarios emerged from these analyses (Fig. 2.6b and 
Supplementary Fig. S2.2). In the first, A3H-I associates with the occurrence of 
APOBEC signature mutations despite contributions from multiple mutational 
processes. Nearly 3-fold more early-clonal APOBEC-signature mutations were 
evident in lung adenocarcinomas with at least 1 copy of A3H-I in comparison to 
tumors with any other A3H haplotype (p=0.0024, Welch’s two-tailed t-test; top left 
histogram in Fig. 2.6b). In contrast and as expected, clonal mutation signatures 
attributable to smoking and ageing did not correlate with A3H haplotype (p=0.48 
and p=0.37, respectively). Subclonal APOBEC-signature mutations also occurred 
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independently of A3H haplotype (p=0.13) and, based on prior studies (2, 4, 34, 
180), are most likely due to the temporally late upregulation of A3B. Clonal 
APOBEC signature mutations also appeared to be enriched in breast tumors with 
A3H-I versus those with any other haplotype, but this difference is not statistically 
significant (p=0.17, Welch’s two-tailed t-test). This result could easily be due to 
A3B upregulation occurring at variable times during the progression of individual 
breast tumors because the trend completely disappears in the analysis of 
subclonal APOBEC signature mutations where A3B has already been implicated 
strongly (1, 2, 4, 34, 179, 180, 182).   
In the second scenario, both clonal and subclonal APOBEC mutation 
signatures are stronger, as judged by the higher percentages of total cytosine 
mutations, and there are no correlations with the presence or absence of A3H-I. 
The clearest example is cervical cancer, where HPV infection is an established 
early event (132), and HPV infection has been mechanistically linked to A3B 
upregulation (59, 60). Here, approximately 10% of overall APOBEC signature 
mutations are clonal for both A3H-I and non-A3H-I cervical tumors, and this 
proportion rises to nearly 15% for APOBEC signature subclonal mutations 
(p=0.69 and p=0.10, respectively, Welch's two tailed t-test; Fig. 2.6b). Thus, in 
this virus-induced scenario, we propose that chronic levels of A3B eclipse any 
mutational contributions from A3H-I or, alternatively, that the A3H gene is not 
expressed at the mRNA level in these tumor types [supported by cell-based HPV 
studies (59)]. Again, as expected, both clonal and subclonal smoking and ageing 
mutation signatures are unrelated to A3H haplotype.  
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In the final scenario, a proportion of cancer types simply do not manifest 
an APOBEC mutation signature (2, 4, 34, 181, 182, 208). For instance, prostate 
cancer and low-grade glioma lack an APOBEC signature at any time point 
(Supplementary Fig. S2.2). There are many possible molecular explanations for 
why the general mutation mechanism described here for A3H-I may not be 
operational in these cancer types. The simplest is that both basal and induced 
levels of A3H-I mRNA expression are likely to be constrained by cell type and 
developmental program, and therefore differences between protein-level 
haplotypes may be irrelevant and incapable of contributing to the overall mutation 
spectrum. 
 
DISCUSSION 
The studies presented here are the first to implicate A3H-I as an 
enzymatic contributor to “APOBEC signature” mutations in breast and lung 
cancer, with a general mechanism that could extend to other cancer types. This 
work was initiated with the goal of providing a molecular explanation to the 
paradox that APOBEC signature mutations still exist in A3B-null breast cancers 
(202). We had independently reached and expanded upon the same conclusion 
(data summarized in Fig. 2.1c), and we set out to test the hypothesis that stably 
expressed variants of the only other functionally dimorphic APOBEC3 family 
member, A3H, would be responsible. To our surprise, stable A3H haplotypes did 
not explain the APOBEC signature mutations in A3B-null tumors; instead, a 
variant previously deemed unstable and inactive, A3H-I, showed a statistically 
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significant association (Fig. 2.1d). A linkage analysis further strengthened this 
possibility and, simultaneously, discounted participation by other APOBEC3 
family members including wild-type A3A and A3A produced by the chimeric A3A-
B fusion gene generated by the 29.5 kbp A3B deletion (Fig. 2.2). Biochemical 
and cell-based studies contrasted with prior reports and clearly demonstrated 
that A3H-I is not only catalytically active but, once protein concentrations were 
equalized, it also proved similarly active to the A3H-II enzyme and yielded a 
near-identical TC-biased single-stranded DNA deamination preference (Figs. 
2.3-2.4). Subcellular localization studies revealed the likely molecular mechanism 
responsible for enzymatically active A3H-I gaining access to the nuclear 
compartment, with A3H-I Gly105 disrupting a likely cytoplasmic retention 
mechanism (Fig. 2.5). Finally, an informatics approach was used to significantly 
associate A3H-I with clonal APOBEC signature mutations in lung cancer (Fig. 
2.6). The high frequency of A3H-I in global populations, 48% (54% in 
Caucasians) based on 1000 genome project data (103), and the general nature 
of the mechanism described here (mislocalization of an active DNA cytosine 
deaminase) combine to suggest relevance to other cancer types.  
As described in the Introduction, previous work has favored A3A and/or 
A3B as the predominant sources of the APOBEC signature mutation in cancer. 
The studies presented here are the first to implicate A3H-I and, simultaneously, 
further support A3B and cast doubt on a possible role of A3A and other APOBEC 
family members in cancer mutagenesis. For instance, if A3A or another family 
member caused the APOBEC signature in A3B-null tumors, then statistically 
 43 
significant associations with A3H-I would never have emerged from the 
comprehensive analyses in Fig. 2.1 for breast cancer and Fig. 2.6 for lung 
cancer. Moreover, because the APOBEC signature is not found in A3B-null/non-
A3H-I breast tumors (Fig. 2.1d), it is possible that A3B and A3H-I account for all 
APOBEC signature mutations in breast cancer. In support of this idea, an 
exhaustive analysis of all TCGA tumor data sets failed to find a single tumor with 
an APOBEC mutation signature that did not have either one copy of A3B or A3H-
I (n=6863 tumors over 15 cancer types). Thus our studies are also the first to 
positively link A3B and A3H-I at the genetic level to the APOBEC mutation 
signature observed broadly in cancer. Future population-focused studies will 
either confirm these data or unambiguously implicate another APOBEC enzyme 
[e.g., analyses of A3B-null/A3H-inactive (haplotypes III, IV, VI) tumors could be 
informative although identifying cohorts with statistically significant numbers will 
be non-trivial].  
Many factors contribute to the composite mutation spectra observed in 
cancer and comparisons with models systems are, at worst, misleading and, at 
best, challenging and inaccurate. For instance, the APOBEC signature of 
cytosine mutations in TCA and TCT motifs (Fig. 2.1) is the net result of the 
intrinsic single-stranded DNA preference of the deaminase (53, 77, 209) and the 
biased uracil excision activity of nuclear UNG2 (likely also influenced by 
contributions from other uracil DNA glycosylases) (57, 210), and the biased 
insertion of adenine or cytosine bases opposite abasic sites by DNA 
polymerization enzymes (most DNA polymerases follow the A-rule with the 
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exception of REV1, which preferentially inserts cytosine and accounts for 
APOBEC-induced C-to-G transversions) (55, 56, 211). The biochemical DNA 
deamination preferences with recombinant A3H-I in Fig. 2.3d are concordant 
with the observed APOBEC signature mutations in cancer with TCA/T/G targets 
preferred over TCC. Although A3H-I (this study) and A3B (1, 77, 194) can 
efficiently deaminate cytosines in TCG, mutations in tumors within this 
trinucleotide context are numerically less common than those in TCA/T because 
CpG motifs are underrepresented in exomic regions of the human genome and 
methylation of these motifs decreases the efficiency of enzymatic deamination in 
vitro by at least 5-fold (51, 76, 212) [further complicated by the fact that 
methylation increases the efficiency of spontaneous hydrolytic deamination 
(213)]. However, if a correction factor for trinucleotide motif frequency is applied 
to the observed mutation frequencies in Fig. 2.1d, then cytosine mutations within 
TCG motifs become enriched relative to the abundance of this motif the human 
genome, fully consistent with the biochemical preferences of A3H 
(Supplementary Fig. S2.3). A3H-catalyzed mutation in Vif-deficient HIV occurs 
most frequently within TCG and TCA motifs and least frequently within TCC and 
TCT motifs, and this result becomes even clearer upon examination of weighted 
mutation frequencies (Supplementary Fig. S2.4) and more closely resembles 
the weighted mutation frequencies of the breast tumor data sets 
(Supplementary Fig. S2.3). These results do not exactly mirror the biochemical 
data, likely because many experimental variables differ (enzyme sources, 
substrates, reaction conditions, etc.). Nevertheless, each approach still 
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contributes an important piece to the overall picture, and the biochemical 
approach was invaluable for demonstrating that A3H-I is active and has 
essentially the same intrinsic DNA deamination preferences as A3H-II. 
How can prior work be further reconciled? One recent study compared 
mutation patterns induced by A3A and A3B in yeast with the actual APOBEC 
signature in human cancer and, relying heavily on comparing frequencies of the -
2 base relative to the mutated cytosine, concluded that A3A was 10-times more 
important than A3B in cancer mutagenesis (207). Unfortunately, this work did not 
consider A3H and other human APOBEC3 enzymes preferring TC substrates. As 
discussed above, it difficult to account for the fact that yeast and human genomic 
structures and DNA repair processes differ and that this is likely to strongly 
influence the distribution of initial uracil lesions that ultimately become mutations. 
Moreover, a re-analysis of breast cancer TCGA WES data sets for C-to-T 
mutations in YTCA versus RTCA contexts revealed that tumors with this bias 
have at least one copy of A3H-I (Supplementary Fig. S2.5). Another recent 
paper also favored A3A and advanced the idea that the A3A-B chimeric gene 
created by the 29.5 kbp A3B deletion disrupts A3A regulation and results in 
elevated A3A protein levels, genomic DNA damage, and cancer mutagenesis 
(89). If this were the case then A3H-I would not have shown statistically 
significant associations with breast and lung cancer APOBEC mutation 
signatures (Fig. 2.1 and Fig. 2.6). This study also relied heavily upon analysis of 
transfected reporter constructs (not endogenous A3A) and failed to do the critical 
cause/effect experiment of specifically depleting endogenous A3A expression in 
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A3B-null SK-BR-3 breast cancer cells and asking if it alone is responsible for the 
DNA damage phenotypes caused by PMA treatment. We investigated this 
possibility using CRISPR to recreate the human A3B deletion in an isogenic 
system, the breast cancer cell line MCF-7, and found no significant change in 
expression of the A3A-B fusion gene after deleting A3B (Supplementary Fig. 
S2.6). An additional critical point is that many studies purporting to document 
A3A expression in tumors may be undermined by A3B RNAseq reads 
mismapping to A3A and/or by A3B cDNA cross-hybridizing to A3A probes on 
microarrays and/or by A3A expressing immune cells infiltrating the analyzed 
tumor tissues (1, 194, 207, 214) (Supplementary Fig. S2.1). Accordingly, to our 
knowledge, no studies to-date have documented A3A protein or enzymatic 
activity in primary tumor samples or tumor-derived cell lines. However, despite 
mounting evidence against A3A and other family members, we acknowledge that 
it is currently difficult to eliminate the possibility that one or more of these proteins 
may be able to contribute to cancer mutagenesis (e.g., in a tumor type not 
addressed here due genetic and statistical constraints of TCGA data sets). 
Our results suggest distinct temporal models for the generation of 
APOBEC signature mutations in cancer. In the first, in A3B-null cancers such as 
in a subset of breast tumors described here, A3H-I may provide a low mutator 
activity that over a long period of time results in the observed APOBEC signature 
mutation spectrum and load (continuous mutator model in Fig. 2.7a). This 
mutation program may be prone to periodic “flares” (not depicted) because at 
least one virus (HIV-1) has been shown to induce A3H expression in primary 
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cells (25, 203), and other viruses may have similar stimulatory effects. This 
model may be particularly relevant to Southeast Asian populations with high 
frequencies of both A3H-I and the A3B deletion allele (Fig. 2.2). In the second 
model, in A3B overexpressing tumors such as many breast cancers and HPV-
positive cancers, the mutational impact of A3B may be early, strong, constitutive, 
and additive to that of A3H-I, and the powerful effect of A3B and its similar TC 
target preferences may rapidly eclipse the A3H-I contribution [activated (early) 
mutator model in Fig. 2.7b]. HPV infection provides a mechanism for A3B 
upregulation in virus-positive tumor types, but the mechanisms responsible for 
early A3B induction in virus-negative tumors are less uniform and less clear (e.g., 
ref. 35). In the third model, the impact of A3H-I is evident among early-arising 
clonal mutation spectrum in lung adenocarcinomas but it eventually becomes 
eclipsed by A3B overexpression at a later point in tumor development 
[continuous mutator plus activated (late) mutator model in Fig. 2.7c]. In a variant 
of this model, the early continuous mutator effect is absent in tumors lacking 
A3H-I [activated (late) mutator model in Fig. 2.7d]. In all of the models, apart 
from those depicting an early smoking signature, other prominent sources of 
mutation are excluded for purposes of focusing on the APOBEC signature and 
the different contributions of A3H-I and A3B observed in this study. Such 
additional sources of mutation are of course capable of contributing to the overall 
mutation loads and spectra in various tumor types. These models may extend to 
APOBEC signature cancers beyond those highlighted here, and future studies 
should be designed to isolate and quantify the mutagenic contributions of A3H-I, 
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A3B, and possibly other family members. Future studies should also examine the 
clinical impact of these different mutational sources together, as well as in 
isolation, in appropriate populations. Indeed, an analysis of lung cancer incidence 
in China indicated that unstable/inactive forms of A3H may be protective and, 
therefore, that A3H-I as the predominant allele in China (~70%) could be a 
significant risk factor (110). 
 
METHODS 
APOBEC genotyping and tumor mutation analyses 
TCGA RNAseq and WES data were obtained between April 2014 and 
January 2016 (https://cghub.ucsc.edu/). Somatic mutation and CNV data were 
obtained in January 2016 
(https://confluence.broadinstitute.org/display/GDAC/Download). Initial candidate 
A3B-null patients were identified using TCGA SNP CNV data with a sample 
segment mean of -1.5 or less with probe start positions 37693565, 37693563, or 
37693530 on chromosome 22. Additional A3B-null candidates were identified 
using WES of the A3A and A3B genes and flanking exons preserved with the 
deletion allele. A3B-null patients were confirmed by manual inspection of WES 
alignments (e.g., Supplementary Fig. S2.7). A3H genotypes were determined 
by extracting base calls, quality, and coverage data from WES alignments 
spanning the APOBEC locus for tumor/normal samples acquired from the TCGA. 
Global A3H allele frequencies were estimated using phased variants from all 
available data as of December 2015 from 1000 Genomes Project (103). 
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All somatic mutations were isolated with adjacent 5’ and 3’ nucleotides 
using the hg19 reference genome. Mutations were binned by trinucleotide 
context and proportions calculated compared to total somatic mutations. No 
statistical difference in the total mutation loads were evident between the various 
genotypic groups of A3B and A3H breast tumors, which is not particularly 
surprising given the fact that the durations of tumor growth are unknown 
(Supplementary Fig. S2.8). To take motif abundance into consideration, we first 
determined the frequency of each trinucleotide motif in the reference sequence 
by counting each observed motif and dividing by the total number of trinucleotide 
motifs possible in the reference (length of sequence - 2). Counts of mutations at 
each trinucleotide motif were then divided by the previously calculated frequency 
of that trinucleotide in the reference and these adjusted counts were divided by 
the sum of all adjusted counts to derive weighted frequencies. 
The chronological timing of somatic mutations was determined using 
published methods and definitions (180, 215) with conservative modifications. 
Specifically, tumor purity as calculated by ESTIMATE from TCGA RNAseqV2 
and GISTIC2 copy-number calls from Broad were used instead of ASCAT data to 
adjust variant allele frequencies (216). 95% confidence intervals (CI) of adjusted 
allele frequencies were determined by resampling the number of reads 
supporting the reference and alternate alleles at half of the observed coverage 
(10,000 bootstraps). Early-clonal mutations were any mutation occurring clonally 
before a copy number altering event. This was defined as a mutation with an 
adjusted allele frequency lower 95% confidence interval that is greater than 1 
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copy (i.e., AF > 0.50) in diploid regions of the genome and any mutation that 
corresponds to 2 or more copies in regions of copy number amplifications (e.g., 
CN = 3, AF = 0.667). Late-clonal mutations (after copy number altering event) 
are identified as those occurring in diploid regions or regions of copy number 
amplification, but the 95% CI of the allele frequencies overlap 1 copy of the 
allele. Non-clonal mutations were defined as any mutation with an upper 95% CI 
allele frequency that falls below one copy indicating that it is present in a 
subpopulation of the cells. Proportion of each base substitution in each 
trinucleotide was calculated on a per patient per temporal category basis. Any 
patient with fewer than 4 somatic mutations in a particular category was excluded 
from the analysis to avoid potential biases.  
DNA constructs 
Epitope (C-terminal 2xStrep-3xFlag)-tagged A3H-I and A3H-II constructs 
for purification from human cells were cloned as PCR fragments into pcDNA4/TO 
restriction sites HindIII-EcoRV using 5’-NNN-AAG-CTT-ATG-GCT-CTG-TTA-
ACA-GCC and 5’-NNN-GAT-ATC-GGC-GGG-ACT-GCT-TTA-TCC and vectors 
described below as amplification templates. Catalytic mutant derivatives were 
constructed by standard site-directed mutation. The GST-A3H-I construct was 
made by PCR subcloning A3H-I cDNA from Open Biosystems (GenBank 
BC069023) using 5’ CCC GGG AAT TGG A AT GGC TCT GTT AAC and 5’ GCG 
GCC GC T CAG GAC TTT ATC CTC TC into SmaI/NotI digested pFastBac1-
GST (Life Technologies). The A3B-HA, A3G-HA, A3H-I (untagged), and A3H-II 
(untagged) expression constructs are based on pcDNA3.1+ (Invitrogen). The 
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A3B-HA, A3G-HA, and untagged A3H-II were constructed by PCR subcloning 
coding sequencing matching Genbank accessions NM004900, NM021822, and 
FJ376614.1, respectively (25, 217). The untagged A3H-I construct was made by 
PCR subcloning A3H-I cDNA (GenBank FJ376611) using 5’-NNN-NGA-GCT-
CGG-TAC-CAC-CAT-GGC-TCT-GTT-AAC-AGC-CGA-AAC and 5’-NNN-NGT-
CGA-CTC-AGG-ACT-GCT-TTA-TCC-TCT-CAA-GCC-GTC into KpnI/XhoI-
digested pcDNA3.1+ (Invitrogen). Sanger sequencing was used to confirm the 
integrity of all constructs. 
Protein purification and DNA deaminase activity assays 
HEK293T cells were transfected with pcDNA4/TO-A3H-I:2xStrep3xFlag or 
pcDNA4/TO-A3H-II:2xStrep3xFlag (or catalytic mutants). Cells were harvested 
48 hrs post-transfection and lysed in 50 mM Tris-HCl pH 8, 1% (v/v) NP-40, 150 
mM NaCl, 0.5% (w/v) deoxycholate, 0.1% (w/v) SDS, 5 mM EDTA, 1x EDTA-free 
Protease Inhibitor Cocktail (Roche), and then further disrupted by sonication. 
A3H proteins were purified using Strep-tactin resin (IBA). Samples were washed 
in high salt buffer (20 mM Tris-HCl pH 7.5, 1.5 mM MgCl2, 1 M NaCl, 0.5 mM 
DTT and 5% glycerol) followed by low salt buffer (high salt with 150 mM NaCl) 
and elution using 2.5 mM desthiobiotin. Normalized amounts of each purified 
protein were incubated with a ssDNA substrate containing a target TCA motif and 
uracil DNA glycosylase for 1 hour, and then treated with mild hydroxide to cleave 
the deaminated/de-uracilated substrate at the position of the abasic site as 
described (1, 51, 59, 77, 194). The products of the assay were run on a 15% 
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urea gel and were imaged using the Typhoon FLA 7000 fluorescent imager (GE 
Healthcare Life Sciences).  
GST-A3H-I was produced using the Bac-to-Bac expression system (Life 
Technologies). Sf9 cells were infected with recombinant GST-A3H-I baculovirus 
at an MOI of 20. Cells were harvested 40 hrs post-infection and lysed as 
described (218). Cleared lysates were incubated with glutathione sepharose 
resin (GE Healthcare) and subjected to washes of PBS with 250 mM NaCl in the 
presence or absence of 1% Triton-X 100. The resin was then resuspended to a 
50% slurry in 100 mM Tris pH 7.5, 100 mM NaCl, 10% glycerol, 1 μM ZnCl2, and 
5 mM DTT. Aliquots of the 50% slurry with bound GST-A3H were incubated with 
100 nM ssDNA substrate for 2 hrs. Deamination events were detected by uracil 
DNA glycosylase and mild alkaline treatment as described (219). Gel images 
were obtained using a FX fluorescence scanner (BioRad) and background 
subtraction and integrated gel band intensities were quantified using ImageQuant 
(GE Healthcare). A3H-I showed no activity after elution of the enzyme from the 
affinity resin, and activity of the resin-bound enzyme diminished with time at 4 °C.  
Virus infectivity and hypermutation experiments were done using 50% 
confluent 293T cells in DMEM (HyClone) with 10% FBS, and 0.5% Pen/Strep. 
Cells were co-transfected with 300 ng pΔNRF (gag-pol-rev-tat), 100 ng pMDG 
(vesicular stomatitis virus G protein), 100 ng pCS-CG (lentiviral transfer vector 
encoding GFP), and a titration (50, 100, 200, and 400 ng) of APOBEC3 
expression plasmids (vector, A3G-HA, A3H I, or A3H II) using TransIT-LT1 
(Mirus Bio). After 24 hrs, the media was removed and replaced with fresh media 
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containing 50 U/ml DNase to digest free plasmid DNA. After another 24 hrs, virus 
containing supernatants were purified with 0.45 μm PVDF filters, treated with 
DNase at 50 U/ml, and used to infect 293T target cells. Virus particles were 
isolated through a 20% sucrose cushion from the remaining supernatant. 
Producer cells were used for flow cytometry (FACSCanto II Ruo; BD 
Biosciences) and analyzed (FlowJo) to monitor transfection efficiency. The 
remaining virus particles and producer cells were lysed in 2.5x Laemmli sample 
buffer and used for immunoblotting. A3H was detected using a rabbit anti-A3H 
polyclonal antibody (Novus Biologicals, NBP1-91682), and A3A-HA and A3G-HA 
were detected using mouse anti-HA monoclonal antibody (Covance). Tubulin and 
p24 served as loading controls and were detected by a mouse anti-tubulin 
mononclonal antibody (Covance) and a mouse anti-p24 monoclonal antibody 
(NIH AIDS Reagent Program). Primary antibodies were detected with anti-rabbit 
and anti-mouse HRP-conjugated secondary antibodies (Jackson 
ImmunoResearch). After 48 hrs infection, target cells were harvested and used to 
analyze infectivity by GFP flow cytometry and to obtain genomic DNA for viral 
hypermutation analyses. 
Genomic DNA from infected 293T target cells was used for viral 
hypermutation studies. Genomic DNA was first treated with DpnI (NEB) to 
remove plasmids that may have carried over from the original transfection. 
Phusion high-fidelity DNA polymerase (NEB) was used in nested PCR reactions 
to amplify a region in GFP with outer primers 5′-CCTRAARTTCATCTRCACCA 
and 5′-CACRCTRCCRTCCTC, followed by the inner primers 5′-
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CCRCTACCCCRACCAC and 5′-TCACCTTRATRCCRTTCTTC. Amplicons were 
cloned into pJET1.2 (Fermentas) and subjected to Sanger sequencing. Each 
sequence was aligned to the GFP reference sequence using BWA (220) and 
mutations were quantified using a custom perl script available from 
https://github.com/gjstarrett/countSangerMuts (Supplementary Software S2.1). 
Immunoblotting 
Transfected 293T cells were lysed with Laemmli sample buffer and 
quantified for total protein by Lowry Assay (Sigma).  35 µg whole cell lysate was 
separated on a 12% SDS-PAGE. A3H was detected using a mouse anti-A3H 
mAb diluted 1:1000 (203) (NIH AIDS Reagent, Cat#12155). Alpha-tubulin was 
detected with a rabbit polyclonal serum (Thermo, PA1-20988). Fluorescent anti-
mouse (680nm, Licor, 926-68070) and anti-rabbit (800nm, Licor, 32211) 
secondary antibodies were used for detection. Scans were performed on a Licor 
Odyssey infrared scanner. 
Immunofluorescent microscopy 
Cell lines were obtained from the ATCC. HeLa cells were cultured in 
DMEM (HyClone) and SKBR3 and U2OS cells in McCoy’s 5A (Corning), each 
supplemented with 10% fetal bovine serum and 0.5% Pen/Strep. 50% confluent 
cells were transfected with 200 ng of A3B-HA, A3G-HA, A3H-I, or A3H-II with 
TransIT-LT1 according to the manufacturer’s instructions (Mirus Bio). After 24 hrs 
incubation, cells were fixed in 4% paraformaldehyde and incubated overnight 
with either rabbit anti-HA (Cell Signaling, #3724; 1:250) or rabbit anti-A3H (Novus 
Biologicals, NBP1-91682; 1:200) followed by a 2 hr incubation with anti-rabbit 
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TRITC conjugated antibody (Jackson ImmunoResearch). The nuclei were 
stained using a 0.1% Hoechst solution. Cells were imaged using 1000X 
magnification on a Nikon Inverted TiE Deconvolution Microscope. Nuclear versus 
cytoplasmic localization of APOBEC3 proteins was calculated from these images 
using MATLAB (MathWorks) with the assistance of the University of Minnesota 
Imaging Center. 
Statistics. 
Statistical significance between categorical data was calculated by 
Welch’s two-tailed t-test using both Graphpad Prism and the R statistical 
computing environment. Trinucleotide enrichments were calculated by Fisher’s 
exact test.  
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Figure 2.1. A3H haplotype I accounts for APOBEC signature mutations in 
A3B-null breast tumors. 
a, Schematic of A3A, A3B, and the A3A-B fusion gene. Exons are numbered and 
indicated by boxes, and coding regions are shaded. A 5 kbp scale is indicated. 
b, Schematic of the A3H gene with haplotype-defining amino acid variants and 
SNP numbers listed below. Labeled as in panel a, except the scale indicates 2.5 
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kbp. 
c, Bar plots depicting the proportions of cytosine mutations occurring in the 
indicated trinucleotide motifs in A3B+/+ and A3B-/- breast tumors with n-values 
and total mutation numbers in parentheses. C-to-T, C-to-G, and C-to-A are 
represented by red, black, and blue shading, respectively.  
d, Bar plots depicting the proportions of cytosine mutations occurring in the 
indicated trinucleotide motifs in A3B-/- breast cancers with the indicated A3H 
haplotype combinations (n-values and total mutation numbers in parentheses). 
C-to-T, C-to-G, and C-to-A are represented by red, black, and blue shading, 
respectively. 
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Figure 2.2. Polymorphisms in A3H are not in linkage disequilibrium with 
A3A or A3B. 
a, Heatmap showing the strength of linkage (r2) of SNPs located within the A3H 
gene versus the rest of the APOBEC3 locus.  
b, Bar plots of the A3B deletion and A3H haplotype frequencies for the indicated 
populations (A3H-I in red; stable A3H-II/V/VII in blue, and unstable A3H-III/IV/VI 
in gray). Superpopulations are color coded for visualization of larger geographic 
areas, and individual 3-letter population identifiers are from the 1000 genomes 
project
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Figure 2.3. A3H haplotype I is an active DNA cytosine deaminase. 
a, Schematic of the single-stranded DNA deamination assay. A3H-mediated 
deamination yields a uracil that, upon excision by excess uracil DNA glycosylase, 
is converted into a hydroxide-labile abasic site.  
b, Image of a Coomassie-stained gel with approximately equal amounts of A3H-I, 
A3H-II, and catalytic mutant derivatives purified from 293T cells.  
c, Activity data for the recombinant A3H proteins shown in panel b (S, substrate; 
P, product). 
d, Activity of GST-A3H-I purified from insect cells using the indicated trinucleotide 
containing single-stranded DNA substrates (S, substrate; P, product).
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Figure 2.4. A3H haplotype I has enzymatic activity against viral DNA. 
a, HIV-1 infectivity assay. Viral and A3 expression vectors are transfected into 
293 producer cells and, after 48 hrs, virus-containing supernatants are titered by 
infecting CEM-GFP reporter cells in which an integrated LTR-GFP cassette is 
activated by the Tat protein expressed from newly integrated viruses. Infectivity is 
quantified by flow cytometry and calculating the percentage of GFP-positive 
reporter cells. 
b, Mean and SEM plotted for three biological replicates of HIV-1 infectivity data 
for Vif-deficient viruses produced in 293 cells expressing a vector control, A3G-
HA, A3H-I, or A3H-II (*p < 0.05, **p < 0.01, ***p < 0.001, Welch’s two sided t-
test). Immunoblots for the indicated proteins in cell lysates and virus containing 
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supernatants are shown below. 
c, C-to-T mutation distribution in viral DNA sequences recovered from CEM-GFP 
reporter cells. C-to-T, C-to-G, and C-to-A are represented by red, black, and blue 
shading, respectively. The mutations are reported for the viral cDNA strand, 
rather than the conventional genomic strand to facilitate comparisons with tumors 
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Figure 2.5. A3H haplotype I has greater nuclear localization than haplotype 
II. 
a, Representative images of A3H-I (untagged), A3H-II (untagged), A3B-HA, and 
 64 
A3G-HA in SK-BR-3, HeLa, and U2OS cells. The 20 µm scale applies to all 
images. 
b, Whisker plots quantifying the subcellular localization data as nuclear-to-
cytoplasmic ratios for n > 50 cells per condition. The average is shown, the error 
box represents the first and third quartiles, and the whiskers extend to the 
highest value within 1.5x the interquartile range (p-values determined by two-
tailed Welch’s t-test). 
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Figure 2.6. A3H haplotype I contributes APOBEC signature mutations to 
lung cancer. 
a, Tree-based cartoon of tumor evolution. To represent the heterogeneity of each 
tumor deep sequencing data set (boxed area), 1 trunk mutation (blue) and 3 
branch mutations (other colors) are depicted on a background of normal germline 
DNA (grey). Trunk mutations occur early and are found in every tumor branch, 
whereas branch mutations occur later in one or more branches (i.e., clonal 
versus subclonal).  
b, Bar plots showing the frequency of clonal and subclonal mutations in the 
indicated cancer types attributable to APOBEC, smoking, and ageing (LUAD, 
lung adenocarcinoma; BRCA, breast cancer; CESC, cervical cancer). Each bar 
represents the average proportion +/- SEM of signature mutations occurring 
within each A3H haplotype group (i.e., A3H-I versus non-A3H-I). The total 
number of tumors with 1 or 2 copies of G105 (A3H-I) or 2 copies of R105 (A3H-II 
and other haplotypes) is indicated within the first set of histogram bars. Welch’s 
two-tailed t-test for each category was used to calculate the p-value above each 
graph. 
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Figure 2.7. Models for differential APOBEC mutation accumulation in 
cancer. 
The far left column describes the A3B and A3H-I genotypes of each model as 
well as examples of relevant tumor types. The middle columns show the average 
mutation rate over time for each model with sources of mutations highlighted in 
different colors, smoking (blue), A3B (red), and A3H-I (maroon). The far right 
column depicts the accumulation of somatic APOBEC signature mutations over 
time, with mutations mediated by A3B and A3H-I represented in red and maroon, 
respectively. Somatic mutations from both APOBEC3 enzymes are shown as 
 68 
red/maroon diagonal stripes to highlight that these mutations from these sources 
are not clearly distinguishable. 
a, The continuous mutator model depicts constant A3H-I mediated mutagenesis 
and subsequent accumulation of APOBEC-signature mutations over time in the 
absence of A3B as may be occurring in some breast cancers. 
b, The activated (early) mutator model depicts a rapid increase in A3B-mediated 
mutations and APOBEC signature mutations after an A3B-activating event such 
as HPV-infection in cervical cancers or a currently unknown mechanism in breast 
cancers.  
c, The continuous mutator plus activated (late) mutator model depicts the 
constant accumulation of APOBEC-signature mutations mediated by A3H-I as 
shown in panel a. For contrast, the distinct contribution from smoking-mediated 
mutagenesis (blue) is shown as an early finite time period. Late activation of A3B 
then leads to a more rapid accumulation of APOBEC signature mutations over 
time effectively eclipsing the A3H-I contribution.  
d, The activated (late) mutator model is nearly identical to the model shown in 
panel c, however the absence of A3H-I results in no early APOBEC-signature 
mutations as may be occurring in some lung adenocarcinomas. 
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Supplementary Fig. S2.1. Evidence for cross-mapping of RNAseq reads 
from A3B to A3A in tumor samples impacting interpretations of mRNA 
expression. 
a, A significant positive correlation is evident between A3B and A3A mRNA 
expression by RNAseq from tumors expressing high levels of A3B and low levels 
of A3A (e.g., BRCA, breast invasive ductal carcinoma; LUAD, lung 
adenocarcinoma). In contrast, consistent with physiological expression of A3A in 
myeloid lineage cell types, the positive correlation disappears in acute myeloid 
leukemia, where A3A appears to be expressed at higher levels (LAML, acute 
myeloid leukemia).  
b, Alignment of synthetically generated Illumina-like reads from A3B mRNA 
sequence mapping to A3B (as expected) and mis-mapping to A3A (~25%). 
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Supplementary Fig. S2.2. A3H-I and temporal separation of mutation 
signature associations in select TCGA cohorts. 
Bar plots showing the frequency of clonal and subclonal mutations in the 
indicated cancer types attributable to APOBEC, smoking, and ageing (PRAD, 
prostate adenocarcinoma; BLCA, bladder urothelial carcinoma; SKCM, skin 
cutaneous melanoma; STAD, stomach adenocarcinoma; HNSC, head and neck 
squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LGG, brain 
lower grade glioma; LUSC, lung squamous cell carcinoma; COAD, colon 
adenocarcinoma; READ, rectum adenocarcinoma; GBM, glioblastoma 
multiforme; THCA, thyroid carcinoma). Each bar represents the average 
proportion +/- SEM of signature mutations occurring within each A3H haplotype 
group (i.e., A3H-I versus non-A3H-I). The total number of tumors with 1 or 2 
copies of G105 (A3H-I) or 2 copies of R105 (A3H-II and other haplotypes) is 
indicated within the “Late APOBEC” set of histogram bars. Welch’s two-tailed t-
test for each category was used to calculate the p-values for all A3H-I and non-
A3H-I pairings and none were significant for APOBEC mutation signatures. No 
data means either truly no available data in the indicated category or insufficient 
data for this analysis. 
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Supplementary Fig. S2.3. Weighted mutation distributions by A3H 
haplotype from TCGA breast cancer data (additional analysis of data 
presented in Fig. 1d). 
Bar plots depicting the proportions of cytosine mutations occurring in the 
indicated trinucleotide motifs weighted by motif abundance in the human genome 
in A3B-/- breast cancers with the indicated A3H haplotype combinations (n-values 
and total mutation numbers in parentheses). C-to-T, C-to-G, and C-to-A are 
represented by red, black, and blue shading, respectively. Aging-related cytosine 
mutations in NCG motifs are prevalent in breast tumors regardless of A3H 
genotype, as expected. In contrast, APOBEC signature mutations are only 
evident in A3B-null tumors with A3H-I genotypes and, after correcting for motif 
abundance, TCG and TCA are mutated more than TCT, and TCC becomes the 
least mutated trinucleotide (analogous to biochemical data in Fig. 3e and HIV 
mutation data in Fig. 4c and weighted by motif abundance in Supplementary Fig. 
4).  
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Supplementary Fig. S2.4. Weighted mutation distribution of mutations in 
viral DNA sequences (additional analysis of data presented in Fig. 4c). 
C-to-T mutation distribution in viral DNA sequences weighted by motif 
abundance (NGN) in amplicon recovered from CEM-GFP reporter cells. C-to-T, 
C-to-G, and C-to-A are represented by red, black, and blue shading, 
respectively. The mutations are reported for the viral cDNA strand, rather than 
the conventional genomic strand to facilitate comparisons with tumor mutation 
data. After correcting for motif abundance, TCG and TCA are mutated more 
than TCT and TCC. 
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Supplementary Fig. S2.5. Re-analysis of mutated YTCA vs RTCA motifs in 
breast tumors. 
Scatterplot of the results of a re-analysis of data shown in Supplementary fig. 4g 
of Chan et al., 2016 (ref. #20). This plot shows a slight enrichment of C-to-T 
mutations in YTCA versus RTCA motifs in TCGA breast tumor exomes (each 
data point is derived from one tumor exome; n=164). This bias may be explained 
by A3H-I (tumors represented by red shaded symbols). 
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Supplementary Fig. S2.6. A3A mRNA levels in MCF-7L cells and derivatives 
engineered by Cas9/CRISPR to have an A3B deletion identical to the naturally 
occurring deletion in humans. 
a, Expression of each APOBEC3 family member relative to house-keeping gene, 
TBP, measured by RT-qPCR on a log10 axis for parent clone prior to engineering 
(A3B +/+) and 4 independent daughter clones after Cas9/CRISPR engineering 
(A3B +/- or -/-). Error bars show the standard error of 3 technical replicates. 
b, Average fold change of APOBEC family member expression for daughter clones 
(right) targeted by Cas9/CRISPR relative to parent clone (left). Error bars show the 
standard error of the fold change in expression levels in the daughter clones (n=4; 
mean +/- SEM shown). The 1- to 2-fold differences seen here are not statistically 
significant and likely due to minor variations between clones. 
 76 
 
 
 
 
 
 
 
 
Supplementary Fig. S2.7. WES read coverage of A3B wild-type and A3B-
null breast tumor specimens. 
Representative depth of coverage histograms from WES alignments used to 
positively identify a representative A3B null patient. The top histogram shows 
peaks mapping to the A3B gene that, in the bottom histogram, are not seen in 
truly A3B null individuals. 
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Supplementary Fig. S2.8. Exome mutation loads as a function of A3B and 
A3H genotypes. 
Whisker plots quantifying the number of mutations per tumor grouped by A3B 
and A3H genotypes. The total number of tumors with each genotype is 
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represented by red numbers above each plots. The average is shown, the error 
box represents the first and third quartiles, and the whiskers extend to the 
highest value within 1.5x the interquartile range. Some genotypes are not 
represented in the entire TCGA breast cancer cohort. 
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Supplementary Table S2.1. Fisher’s exact test for cytosine mutation types 
occurring in A3H-I tumors versus A3H-II/III tumors. This table is a statistical 
accompaniment to Fig. 1d. The proportion of each type of cytosine mutation in the A3H-
II/III tumors was compared pairwise to the proportion of the same type of mutation in 
A3B-null breast tumors with the indicated A3H haplotypes. 
 
Tumor 
A3H 
haplotype 
C-to-T transition mutation 
motif C-to-G transversion motif 
TCA TCC TCG TCT TCA TCC TCG TCT 
A3H-I/I 
8.50
E-18 
9.33
E-06 
1.08
E-03 
2.13E-
07 
1.14
E-17 
5.47
E-05 
3.18
E-01 
4.42
E-17 
A3H-II/III 
1.80
E-22 
2.50
E-05 
3.39
E-04 
6.03E-
10 
5.87
E-19 
7.28
E-03 
2.11
E-02 
2.87
E-15 
A3H-I/III 
5.83
E-06 
1.00
E+0 
1.00
E+0 
2.07E-
01 
3.68
E-05 
9.45
E-02 
1.00
E+0 
7.10
E-03 
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Supplementary Software S4.1. countSangerMuts. Perl script to take fastq files 
produced from Sanger sequencing and a reference sequence and then output 
low frequency point mutations with context and whether or not the position or 
read is hypermutated. Available from: 
https://github.com/gjstarrett/countSangerMuts. 
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CHAPTER 3: 
Functional upregulation of the DNA cytosine deaminase APOBEC3B by 
polyomaviruses 
This chapter was adapted with permission from: Verhalen and Starrett, Harris 
and Jiang. (2016) J Virol. 90(14):6379-6386 
Authors: Brandy Verhalen1*, Gabriel J. Starrett2*, Reuben S. Harris2,3 and 
Mengxi Jiang1 
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SUMMARY 
The APOBEC3 family of DNA cytosine deaminases has important roles in 
innate immunity and cancer. It is unclear how DNA tumor viruses regulate these 
enzymes and how these interactions, in turn, impact the integrity of both the viral 
and cellular genomes. Polyomavirus (PyVs) are small DNA pathogens that 
contain oncogenic potentials. In this study, we examined the effects of PyV 
infection on APOBEC3 expression and activity. We demonstrate that 
APOBEC3B is specifically upregulated by BK polyomavirus (BKPyV) infection in 
primary kidney cells and that the upregulated enzyme is active. We further show 
that the BKPyV large T antigen, as well as large T antigens from related 
polyomaviruses, is alone capable of upregulating APOBEC3B expression and 
activity. Furthermore, we assessed the impact of A3B on productive BKPyV 
infection and viral genome evolution. Although the specific knockdown of 
APOBEC3B has little short-term effect on productive BKPyV infection, our 
informatics analyses indicate that the preferred target sequences of APOBEC3B 
are depleted in BKPyV genomes and that this motif underrepresentation is 
enriched on the nontranscribed stand of the viral genome, which is also the 
lagging strand during viral DNA replication. Our results suggest that PyV infection 
upregulates APOBEC3B activity to influence virus sequence composition over 
longer evolutionary periods. These findings also imply that the increased activity 
of APOBEC3B may contribute to PyV-mediated tumorigenesis. 
 
IMPORTANCE 
 83 
Polyomaviruses (PyVs) are a group of emerging pathogens that can 
cause severe diseases, including cancers in immunosuppressed individuals. 
Here we describe the finding that PyV infection specifically induces the innate 
immune DNA cytosine deaminase APOBEC3B. The induced APOBEC3B 
enzyme is fully functional and therefore may exert mutational effects on both viral 
and host cell DNA. We provide bioinformatic evidence that, consistent with this 
idea, BK polyomavirus genomes are depleted of APOBEC3B-preferred target 
motifs and enriched for the corresponding predicted reaction products. These 
data imply that the interplay between PyV infection and APOBEC proteins may 
have significant impact on both viral evolution and virus-induced tumorigenesis. 
 
INTRODUCTION 
Polyomaviruses (PyVs) are a family of small nonenveloped viruses 
containing an ∼5-kb circular double-stranded DNA genome. Most human PyVs 
establish a subclinical persistent infection in healthy individuals (221). These 
viruses can reactivate under various immunosuppression conditions and cause a 
variety of severe diseases, including cancers (222). Among them, BK 
polyomavirus (BKPyV) reactivation is a major concern in kidney and bone 
marrow transplant patients due to the possibility of development of polyomavirus-
associated nephropathy and hemorrhagic cystitis, respectively (223). Recently, 
there have also been increasing reports demonstrating an association between 
BKPyV infection and the occurrence of renourinary tumors (61). JC polyomavirus 
(JCPyV) reactivation can lead to progressive multifocal leukoencephalopathy 
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(PML), a serious demyelinating disease of the brain most prevalent in AIDS 
patients or associated with certain immunosuppressive or immunomodulatory 
treatments (224). Merkel cell polyomavirus (MCPyV) is so far the only human 
PyV directly linked to cancer, having been established to be the etiologic agent 
for Merkel cell carcinoma (MCC) (225). In most MCC cases, MCPyV is found 
integrated into the host DNA, leading to mutations that render the virus 
replication incompetent and simultaneously promoting tumorigenesis (226). 
Even though PyVs have been studied since the 1950s, there are several 
knowledge gaps in PyV biology. First, innate immune responses to PyV infection 
are poorly understood. PyV large T antigens (TAgs) can induce interferon-
stimulated genes (ISGs) in mouse embryonic fibroblasts (227). In contrast, 
studies with BKPyV infection of primary kidney cells have found little evidence of 
ISG activation (228). It is unclear how viral DNAs are recognized and reacted to 
by host immune DNA sensors. Second, there is limited knowledge with regard to 
how these DNA viruses evolve. For BKPyV, different subtypes of viral genomes 
have been demonstrated to evolve from distinct human populations, with the 
archetypal variants being the dominant circulating virus (229). The host cell 
factors that contribute to the molecular evolution of PyVs remain to be 
determined. Finally, although intensely studied, mechanistic details explaining 
how PyVs interact with cellular pathways to influence malignant transformation 
are still far from complete. In addition to the well-known functions of TAg to 
inactivate tumor suppressors such as retinoblastoma protein (Rb) and p53, novel 
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functions of PyV oncoproteins that impact cellular proliferation, transformation, 
and tumorigenesis continue to be discovered (230, 231). 
One arm of the innate immune response in humans is comprised of the 
seven-membered APOBEC3 (A3) family of single-stranded DNA cytosine-to-
uracil (C-to-U) deaminases: A3A, A3B, A3C, A3D, A3F, A3G, and A3H (183). 
Considerable evidence has shown that these enzymes combine to suppress the 
replication of many different DNA-based viruses (183, 232). Susceptible 
pathogens include retroviruses, parvoviruses, herpesviruses, papillomaviruses, 
and hepadnaviruses as well as endogenous retroelements. In contrast to these 
beneficial innate immune functions, recent studies have demonstrated that A3B 
and at least one other A3 enzyme deaminate genomic DNA and are responsible 
for cytosine-biased mutation patterns in many different human cancers (1, 2, 34, 
81, 202, 233). Key evidence includes positive correlations between A3B 
expression levels and genomic mutation loads and the intrinsic biochemical 
preference of the enzyme closely matching the observed cytosine mutation 
biases (i.e., C-to-T and C-to-G mutations occurring within 5′-TCA, TCG, and TCT 
trinucleotide contexts). Moreover, these signature mutations are sometimes 
found in strand-coordinated clusters termed kataegis, which can be coincident 
with sites of DNA rearrangement (179). Finally, there appears to be a 
mechanistic relationship between the antiviral response and cancer mutagenesis, 
as human papillomavirus (HPV)-associated tumor types (cervical, head and 
neck, and bladder cancers) often manifest the highest levels of A3B expression 
and global DNA cytosine mutation biases, A3B expression is induced specifically 
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by HPV infection in relevant cell types (59), and the spectrum of PIK3CA 
activating mutations is biased toward an A3B deamination motif in HPV-positive 
head and neck tumors (60). 
In this study, we set out to determine the relationship between PyV 
infection and the regulation of A3 family members. Using a relevant primary cell 
culture system, we demonstrated a unique and specific regulation of APOBEC3B 
by PyV and its encoded TAg. We also present evidence pointing to potential 
long-term effects of APOBEC-mediated deamination on PyV DNA genome 
composition and evolution. 
 
MATERIALS AND METHODS 
Cell culture, virus growth, and lentivirus production. 
Primary renal proximal tubule epithelial (RPTE) cells were expanded and 
maintained as described previously (234, 235). BKPyV Dunlop strain was grown 
in Vero cells, and titers were determined using an infectious-unit assay (236). 
RPTE cells were infected with BKPyV at a multiplicity of infection (MOI) of 0.5 
infectious unit (IU)/cell as described previously (237). For TAg-expressing 
lentiviruses, JCPyV and MCPyV TAg cDNAs were subcloned from pBS-JT(Int-) 
(238) and pcDNA6.MCV.cLT206.V5 (Addgene), respectively, into lentivirus 
vector pLentiloxpuro (239). Lentiviruses expressing BKPyV TAg, JCPyV TAg, or 
MCPyV TAg were grown in 293T cells and transduced into RPTE cells as 
described previously (239). 
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Western blotting, RNA isolation, RT-qPCR, and single-stranded DNA (ssDNA) 
deaminase assays. 
Protein lysates were harvested at one or 3 days postinfection (dpi) or 
posttransduction, quantified, and immunoblotted as described previously (236). 
The anti-A3B antibody 5210-87-13 is a rabbit monoclonal antibody used at a 
dilution of 1:50 (74). This antibody recognizes both A3B and A3G; however, the 
two proteins can be distinguished by differential gel migration ((74); this study). 
Mouse monoclonal antibody sc-136172 recognizing MCPyV-TAg was used at a 
dilution of 1:500 (Santa Cruz). JCPyV-TAg was recognized by pAb416 as 
described for BKPyV-TAg (236). Total RNA was harvested by removal of 
medium and resuspension in TRIzol (Thermo Fisher), and purification was done 
per the manufacturer's protocol. Reverse transcription-quantitative PCR (RT-
qPCR) was used to quantify A3 transcripts as described previously (59). DNA 
deaminase activity assays were implemented as described previously (59). 
 
siRNA knockdown. 
Nontargeting control and A3B-targeting ON-TARGET plus small interfering 
RNAs (siRNAs) were purchased from Dharmacon (GE Healthcare). Each siRNA, 
at a concentration of 20 nM, was reverse transfected into RPTE cells as 
described previously (234). The cells were infected with BKPyV at 3 days 
posttransfection at an MOI of 0.5 IU/cell as described above. Total cell protein 
lysates were harvested, transferred, and probed for A3B, TAg, VP1 (236), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described above. For 
 88 
viral DNA quantitation, low-molecular-weight DNA was purified and quantified 
using qPCR (29). Viral progeny were quantified using an infectious-unit assay 
(234). 
 
Bioinformatic analyses. 
Sequences from all available complete BK polyomavirus genomes (n = 
302) were acquired from GenBank and aligned using Clustal Omega (240) to 
ensure that the homologous bases from each genome are in identical positions. 
Dinucleotide and trinucleotide motif enrichments for each aligned genome were 
calculated using Markov modeling as described by Ebrahimi and colleagues 
(119). Standard error was calculated and data were plotted using GraphPad 
Prism. Spearman's linear correlation coefficients of the enrichment between 
APOBEC target and product trinucleotides were calculated in the R statistical 
environment. Dinucleotide density was calculated across the BKPyV genome 
using 100-bp nonoverlapping windows. Smoothed fitted lines and 95% 
confidence intervals of these densities were calculated and plotted using the 
ggplot2 package in the R statistical environment. 
 
RESULTS 
BKPyV infection upregulates A3B specifically. 
We first asked whether polyomaviruses modulate cellular A3 levels and 
activity since these viruses have oncogenic potential (241). Using BKPyV and an 
established primary renal proximal tubule epithelial (RPTE) cell culture system 
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(234, 235), we determined whether virus infection alters A3 gene expression 
(Fig. 1). RPTE cells were infected with BKPyV at an MOI of 0.5 IU/cell, and total 
RNA was extracted 1 and 3 days postinfection (dpi) and subjected to RT-qPCR 
analyses (59). One day postinfection is an early time point when the input virus 
has just entered the nucleus (236), whereas 3 dpi represents a time when viral 
replication is robust (234). Among all A3 family members, only A3B expression 
changed significantly by BKPyV infection at 3 dpi (Fig. 3.1). 
We then asked whether the observed increase in A3B mRNA also occurs 
at the protein level (Fig. 3.2A). Total cell lysates were immunoblotted for A3B, 
TAg, and GAPDH. Although the anti-A3B MAb recognized both A3B (lower band) 
and A3G (top band) (74), the immunoblots clearly show A3B protein upregulation 
by 3 dpi (Fig. 3.2A). It is notable that 3 dpi is around the time point that viral TAg 
becomes highly expressed (239). A3G protein levels are also upregulated at 3 
dpi in both mock-infected and virus-infected cells, which could be due to a 
posttranscriptional regulatory process triggered by cellular growth. 
To determine whether increased A3B protein levels also correlate with 
elevated activity, we performed a series of DNA deaminase activity assays using 
whole-cell extracts and an ssDNA oligonucleotide containing a single TCA target 
motif (59). All APOBEC family members, except A3G, prefer this trinucleotide as 
a deamination target. A representative gel and quantification of 3 independent 
experiments are shown in Fig. 2B and C. C-to-U deamination, uracil excision, 
and mild hydroxide treatment combine to break the ssDNA at the site of 
deamination and result in a smaller, faster-migrating fragment. The positive 
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control, purified A3A, converted nearly all of the substrate to product. In 
comparison, all mock-infected or 1-dpi RPTE cell extracts yielded only 5 to 10% 
product accumulation, whereas 3-dpi BKPyV-infected RPTE cell extracts showed 
∼50% product accumulation. Thus, the increase in A3B mRNA and protein levels 
correlated with increases in measurable enzymatic activity that were similar and 
of significant magnitude in RPTE cell extracts. 
 
Polyomavirus TAg is sufficient for A3B upregulation. 
For high-risk HPV, the viral E6 oncoprotein alone is sufficient to trigger 
A3B upregulation (59). Therefore, we hypothesized that polyomavirus TAg may 
trigger a similarly specific response, since TAg and E6 share some overlapping 
functions. To test this idea, we expressed BKPyV TAg in RPTE cells using a 
previously reported lentivirus delivery system (237) and measured the A3 mRNA 
levels as for Fig. 1. Consistent with the BKPyV infection data, the expression of 
TAg increased A3B transcript levels specifically (Fig. 3.3A). As with the full virus, 
A3B upregulation also manifested at the protein level (Fig. 3.3B). Interestingly, 
as previously shown for HIV-1 infection of T lymphocytes (25), the lentiviral 
vector itself caused A3G induction, which was evident at both the mRNA and 
protein levels (Fig. 3.3). 
We then investigated whether A3B upregulation might be a general 
feature of the polyomavirus family. To address this point, we subcloned JCPyV 
and MCPyV TAg cDNA into the lentiviral expression vector pLentiloxpuro as was 
done for BKPyV TAg (239). Similar to the case with BKPyV TAg, we found by 
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both RT-qPCR (Fig. 3.4A) and immunoblotting (Fig. 3.4B and C) that both 
JCPyV and MCPyV TAg induced A3B levels. Interestingly, the magnitudes of 
A3B induction at the mRNA level were similar, whereas the magnitudes at the 
protein level were considerably more variable, with JCPyV causing the highest 
level of induction (Fig. 3.2 to to 3.4). The molecular explanation for this 
difference is not clear at this time, but the data suggest that the different PyV TAg 
proteins may impact A3B regulation differentially at multiple levels. 
 
A3B is not required for productive BKPyV infection. 
Next, we investigated whether upregulated A3B impacts BKPyV 
productive infection. To do this, we used siRNA to specifically knock down A3B in 
RPTE cells and assessed the effects of the knockdown on both cellular 
deaminase activity and viral life cycle. The knockdown of A3B was robust and 
specific, as evidenced by RT-qPCR and immunoblot data (Fig. 3.5A and B, 
respectively). A3B siRNA completely abolished the cellular deaminase activity, 
further confirming that the increased deaminase activity observed in BKPyV-
infected cells originated solely from A3B upregulation (Fig. 3.5C). The specific 
depletion of A3B, however, did not affect viral TAg expression (Fig. 3.5B), viral 
DNA replication (Fig. 3.5D), or production of infectious viral progeny (Fig. 3.5E). 
Collectively, these data suggest that A3B is not necessary for short-term acute 
BKPyV productive infection. 
 
BKPyV genomes display A3B-mediated mutation signatures. 
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To address whether A3B upregulation by BKPyV TAg has had an impact 
on BK polyomavirus genome composition over an evolutionary time frame, we 
acquired and analyzed all available BKPyV complete genomes from GenBank (n 
= 302). We then calculated the enrichment of all dinucleotide motifs using the 
ratio of observed dinucleotides versus expected determined by Markov modeling 
and then focused on dinucleotides containing 3′ cytosines on the positive or 
negative strand (NC or GN, respectively) that can be targeted by APOBEC family 
member deamination and the dinucleotide product that would be produced upon 
deamination and replication of the viral genome (NT or AN). This analysis 
revealed an underrepresentation of TC:GA dinucleotides and an 
overrepresentation of TT:AA dinucleotides, which reflects the preferred 
deamination target of most APOBEC3 family members, including A3B, and the 
products of deamination without repair, respectively (Fig. 3.6A and B). Targets 
and their respective products of deamination by other APOBEC family members, 
such as A3G (CC:GG) or AID (RC:GY), were not observed to be distinctly 
depleted or enriched. 
We next looked at the linear correlation between the A3B strongly 
preferred TCA:TGA trinucleotide to see if the reduction of specific target motifs in 
each genome directly correlated with the enrichment of product trinucleotides 
independently of spontaneous deamination of methylcytosines that would reduce 
NCG motifs, which are known to be underrepresented in polyomavirus genomes 
(35). We observed strong negative linear correlations for both TCA-TTA and 
TGA-TAA trinucleotide pairs, indicating that as one motif is depleted the other 
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increases, strongly supporting a model in which deamination and mutation by 
A3B has shaped BKPyV evolution (Fig. 3.6C and D). Finally, we observed a 
clear inverse relationship between TC and GA dinucleotide density that 
corresponds to either the deamination of the nontranscribed strand of the viral 
genome during transcription or the lagging strand during replication in the BKPyV 
genome (Fig. 3.6E). The latter is supported by several recent studies 
investigating the nature of APOBEC-mediated mutations in various cancers (15, 
44, 66, 67, 242). However, considering the gene organization of the BKPyV 
genome and the bidirectional nature of its genome replication, we cannot at this 
time definitively determine whether transcription or lagging-strand DNA 
replication predisposes to more viral genomic mutation. 
 
DISCUSSION 
In summary, we report here that polyomavirus infection specifically 
upregulates A3B expression and activity and that the viral TAg is sufficient to 
mediate this response. To our knowledge, this is the first work to show a direct 
link between polyomavirus infection and A3B upregulation. Our results also 
reveal that TAgs from multiple human PyVs are capable of upregulating the 
expression and activity of A3B. Given the fact that other small DNA viruses, such 
as HPV, also specifically increase A3B (59), these findings suggest that A3B 
upregulation may be a conserved response to small DNA tumor virus infections. 
Using siRNA knockdown, we showed that A3B is indeed responsible for 
the increased cellular deaminase activity in BKPyV-infected cells (Fig. 3.5C). 
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However, A3B expression does not facilitate or impair productive BKPyV 
infection, as neither viral DNA replication nor viral progeny production was 
affected by A3B depletion (Fig. 3.5D and E). It is possible that since our assays 
only measured initial rounds of viral infection, any subtle restrictive effects of A3B 
may have been missed. Additional investigation of long-term A3B depletion will 
be necessary to assess the functional significance of A3B upregulation over an 
evolutionary time span. 
Although we did not detect immediate viral infection or replication defects 
associated with A3B knockdown, our computational analysis of all publicly 
available BKPyV genomes revealed that BKPyV genomes are depleted of the 
A3B preferred target dinucleotides (TCA:TGA), with a concomitant 
overrepresentation of the corresponding deamination products (TTA:TAA) (Fig. 
3.6A to D). These results suggest that the functional increase in A3B activity has 
exerted long-term evolutionary pressure on the nucleotide composition of the 
viral genomic DNA. It is unclear whether the virus directly induces the A3B 
response to such a level as to avoid restriction while generating additional 
genetic diversity for better fitness as has been observed in HIV-1 (243, 244). Our 
data are also consistent with recent reports that point to possible roles of A3 
enzymes during HPV evolution (143). Interestingly, we also identified a strong 
asymmetry in the abundance TC or its reverse complement GA that corresponds 
to the direction of both transcription and viral genomic DNA lagging-strand 
replication. In support of this potential mechanistic relationship, several groups 
recently reported that APOBEC-mediated mutation of cancer (and model) 
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genomes is preferentially linked to the lagging strand of DNA replication, where 
more ssDNA intermediates would be expected to occur (15, 44, 66, 67). 
 
A range of A3B transcriptional regulation mechanisms in both viral and 
nonviral cancers have been reported (59, 74). It has been postulated that E6 
protein from high-risk HPV derepresses A3B gene transcription via p53 
inactivation (59). From our results, this is an unlikely mechanism for 
polyomavirus-mediated upregulation of A3B, since MCPyV TAg does not bind 
p53 (226) yet it clearly triggers an increase in A3B level (Fig. 3.4C). Another 
study reported that HPV E7 protein, which is known to inhibit Rb function, is 
required for upregulation of both A3A and A3B in HPV-positive normal human 
immortalized keratinocyte cells (140). In multiple cancer cell lines not associated 
with virus infection and for which A3B overexpression is observed, the protein 
kinase C (PKC)/noncanonical NF-κB signaling pathway has been shown to be 
necessary for A3B induction (74). It is possible that each of these studies reveals 
separate pathways regulating the expression and activity of A3B or that may be 
connected through yet-to-be-determined mechanisms. Future investigation on 
polyomavirus TAg will be valuable to determine if a direct or indirect function of 
the TAg is responsible for A3B upregulation. 
Finally, it is possible that TAg-mediated upregulation of A3B may also lead 
to host genomic DNA mutations that contribute to carcinogenesis. Several recent 
studies have implicated BKPyV seropositivity with the development of urothelial 
cancers in immunocompromised patients (61). Polyomavirus-mediated 
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upregulation of A3B may contribute to carcinogenesis in these patients much as 
HPV-mediated upregulation of A3B likely contributes to the tumor evolution and 
the dominant APOBEC signature mutation spectra observed in cervical and 
HPV-positive head and neck cancers (59, 60). Future studies on the host 
genomic DNA mutations occurring in cells infected with BKPyV and tumors 
expressing TAg will address this issue. If this contribution is confirmed, it will add 
to the already diverse functions of TAg for its oncogenic potential. 
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Figure 3.1. BKPyV infection upregulates A3B transcripts. 
RNA was harvested and purified from mock-infected or BKPyV-infected cells, 
and A3 mRNA levels were quantified by RT-qPCR. Histograms report mean A3 
mRNA expression levels in mock- or BKPyV-infected RPTE cells in three 
independent experiments normalized to those of the housekeeping gene TBP. 
Error bars show standard deviations, and Student's t test was used to assess 
significance (**, P < 0.01). APOBEC1, APOBEC2, APOBEC4, and AID mRNAs 
were not detectable. 
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Figure 3.2. BKPyV infection increases A3B protein and cellular deaminase 
activity.  
(A) Total protein lysates from representative cells in Fig. 1 were immunoblotted 
for A3B (the antibody also recognizes A3G), TAg, and GAPDH. Shown are 
representative blots from three independent repeats. (B) Representative gel 
image of a DNA cytosine deaminase assay performed with cell extracts from 
mock- or BKPyV-infected cells as in panel A. Recombinant purified APOBEC3A 
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was used as a positive control, and reaction buffer alone was used as a negative 
control. S, substrate; P, product. (C) The deaminated products were quantified by 
the Fiji gel analysis tool (http://fiji.sc/). Shown are combined results from three 
independent repeats. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
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Figure 3.3. PyV large T antigen is sufficient for A3B upregulation.  
RPTE cells were mock transduced, transduced with an empty lentivirus control, 
or transduced with a lentivirus expressing BKPyV TAg. A3 family member mRNA 
levels (A) and A3B protein levels (B) were examined as for Fig. 3.1 and 3.2, 
respectively. Note that A3A mRNA was detected but at too low a level to be 
graphed in panel A. **, P < 0.01; ****, P < 0.0001. 
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Figure 3.4. Other human PyV large T antigens also upregulate A3B.  
RPTE cells were transduced with lentivirus expressing JVPyV or MCPyV Tag, 
and A3B mRNA and protein levels were determined by RT-qPCR (A) and 
immunoblotting (B and C), respectively, as in Fig. 3.3. 
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Figure 3.5. Knockdown of A3B eliminates deaminase activity during BKPyV 
infection but does not affect BKPyV lytic infection. 
Cells were left untreated or treated with nontargeting control (NTC) siRNA or 
A3B-targeting siRNA for 3 days, followed by mock infection or infection with 
BKPyV for 3 days. (A) A3 family member mRNA levels were determined as for 
Fig. 1. Shown are combined results from three independent experiments with 
infected cells. (B) Total protein lysates were immunoblotted for A3B, TAg, and 
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GAPDH. Shown is a representative result from three independent repeats. (C) 
Representative gel image and quantitation of a DNA cytosine deaminase assay 
(as for Fig. 2) performed with cell extracts as for panel B. (D and E) Bar graphs of 
BKPyV viral DNA fold replication (D) and viral infectious units (E) produced from 
infected cells treated with NTC or A3B-targeting siRNA. Shown are combined 
results from three independent repeats. 
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Figure 3.6. Evidence for APOBEC mutagenesis on the BKPyV polyomavirus 
genome.  
(A) Over- and underrepresentation with standard errors of potential APOBEC-
targeted cytosine dinucleotides in the BKPyV genome. (B) Over- and 
underrepresentation of dinucleotides produced by the deamination of the target 
dinucleotides in panel A. (C and D) Scatter plots and best-fit lines representing 
the linear correlations between A3B preferred target and the respective product 
 105 
trinucleotides TCA/TTA (C) and TGA/TAA (D). (E) Line graph of TC/GA 
dinucleotide density across the BKPyV genome with viral genes and transcription 
direction annotated at the bottom. 
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SUMMARY 
 
Merkel cell polyomavirus is the primary etiological agent of the aggressive 
skin cancer, Merkel cell carcinoma (MCC). Recent studies have revealed that UV 
radiation is the primary mechanism for somatic mutagenesis in non-viral forms of 
MCC. Here we analyze the whole transcriptomes and genomes of primary MCC 
tumors. Our reveal that virus-associated tumors have minimally altered genomes 
compared to non-virus-associated tumors, which are dominated by UV-mediated 
mutations. Although virus-associated tumors contain relatively small mutation 
burdens, they exhibit a distinct mutation signature with observable 
transcriptionally biased kataegic events. In addition, viral integration sites overlap 
focal genome amplifications in virus-associated tumors suggesting a potential 
mechanism for these events. Collectively, our studies indicate that Merkel cell 
polyomavirus is capable of hijacking cellular processes and driving tumorigenesis 
to the same severity as tens of thousands of somatic genome alterations. 
 
IMPORTANCE  
 
A variety of mutagenic processes that shape the evolution of tumors are 
critical determinants of disease outcome. Here we sequenced the entire genome 
of virus-positive and virus-negative primary Merkel cell carcinomas (MCC) 
revealing distinct mutation spectra and corresponding expression profiles. Our 
studies highlight the strong effect that Merkel cell polyomavirus has on the 
divergent development of viral MCC compared to the somatic alterations that 
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typically drive non-viral tumorigenesis. A more comprehensive understanding of 
the distinct mutagenic processes operative in viral and non-viral MCC has 
implications for the effective treatment of these tumors. 
 
INTRODUCTION 
 
Merkel cell carcinoma (MCC) is an aggressive skin cancer, associated with 
advanced age, excessive UV exposure, immune deficiencies and presence of 
the human virus, Merkel cell polyomavirus (MCPyV) (155, 245). MCPyV DNA is 
clonally integrated in approximately 80% of MCC and the expression of viral T 
antigens is required for driving tumor cell proliferation (155, 246, 247). Deletion 
mutations of the C-terminus of the viral large T antigen are common in MCC 
tumors, rendering the viral genome replication-deficient (248). The effect of this 
integration event and the constitutive expression of viral proteins on the host 
genome structure and somatic mutation profile of the tumor genome have not 
been studied in depth. Using in vitro models, it has been suggested that 
expression of full length MCPyV large T antigen is able to disrupt the stability of 
the host genome and upregulate the mutagenic enzyme APOBEC3B (192, 249). 
Another small DNA tumor virus, human papillomavirus (HPV), also triggers the 
upregulation of the DNA cytosine deaminase, APOBEC3B, and is likely 
responsible for the majority of mutations observed in HPV-positive cervical, head 
and neck squamous cell, and bladder carcinomas (2, 34, 59, 138, 250). To date, 
there has been no high-coverage whole genome sequencing performed in MCC. 
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High-throughput sequencing has been highly beneficial to many fields 
including cancer biology and virology. Sequencing shows individual mutations as 
well as mutation patterns or signatures, which implicate distinct mutational 
processes acting within tumors over time. These processes are responsible for 
intratumoral genetic heterogeneity and provide the necessary substrate for 
evolution, survival, and metastasis (4, 16, 179, 180). Additionally, these studies 
have been critical for our understanding of cancer subtypes and how to better 
improve targeted therapies. However, to date, deep sequencing projects have 
been restricted to more common cancers studied such as breast cancer by large 
consortia. Now due to decreased sequencing costs, rare cancers can be 
sequenced to expand our knowledge on how these tumors arise. In fact, early 
next-generation sequencing was used to discover MCPyV from primary human 
tumors in 2008 (157). Here we leverage modern sequencing platforms to 
sequence the RNA and DNA from six primary MCC tumors and analyzed both 
the mutation spectra and corresponding transcriptome characteristics based on 
detectable Merkel cell polyomavirus transcripts.  
 
RESULTS 
 
Virus-negative MCC tumor genomic DNA is heavily mutagenized.  
To determine if a tumor expressed viral genes, RNAseq reads obtained from 
6 MCC tumor specimens were aligned to a reference containing both the human 
(hg19) and MCPyV (NCBI) genomes (Table 4.1). Merkel cell polyomavirus T 
antigen transcripts were readily detected in 4 out of 6 tumors. Tumors with viral 
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transcripts were defined as virus-positive, whereas those without were defined as 
virus-negative. 
We performed high-coverage (~100X) whole genome sequencing of two 
virus-positive MCC tumors and one virus-negative MCC tumor and analyzed 
somatic mutations, copy number variants and structural rearrangements 
compared to the normal somatic DNA isolated from PBMC isolated from the 
corresponding patients. What was exceptionally striking was that the virus-
negative MCC tumor had over 30 fold more somatic mutations with a total of 
127,236 mutations in addition to many copy number alterations and inter-
chromosomal translocations compared to the two virus-positive tumors (Fig. 
4.1A-B, Table 4.1). This mutation load is consistent with recent reports from 
targeted sequencing (159, 251, 252). Within all tumors, the majority of mutations 
fell into intergenic regions, but a large fraction of these mutations (37.7%) 
occurred near or within genes that did not significantly differ based on tumor type 
(Table 4.2). Within the intergenic regions, virus-positive tumors did show greater 
than two-fold enrichment of mutations in both HERVK and simple repeat regions 
of the genome, but not in any other type of mobile element compared to the 
virus-negative tumor. 
By functionally annotating the mutations overlapping genes, the virus-positive 
tumors had a cumulative total of 12 missense and nonsense mutations targeting 
genes implicated in cancer as annotated by COSMIC; whereas, the virus-
negative tumor harbored 51 missense and nonsense mutations targeting 
COSMIC annotated genes. Of these 51 mutations, 34 were predicted by either 
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SIFT or PROVEAN to be deleterious to the function of the primary protein 
product. The effects of these mutations on all potential protein products are 
detailed in Table 4.S1. Of note, there are damaging mutations predicted to occur 
in CBFA2T3, CHEK2, FANCC, FLI1, ITPR1, MUC16, NF1, NUTM, PTPRB, 
PTPRR, SETX, and STK11IP in the virus-negative tumor, which may further 
promote tumor survival and evolution. 
The relative abundance of structural variants in each tumor genome 
mimicked the profiles of the aforementioned somatic mutations. Tumor-088 had 
no amplifications or deletions corresponding to known copy number variations in 
cancer. The other virus-positive tumor-076 had a single copy amplification of 
MDM4 and single copy deletions of PTEN and SUFU. In stark contrast to the 
virus-positive tumors, the virus-negative tumor-050 had single copy 
amplifications of EGFR and JUN and single copy deletions of APC, ATM, BIRC, 
BRCA1, BRCA2, FANCA, FANCD2, CDKN2A, MLH1, PAX5, PBRM1, RB1 and 
VHL. RB1 function may be absent in sample-050 as there was a somatic G-to-A 
transition mutation in the remaining allele at position chr13:49047495. This base 
substitution is predicted to interfere with the splice acceptor for the adjacent exon 
20 with the potential to produce a non-functional protein. Of the detected inter-
chromosomal translocations in these tumors, none of them reflected known 
annotated translocations in cancer. To further define and consolidate the impact 
of the sheer number of somatic alterations in the non-viral tumor we performed 
pathway analysis on the aforementioned variants. This analysis predicted 
significant inhibition of p53, ATM, and BRCA1 signaling and inhibition of DNA 
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damage checkpoint regulation all of which would contribute to the observed 
severe genome instability and the ability of the tumor to survive the 
corresponding stress (Fig. 4.1C). Activation of pathways observed in other 
cancers such as glioma, glioblastoma, and metastasis in colorectal cancer were 
also predicted and were commonly linked by the inactivation of ATM and 
CDKN2A and amplification of EGFR. Although EGF signaling was also predicted 
to be significantly impacted, it was neither activated nor inhibited due to 
inactivation of ATM and ITPR1 and amplification of EGFR and JUN. 
 
Different mutation signatures occur in virus-positive and virus-negative tumors.  
Recent studies have highlighted and classified the multitude of mutation 
processes critical for shaping tumor development and evolution across cancers 
(176, 215, 253). Upon subdividing the detected somatic mutations in these MCC 
tumors by base change and trinucleotide context to visualize the overall mutation 
landscapes of these tumors, even more differences were revealed between 
virus-positive and virus-negative tumors. The MCPyV-positive tumors were highly 
similar to each other and showed mutation profiles that were modestly enriched 
for both C-to-T and T-to-C mutations (Fig. 4.2A). In contrast, the MCPyV-
negative tumor showed a dominant proportion of C-to-T mutations in both TCN 
and CCN trinucleotides, corresponding to cross-linked pyrimidine dimers induced 
by UV-radiation and subsequent error-prone repair (8, 19). Using somatic 
signature prediction software, we modeled three signatures from these samples 
and determined their relative contribution to each tumor indicating that the virus-
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associated tumors may represent a mixture of mutational processes including a 
small proportion of UV-mediated mutations evident through a slight enrichment 
for C-to-T mutations in dipyrimidine contexts (Fig. 4.2A and data not shown). 
Hierarchical clustering revealed that these mutation profiles are most similar to 
signatures 5 and 16 for the MCPyV-positive tumors and signature 7 for the 
MCPyV-negative tumor as defined by Alexandrov and colleagues (4) (Fig. 4.2B).  
At this time, signatures 5 and 16 currently have no known etiologies. 
However, it was recently reported that the mutations commonly observed in liver 
cancer, corresponding to signature 5, exhibit a bias for mutations on the non-
transcribed strand of genic DNA, termed transcription-coupled damage (TCD) 
(15). To address whether the observed signatures from MCC exhibit similar 
mutation asymmetries, we analyzed the replication and transcription strand 
biases of the somatic mutations for the MCPyV-negative and MCPyV-positive 
tumors using methods published by Haradhvala and colleagues (15). Consistent 
with observations in liver cancer, the T-to-C base substitutions in the virus-
positive MCC tumors had a clear preference to accumulate on the non-
transcribed strand of genes. The overall mutation density remained constant or 
increased and the bias became more pronounced as the expression of the gene 
increased strongly indicating that these were mediated by TCD (Fig. 4.2C). 
Additionally, the C-to-T mutations in the virus-negative tumor, corresponding to 
signature 7 and attributable to UV-mediated DNA damage, exhibited a strong 
bias for the non-transcribed strand, with mutation density decreasing as 
expression of the gene increased. Signature 7 mutations are also dominant in 
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other forms of skin cancer such as basal cell carcinoma, squamous cell 
carcinoma, and melanoma (254–256). The transcription-biased mutation 
asymmetry we observed is also consistent to that observed in melanoma and 
transcription-coupled repair of UV-mediated damage. No significant replication-
biased mutation asymmetries were observed in MCPyV-positive or negative 
tumors (Fig. 4.2C). Interestingly there was also no strong evidence for signature 
1 mutations in either tumor type, which are the most common mutations detected 
in cancer and are associated with aging and the spontaneous deamination of 5-
methycytosines in CpG motifs. Furthermore, there was no similarity to signatures 
2 or 13 attributed to APOBEC-mediated mutation and have been observed in 
many cancers and are especially prominent in HPV-associated cancers (2, 34). 
To further characterize the mutational processes in MCC, we evaluated the 
density and distribution of mutations across the entire genome by calculating 
intermutational distance for each somatic base substitution and plotting the 
values by position (Fig. 4.3A). As anticipated from other UV-mutated tumors and 
the high mutation burden the virus-negative tumor had a generally dense 
distribution of mutations across the genome with any clusters or other patterns 
occluded by the UV-attributable C-to-T transitions. The virus-positive tumors had 
a sparser distribution of mutations across the genome, but this highlighted 
several unique mutation clusters or kataegis events in tumor-076, but none in 
tumor-088 (Fig. 4.3A). Several non-specific clusters were observed in more than 
one sample and are likely due to errors from the sequencing platform. The 
clusters observed on chromosome 10 for tumor-076 appear to correspond to 
 116 
several copy number alteration events that were observed and this is consistent 
with kataegis events typically being associated with DNA double stranded breaks 
(Fig. 4.3B). The minimal amount of copy number alterations in tumor-088 further 
supports that kataegis events in viral MCC correspond to DNA breaks. By 
plotting the abundance and context of each base substitution located at these 
kataegis events reveals a mutation profile similar to both APOBEC and the 
recently identified non-APOBEC mediated kataegis events as observed in breast 
cancer whole genome sequencing implicating multiple sources of DNA damage 
(Fig. 4.3C) (181). Evaluation of more viral MCC tumors at the whole genome 
level will reveal whether kataegis is a common characteristic of the mutation 
profile and the mechanism by which they occur.  
 
Whole transcriptome analysis reflects the state of the genome. 
To further delineate the differences between virus-positive and virus-negative 
tumors and establish potential mechanistic effects of the previously reported 
somatic genome alterations, we used RNAseq to analyze the full transcriptomes 
of the 4 virus-positive and 2 virus-negative MCC tumors. At the transcriptome 
level, all MCPyV-positive tumors formed a discrete cluster when analyzed by 
principal component analysis indicating a high level of homogeneity while the 
MCPyV-negative tumors were highly divergent and did not form a cluster (Fig. 
4.4A). There were over 1100 significantly differentially expressed genes between 
MCPyV-positive and -negative tumors (Table 4.S2). Notably, the MCPyV-
negative tumors expressed significantly reduced levels of DNA damage response 
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genes, such as MSH2, MLH1 and Fanconi Anemia family genes, FANCA and 
FANCC, suggestive for a potential mechanism for the accumulation of the large 
amount of somatic mutations identified in the MCPyV-negative genome and the 
low number of somatic mutations in the MCPyV-positive tumors (Table 4.S2). 
Many of these relative decreases in gene expression levels, such as MLH1, 
correspond to our previously described alterations to genomic DNA indicating 
functional implications of these variants. Of particular interest, the P16INK4A 
isoform of the tumor suppressor CDKN2A shows a significant decrease in the 
virus-negative tumors compared to the virus-positive tumors. This alteration 
suggests that a common mechanism may promote tumor development, 
potentially mediated by the aforementioned single copy deletion of the CDKN2A 
locus observed in our virus-negative whole genome sequencing data (Fig. 4.4B). 
We used Ingenuity Pathway Analysis software (Qiagen) to study differentially 
expressed genes. These results indicated that virus-negative MCC tumors were 
significantly enriched for genes associated with basal cell carcinoma signaling 
pathways and many of these genes are associated with the WNT signaling 
pathway, which is consistent with results inferred previously for MCC from 
microarray data (Fig. 4.4C) (257). Many of these pathways were also predicted 
by the pathway analysis of somatic variants shown in Fig. 4.1C and highlighted 
in bold. In contrast, virus-positive tumors show significant upregulation of the 
GABA receptor signaling pathway, commonly associated with neuronal 
development, estrogen-mediated S-phase entry, and a mild, positive enrichment 
for WNT signaling. GABA receptor signaling pathway enrichment was defined by 
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elevated expression of GABRB3 and potassium channel genes, KCNN1, 
KCNN2, and KCNQ3, and decreased expression of ADCY2, which have all been 
indicated as important in tumor growth (258–260). Interestingly the pathways 
enriched in our MCPyV-positive tumors also included cell cycle genes, cyclin A1 
and cyclin D1, which are detailed in Fig. 4.4C. However, in contrast with a 
previous publication, we did not observe a difference between tumor types in 
regards to the expression of genes associated with tumor-infiltrating 
lymphocytes, such as CD3D (257).  
 
Virus integration sites result in focal host genome amplifications and fusion 
transcripts.  
Virus integration has the potential to disrupt or alter the function of genes 
as well as produce novel fusion transcripts. To identify the integration sites in our 
virus positive whole genome alignments, we used a custom pipeline to discover 
reads that map to both the host and viral genomes. Tumor-076 revealed two 
integration sites on chromosome 1 that are approximately 40kb apart. Discordant 
read pairs show that these insertional breakpoints are linked to the C-terminus 
end of Large T antigen (Fig. 4.5A). Tumor-088 had one integration site detected 
on chromosome 6, which mapped to the N and C termini of Large T antigen with 
a proportion of reads supporting the deletion of the DNA binding domain (Fig. 
4.5B). 
 A previous publication reported that HPV integrants frequently coincide 
with focal copy number alterations in cancer cell lines and HNSCC primary 
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tumors (261). To determine if this was also a characteristic of MCPyV integration 
events, we examined relative copy number of the host genomes across these 
regions. The location of all integration events in each patient overlapped with 
single copy amplifications of the host genome (Fig. 4.5C, 4.5D). The integrants in 
tumor-076 flank a tandem duplication indicating that this amplification and these 
copies of the viral genome were mediated by the same viral integration event 
(Fig. 4.5C). The insertion site in tumor-088 is located near the 3’ edge of and 
within a tandem duplication event amplifying chr6:20646000-20768000 (Fig 
4.5D).  
To resolve the insertion sites between viral and host DNA, we de novo 
assembled all of the read pairs that mapped to the host and viral genomes into 
fusion contigs. The reads were remapped to these contigs to identify their original 
positions from the viral and host genomes (Fig. 4.5G, 4.5H). We do not detect 
host-virus fusion contigs that fully explain the integration events in tumor-076 and 
instead have numerous contigs comprised of only viral sequences (Fig. 4.5E, 
4.5G & Fig. 4.S1). This analysis indicates that the integration event likely has 
complex rearrangements and potential amplifications of the MCPyV genome at 
the 5’ end of the amplification. Generally, these data do support a common 
breakpoint in the C-terminus of Large T antigen and a DNA level deletion of the 
DNA binding domain of Large T antigen that was observed in the RNAseq data 
(Fig 4.5A, 4.6A). For tumor-088, we assembled two contigs containing host and 
viral sequences that support the junctions of a single identical integrant and the 
deletion of the DNA binding domain of Large T antigen (Fig. 4.5F, 4.5H).  
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 As was proposed for HPV integration, our data support a similar looping 
model for the focal amplifications observed near the MCPyV integration sites in 
MCC (Fig. 4.5I, 4.5J) (261). This model proposes that after MCPyV integration, 
transiently circular DNA is formed and activation of the viral origin of replication 
amplifies neighboring regions of the host genome. Dissociation of this transiently 
circular DNA then is followed by recombination of the newly amplified regions 
and subsequent repair. Depending on the location of recombination and repair, 
the amplified regions can result in multiple virus-host concatemers as observed 
in tumor-076 or can appear as a single virus integration event within a tandem 
duplication as observed in tumor-088 (Fig. 4.5I, 4.5J). 
To further characterize the integration sites of MCPyV and address whether 
these are affecting host genes, we aligned RNAseq reads from the virus positive 
tumors to the viral genome and assembled viral contigs from these reads using a 
custom analysis pipeline (262). Each of these tumors expressed at least part of 
the viral early region and in each of these cases the Large T antigen was 
truncated and nearby host gene expression was unaffected. Of the two tumors 
that we also had WGS data for, sample-088 (Fig. 4.6B) contained a single 
chimeric junction within two overlapping genes RP3-348I23.2 and CDKAL1 (at 
chr6: 20,757,000). The observed contig indicates a deletion between coordinates 
1,560-2,754 of the viral genome, causing a frameshift after V311 that results in a 
321aa amino-terminal truncation of Large T antigen, which are also supported by 
the integration analysis from the WGS reads. Analysis of tumor-076 (Fig. 4.6A) 
resulted in one MCPyV contig, which aligns to positions 146-429, 861-1,580 and 
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2,254-3,096. The deletion causes codon D318 (positions 1,578-1,580) to be 
placed immediately in frame with a stop codon (positions 2,254-2,256) encoding 
a 318aa amino-terminal truncation of Large T antigen. However, no chimeric 
junctions were detected in this sample. 
For tumor-090, the read depth graph shows expression of the full-length 
Large T antigen transcript and truncated variants (Fig. 4.6C). One chimeric 
junction was mapped at chr20:32,132,694 within CBFA2T2. Another chimeric 
junction was mapped between exon 1 of CBFA2T2 and the large T antigen splice 
acceptor at position 861 in MCPyV. This analysis also suggests additional copies 
of the viral genome, either integrated or episomal, are present in this sample. 
There are two C-to-T nonsense mutations that change Q432 and Q504 to stop 
codons that we predict to encode for a 432aa C-terminal truncated large T 
antigen. We mapped four chimeric junctions in tumor-146 (Fig. 4.6D). One 
chimeric junction was mapped within an intron of FLJ46066 (approximately at 
chr3: 182,180,601) indicating a chimeric transcript anti-sense to the FLJ46066 
gene. The other three chimeric junctions mapped within the ECH1 (at host 
positions chr19: 39,307,703 and chr19: 39,307,378). The viral detection pipeline 
resulted in two MCPyV contigs. One contig shows a deletion occurring between 
coordinates 1,330-1,877 of the viral genome. This results in a frameshift after 
codon P234 resulting in a 240aa amino-terminal truncation of Large T antigen. 
The other contig aligns to VP1 and VP2. 
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DISCUSSION  
 
By combining the analyses of point mutations, copy number alterations, 
structural variants, and viral integration sites of primary MCC tumors at the single 
nucleotide resolution level for both the transcriptome and whole genome, we 
identified numerous common features and pathways manipulated in virus-
associated MCC and distinct features from non-viral associated MCC. First, the 
distinct dichotomy between the number of mutations and the mutation signatures 
of the virus-positive and the virus-negative tumors is surprising, since UV-
damage has generally been thought to be a significant contributing factor to both 
types of MCC (245, 263). Although only one virus-negative MCC tumor was 
subjected to WGS here, recent targeted sequencing studies support the 
likelihood that this tumor type is likely to have a high UV mutation burden (159, 
251).  
Conversely, viral MCC has a low mutation load and is enriched for signature 
5, which has been identified previously in many cancers, but most well defined in 
hepatocellular carcinomas (15). Although signature 5 does not yet have a 
accepted mechanism, it is linked to the recently identified process of 
transcription-coupled damage, which results in an enrichment of T-to-C 
mutations on the transcribed strand (15). Liver tumors harboring this signature 
were not enriched for hepatitis virus infection, indicating that, at this time, this is 
not a common virus-mediated mutation process (4, 6). Our work also identified 
kataegis in one virus-positive tumor overlapping with apparent sites of DNA 
breaks, which previously had been associated primarily with APOBEC-mediated 
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cancers, with non-APOBEC related events only recently identified in a large 
study of 560 breast cancer genomes (181). The similarity of these events in MCC 
to both types of kataegis has the potential to better characterize the mutagenic 
processes active in virus-associated MCC and how this contributes to 
tumorigenesis.  
Nearly all cervical and a growing proportion of head and neck carcinomas 
are caused by the similar small dsDNA virus, HPV, and exhibit high APOBEC3B 
expression and a dominant proportion of APOBEC-signature mutations (34, 59, 
60, 131, 264). Considering this, it is unusual that there is no strong evidence of 
APOBEC3 family upregulation or activity in MCPyV-positive tumors. A recent 
study also demonstrated that another human polyomavirus, BK polyomavirus, is 
able to upregulate APOBEC3B in infections of primary renal tubule epithelial cells 
and this is at least partially mediated by large T antigen expression (192). This 
same study also demonstrated that MCPyV Large T antigen is able to upregulate 
APOBEC3B in this cell culture system. Possible explanations for this paradox is 
that upregulation of APOBEC3B in the cell of origin for viral MCC is not possible 
due to chromatin-mediated gene silencing or, since only Large T antigen was 
tested, another protein involved in MCPyV infection prevents TAg-mediated 
activation of APOBEC3B. 
It is curious that the continued expression of viral genes in patients appears 
to associate with the maintenance of the host genome integrity compared to 
virus-free tumors considering the ability of MCPyV to integrate into the host 
genome and the apparent necessity of this event to establish cancer. From the 
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standpoint of the virus, less DNA damage is beneficial for continued proliferation 
of the host cell and the virus as integration is not part of the normal viral life cycle 
and results in a replication deficient virus. This provides a potential explanation 
as to why MCC is an exceptionally rare cancer despite upwards of a 90% 
prevalence of MCPyV infection in the human population (265). As seen in this 
study, when integration does occur, these events coincide with host genome 
amplifications. These amplifications flanking MCPyV integrants are consistent 
with observations of CNVs flanking HPV and HBV integrants in HNSCC and 
HCC, respectively (261, 266–268). Additionally, integration of MCPyV into 
chromosomes 1 and 6 have both been previously observed at elevated 
frequencies with breakpoints primarily occurring in the second exon of Large T 
antigen (269). This suggests potential integration hotspots, yet all observed 
integration sites have been unique. Compared to HPV-positive tumors and cell 
lines, we observed less complex integration events in each tumor and these 
events overlapped with single copy amplifications, whereas, HPV integrants have 
been shown to flank amplifications up to 90-fold. 
Generally, our data support the hypothesis that oncogenic viruses, including 
HPV, HBV and MCPyV, are able to induce focal genomic CNVs and potentially 
greater genomic instability through the activation of their origin of replication after 
integration into the host genome. Despite CNVs being infrequent in virus-
associated MCC, there are several recurrent copy number alterations that have 
been observed between studies that may be initiated by virus mediated genome 
instability. For example, SUFU in our virus-positive tumor-076, which mirrors a 
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recent report that identified an inactivating mutation of SUFU in another MCC 
tumor. This particular tumor was characterized by an absence of mutations in 
any of more than 300 cancer related genes sequenced, which based on our 
results and others suggests that it was also a virus-associated MCC (270). 
Analysis of the host-virus DNA junctions were limited in this study by the insert 
size and the 20bp mappable length of the reads, but can be improved in future 
studies using different sequencing technologies. It would also be interesting to 
test whether MCPyV can seed recurrent CNV. Expanded genome-wide studies 
of virus-associated MCC will also reveal if the observed copy number alterations, 
structural variants, and integration sites are common characteristics and 
mechanisms of virus-associated MCC. The non-virus-associated tumor in this 
study exhibited many more somatic alterations compared to the virus-associated 
tumors that frequently observed in other skin tumors (10). Many of these 
alterations affected the DNA damage response in the cell, which have important 
implications for treatment and the evolution rate of the tumor. Ultimately our 
study highlights the overwhelming ability of Merkel cell polyomavirus to hijack 
specific cellular processes and produce a tumorigenic phenotype without 
necessitating the accumulation of hundreds or thousands of somatic mutations 
and may have important implications for how these tumors progress.  
 
MATERIALS AND METHODS 
 
Sample collection.  
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Primary tumor tissue and whole blood were collected from a cohort of six 
individuals summarized in Table 1. Patients ranged from 64 to 82 years of age, 
five white males and one white female. Most shared a previous medical history of 
non-melanoma skin cancer and actinic keratosis. Other medical history includes 
coronary artery disease, gout and rheumatoid arthritis. Primary tumor sites were 
variable for each patient, although most tumors were found in areas of the skin 
susceptible to increased sun exposure including the forehead, arm and ear.  
 
DNA sequencing, alignment and analysis.  
Tumor and normal (PBMC) DNA preparations (10 g) were sequenced by 
the Beijing Genome Institute (BGI) on the Complete Genomics platform to an 
average of 100x depth (271). Alignment of reads and calling of somatic mutation, 
copy number, structural variants and annotation of repetitive elements were 
performed by BGI using their analysis pipeline. Somatic mutations were filtered 
out if they did not score as SQHIGH as defined by BGI analysis workflow. 
Additionally, somatic mutations that had identical 41mer flanking sequences were 
removed. Only mutations occurring in genes implicated in cancer by the COSMIC 
cancer gene census were further characterized (272). Functional implications for 
missense mutations were determined using the SIFT and PROVEAN v1.1.3 
protein batch analysis tool submitted through the J. Craig Venter website (273–
276). COSMIC annotations were further used to annotate copy number 
alterations and structural variants for genes commonly altered in cancer. 
Pathway analysis was conducted using the core analysis pipeline of the Ingenuity 
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Pathway Analysis software (IPA) (Qiagen) and pathways were only further 
analyzed if an enrichment z-score was able to be calculated and only pathways 
with an enrichment p-value less than 0.05 were considered statistically 
significant. Z-scores are a measure of the relative enrichment or depletion of a 
pathway in the dataset. 
 
RNA sequencing, alignment and analysis.  
RNA was purified using Ultra RNA Library Prep Kit (New England 
BioLabs) and was sequenced (0.1 g total) on the Illumina HiSeq 2500 platform 
with paired end flowcells and 50 cycles in each direction. Sequences were 
aligned to a combination of the hg19 and MCPyV genomes (NCBI) using 
TopHat2 (277). Differential expression analysis was performed with CuffLinks 
and DESeq2 (277, 278). Only genes with a differential expression q-value of less 
than 0.05 and a greater than or equal to 3-fold change in expression in virus-
positive vs. virus-negative samples were considered significant. To focus on 
relevant genes, only genes implicated in cancer by the COSMIC cancer gene 
census, E2F-regulated genes, and leukocyte-related genes were further 
characterized (272). Pathway analysis was completed by submitting the log-
base-2-fold change of the top differentially expressed genes between MCPyV 
positive and negative tumors into the core analysis pipeline of IPA (Qiagen). The 
nature of this analysis indicated that pathways enriched for virus-positive tumors 
were pathways with the highest positive z-scores as calculated by IPA and virus-
negative tumors were pathways with the lowest negative z-score, only pathways 
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with an enrichment p-value less than 0.05 were considered statistically 
significant. Principal component analysis was performed using the R statistical 
package with all annotated genes. 
 
Mutation profile analysis.  
Flanking 5’ and 3’ bases at the site of each somatic mutation were collected 
from the hg19 reference genome. Proportion of each mutation in its trinucleotide 
context was calculated in respect to the total number of somatic mutations. 
Mutation profiles were plotted using the R statistical software with the 
“SomaticSignatures” package (279). This package was also used to predict 
mutation signatures from the somatic mutations of each tumor genome. To 
determine mutation strand asymmetries and produce subsequent plots, we input 
somatic mutations grouped by MCPyV status into the AsymTools MatLab script 
(15). 
Mutation clusters (kataegis) was evaluated by taking the distance in base 
pairs from one somatic single base substitution to the previous mutation or 
intermutational distance (IMD). The genomic distributions of mutations were 
plotted using ggplot2. Clusters of mutations were determined by the same 
method as Alexandrov and colleagues (4), which they defined as at least six 
concurrent mutations with an average intermutational distance less than 1000bp. 
Unique events did not overlap clusters observed in other samples, which are 
likely a byproduct of sequencing errors. 
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Virus integration site identification pipeline.  
Half mapped read pairs were extracted from the whole genome 
alignments using a custom script. Due to the variable, gapped structure of 
Complete Genomics reads we only used the 20bp continuous segment located at 
the beginning of the read (271). These read pairs were then mapped back to the 
reference genome using Bowtie2 and the virus-host reference genome used for 
the RNAseq analysis (280). After determining their mapping coordinates from the 
Bowtie2 alignment, discordant read pairs were extracted and de novo assembled 
using velvet with a word size of 11bp (281). The discordant reads were then 
remapped to the new contigs using nucleotide BLAST with “short” settings and a 
word size set to 9bp (282). Using these BLAST results, the de novo assembled 
contigs were filtered to identify those that contained reads that initially mapped to 
the human and viral genomes. The resulting junctions were visualized by plotting 
out the mapped starting positions of the reads fitting the aforementioned criteria 
(according to the BLAST alignment) and coloring them by origin (viral or host) 
with ggplot2. 
 
Virus-host fusion transcript identification pipeline.  
Identification of viral integration sites follows the pipeline suggested by the 
SummonChimera (http://www.biomedcentral.com/1471-2105/15/348) software. 
Raw fastq paired-end reads were mapped with default Bowtie2 parameters to a 
database composed of the Merkel Cell Polyomavirus (HM355825.1) and Human 
hg19 genomes. Next, all unmapped reads are input into BLASTN with 
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parameters ‘–word_size 16’ and ‘-outfmt 6’ and compared against the Merkel Cell 
Polyomavirus genome. Then, all reads with a BLASTN hit to the viral genome are 
run through BLASTN against the hg19 genome, using the same parameters. 
Finally, SummonChimera was run with the BLASTN and SAM report files and 
generated a report containing all detected chimeric junctions. 
 
Virus identification pipeline.  
Raw fastq reads were mapped to the hg19 version of the human genome 
and a human mRNA database (to remove spliced reads) with Bowtie2 using 
default parameters (280). Then unmapped reads were extracted and low quality 
reads were removed and poor quality ends were trimmed with Prinseq 
(http://prinseq.sourceforge.net/). High quality reads were assembled with CLC 
Assembler. Contigs >= 500bp were masked with Repeat Masker and filtered as 
described(283). Then, high quality contigs were annotated by a computation 
subtraction pipeline: (i) the human genome using BLASTN; (ii) GenBank nt 
database using BLASTN; (iii) GenBank nr database using BLASTX; and (iv) the 
NCBI viral refseq genome database using TBLASTX. Minimal E-value cutoff of 
1e-5 for all steps were applied. Additionally, a minimal query coverage of 50% 
and minimal percent identity of 80% were applied to the BLASTN steps. 
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Tables 
Table 4.1. Summary of patients and tumors used in this study. 
ID Sex 
Age at 
Diagnosis 
Past Medical 
History 
Primary 
Tumor Site 
Viral 
Reads 
WGS 
Somatic 
mutations 
09156-
050 
M 76 
Actinic keratosis, 
basal cell 
carcinoma, 
squamous cell 
carcinoma 
Right 
forehead 
0 Yes 127236 
09156-
076 
M 82 
Hypothyroidism, 
Diabetes mellitus, 
Hypoaldosteronism 
Left third 
finger 
10441 Yes 4132 
09156-
088 
M 64 
Rheumatoid 
arthritis 
Right upper 
medial thigh  
5449 Yes 3397 
09156-
090 
F 77 
Basal cell 
carcinoma, 
hypothyroidism 
Right dorsal 
foot 
26289 No NA 
09156-
142 
M 79 
Actinic keratosis, 
Basal cell 
carcinoma, 
Squamous cell 
carcinoma, 
Polymyalgia 
rheumatica 
Right 
postauricular 
0 No NA 
09156-
146 
M 77 
Actinic keratosis, 
Basal cell 
carcinoma, 
polymyalgia 
rheumatica 
Left upper 
arm 
18947 No NA 
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Table 4.2. Annotation of somatic point mutations in MCC tumors. 
  09156-050 09156-076 09156-088 
Log2 
fold 
change 
Upstream 4129 3.25% 170 3.99% 169 4.79% 0.43 
CDS 1107 0.87% 44 1.03% 35 0.99% 0.22 
Synonymous 1087 0.85% 43 1.01% 35 0.99% 0.23 
Missense 658 0.52% 28 0.66% 21 0.59% 0.27 
Nonsense 47 0.04% 5 0.12% 2 0.06% 1.23 
Stop loss 1 0.00% 0 0.00% 0 0.00% 0.00 
Intron 40809 32.07% 1417 33.22% 1195 33.84% 0.06 
UTR3 612 0.48% 33 0.77% 27 0.76% 0.68 
UTR5 155 0.12% 7 0.16% 6 0.17% 0.46 
Total in genes 45603 35.84% 1620 37.98% 1389 39.34% 0.11 
                
Alu 12406 9.75% 612 14.35% 483 13.68% 0.52 
ERV1 4964 3.90% 210 4.92% 181 5.13% 0.37 
ERVK 469 0.37% 45 1.06% 25 0.71% 1.26 
ERVL 10045 7.89% 249 5.84% 178 5.04% -0.54 
hAT 2293 1.80% 47 1.10% 49 1.39% -0.53 
L1 23438 18.42% 948 22.23% 756 21.41% 0.24 
L2 4786 3.76% 104 2.44% 104 2.95% -0.48 
MIR 3267 2.57% 85 1.99% 69 1.95% -0.38 
RTE 129 0.10% 8 0.19% 3 0.08% 0.43 
                
Low complexity 551 0.43% 31 0.73% 29 0.82% 0.84 
Simple repeat 361 0.28% 78 1.83% 69 1.95% 2.74 
                
Total 127236   4132   3397     
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Figure 4.1. Circos plots and functional annotation of genomic alterations in 
MCC tumors 
(A-B) The MCPyV-positive tumors are highlighted in red and the MCPyV-
negative tumor is highlighted in blue. The outermost ring represents each 
chromosome. The next ring represents the density of somatic mutations 
calculated in 1 Mbp regions. The inner most ring represents the copy number 
alterations of each chromosome. The colored lines in the inner circle represent 
inter-chromosomal translocations. (C) Bar plot of the enrichment z-score (blue) 
and p-values (black) of pathways predicted from somatic variants in tumor-050. 
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Figure 4.2. Summary of mutation signatures detected in MCPyV positive 
and negative MCC. 
(A) Bar plot of the average contribution of each base substitution at each 
possible trinucleotide context across the genome in MCPyV-positive and 
MCPyV-negative tumors. (B) Dendrogram representing the similarity of mutation 
signatures detected in each tumor to known mutation signatures in cancer. 
MCPyV-positive tumors are highlighted in red and -negative tumors are in blue. 
(C) Bar plots of the transcriptional strand asymmetry measured for “UV-
signature”, C-to-T, and “signature 5”, T-to-C, over four quartiles of expression 
and divided by MCPyV-positive and MCPyV-negative tumors. Upper plots show 
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mutation density by each base substitution and its complement substitution. The 
lower plots show the log2 ratio representing the degree of transcriptional 
asymmetry. More positive denotes enrichment for the non-transcribed strand; 
more negative denotes enrichment for the transcribed strand.  
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Figure 4.3. Summary of mutation clusters observed in MCC.  
(A) Rainfall plot of intermutational distances between somatic single base 
substitutions by genome position. Colors for each type of base substitution are 
the same as in Figure 2A. Unique kataegis events are indicated by arrows. The 
kataegis event expanded in B is indicated by a filled in black arrow (B) 
Coincidence of kataegis events and structural alterations along the X axis 
representing genomic position, which are indicative of DNA breaks are 
highlighted by dotted red boxes. Relative DNA copy number is shown as a grey 
line graph using the left Y axis for its scale. The intermutational distance for each 
point mutation is shown by a black dot using the right Y axis. (C) Bar graph of the 
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number of mutations observed by base substitution and context in the kataegis 
events in tumor-076. 
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Figure 4.4. Summary of MCPyV positive and negative MCC transcriptome. 
(A) Plot of the first two principal components from PCA of the transcriptomes of 
each MCC tumor colored by the presence of MCPyV, red for positive, blue for 
negative. (B) Sashimi plots showing the number of reads spanning the exon 
junctions of the CDKN2A locus for each tumor samples, labeled on the left. 
Virus-positive samples are in red; virus-negative tumors are in blue. Known 
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transcript variants of CDKN2A are shown below the sashimi plots. (C) Bar plot of 
the enrichment z-score (red for MCPyV-associated and blue for non-MCPyV-
associated) and p-values (black) of pathways predicted from significantly 
differentially expressed genes. Pathways supported by somatic variants are bold. 
Below the bar plots, details of the log2 fold change and predicted direction of 
expression of genes significantly differentially regulated and associated with the 
pathways attributed to MCPyV-positive tumors. For both observed and expected 
expression changes, increased fold change is in red and decreased is in blue 
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Figure 4.5. Detailed evaluation of MCPyV insertion sites in MCC tumors. 
A,B. Diagrams of discordant read pairs and association with observed RNAseq 
coverage from MCC tumors. Depth of coverage histograms for RNAseq reads 
across the MCPyV genome are shown in the upper section. Discordant read 
pairs are shown in the lower section as transparent black lines linking the MCPyV 
genome to putative insertion sites in the human genome. C,D. Relative copy 
numbers from each patient near the detected viral integration sites are shown in 
the upper panel. Depth of coverage of read pairs that map to the host and viral 
genomes are shown in red in the lower panel. E,F. Diagram of the de novo 
assembled virus-host fusion contigs. The start positions of each read are 
connected from the viral genome (red, left) and the host genome (blue, right) to 
the de novo assembled fusion contig representing the integration event (center) 
via colored arches. Virus and host genes are shown below the arch diagram.  
G,H. Simplified schematic of the integration events interpreted from the 
corresponding data in E and F. The viral and host genomes are shown in red and 
blue respectively. Deletions in the viral genome are represented by red dotted 
lines and junctions without support from the de novo assembled contigs are 
shown in grey dotted lines. Host chromosome positions are in blue adjacent to 
the schematic. I,J. Model for MCPyV-insertion-mediated host structural variants. 
DNA double strand break initiates insertion of the linearized MCPyV genome into 
the host genome. After insertion DNA loops over, forms transiently circular DNA, 
and allows for rolling circle DNA replication initiated from the viral origin of 
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replication. Separation of the transiently circular DNA results in a focal 
amplification of the host genome flanked by viral DNA. 
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Figure 4.6. MCPyV genome coverage and diagrams of the detected viral-
host transcript chimeras.  
(A-D) Plot of depth of coverage over MCPyV genome for each patient tumor. 
Known T antigen isoforms are represented below with known splice junctions, 
virus host splice fusions, and potential DNA chimeric junctions indicated by red, 
blue and black vertical lines on the X axis, respectively. Overlapping junctions 
are represented by dashed lines. Asterisks on the x-axis represent stop codons 
introduced by mutation within the Large T antigen coding region. Diagrams of the 
detected viral-host fusion transcripts for the corresponding patient are below the 
depth of coverage plots. Arrows indicate the direction of transcription. Human 
genes are represented in blue and the MCPyV genome is represented in red, 
only Large T antigen exons are diagramed with red boxes. Chromosome and 
 145 
position of each DNA junction is labeled above the diagrams. (D) Tumor 
corresponding to 09156-076 had no detected integration or fusion transcripts. 
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CHAPTER 5: 
Conclusions and Discussion 
 
Author: Gabriel Starrett 
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CONCLUSIONS 
Chapter 2: APOBEC3H haplotype I is a likely contributor to breast and lung 
cancer mutagenesis (90) 
Since the discovery of APOBEC3B as a major contributor to mutagenesis 
in breast and others cancer types (1, 34), the geographically distributed germline 
deletion of APOBEC3B (82) has proved to be a difficult paradox to address. 
Many studies have shown that this germline deletion corresponds to increased 
risk (not a decreased risk as expected from aforementioned discoveries) for the 
development of breast cancer.  Further complicating the story these tumors still 
bear a strong APOBEC-mediated mutation signature (83, 84, 86, 202). Several 
other APOBEC3s have been implicated as mutagens in the absence of 
APOBEC3B. APOBEC3A has been the leading candidate for the source of these 
mutations as it is the most active of the human APOBEC3s and the transcript is 
modified with the deletion allele (89). However, APOBEC3A is expressed at 
nearly undetectable levels in most tumors and there has not been consistent 
evidence that the APOBEC3A is differentially regulated by the deletion allele (34, 
90). 
We mined the Cancer Genome Atlas (TCGA) to identify individuals 
homozygous for the APOBEC3B deletion. We then determined the APOBEC3H 
haplotype for each of these tumors. APOBEC3H is the most polymorphic of the 
human APOBEC3 genes. This surprisingly revealed that only individuals with at 
least one copy of APOBEC3H-I haplotype had significant APOBEC-associated 
mutation signatures. APOBEC3H-I has traditionally been considered partially 
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unstable and inactive. We demonstrated that APOBECH-I is equally active to 
APOBEC3H-II, which is normally considered the HIV-1 restrictive haplotype, in 
virus restriction and deaminase assays when normalized to equal protein levels. 
In these assays we were also able to show that APOBEC3H is able to produce a 
mutation profile that is strikingly similar to that observed in APOBEC3B-null 
cancers. Lastly, we were able to show that APOBEC3H-I has greater nuclear 
localization in several cell lines than APOBEC3H-II. Providing further evidence 
for APOBEC3H-I involvement in cancer, early clonal mutations were significantly 
enriched for the APOBEC signature only in lung adenocarcinoma, but with a 
strong trend in breast cancer. We concluded that the combination of APOBEC3B 
and APOBEC3H-I accounts for the bulk of, and perhaps all, APOBEC signature 
mutations in cancer. 
Chapter 3: Functional upregulation of APOBEC3B by polyomaviruses (192) 
 Previously the E6 oncoprotein of high-risk HPV has been shown to 
specifically upregulate APOBEC3B expression in keratinocyte cell lines and is 
supported by increased expression of APOBEC3B in HPV+ head and neck 
squamous cell carcinomas over those that are HPV- (59). This ultimately led to 
the hypothesis that, generally, small DNA tumor viruses are capable of 
upregulating APOBEC3B and this is part of their mechanism of tumorigenesis. 
To test this, we utilized BK polyomavirus and the primary renal proximal tubule 
epithelial cell culture system (RPTE). BK polyomavirus is the leading cause of 
kidney transplant rejection and has a growing association with bladder cancer 
(61, 284, 285). Half the polyomavirus genome is dedicated to encoding the large 
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tumor antigen (LTAg) which overlaps both the functions of HPV E6 and E7, 
inhibiting p53 and pRB1, respectively (135, 136, 286, 287). 
 At one-day post infection, the viral capsid has yet to reach the nucleus and 
release the viral genome. At three days post infection, BKPyV infected cells 
express high levels of LTAg and actively replicate the viral genome (236). Also at 
this timepoint, APOBEC3B is the only APOBEC family member that is 
significantly upregulated. This upregulation corresponds to increased deaminase 
activity within the infected RPTEs. Knockdown of APOBEC3B does not affect 
BKPyV replication dynamics, indicating that APOBEC3B does not overtly 
promote or inhibit BKPyV infection. Nucleotide motif analysis of the publicly 
available BKPyV sequences from Genbank revealed the BKPyV genome is 
depleted for APOBEC-target TC motifs and enriched for the product TT motifs. 
Additionally, these motifs are depleted in a strand-biased manner that is 
consistent with the preferred function of APOBEC3B to deaminate the lagging 
strand of replicating DNA. We concluded that the Large T antigen of multiple 
different human polyomaviruses is able to upregulate APOBEC3B and this 
upregulation has likely influenced the nucleotide motif abundance in genomes of 
polyomaviruses. 
Chapter 4: Merkel cell polyomavirus has dominant control over the tumor 
genome and transcriptome of Merkel cell carcinoma (161) 
HPV-mediated cancers consistently show some of the highest 
APOBEC3B expression and strongest APOBEC-mediated mutation signatures of 
any type of cancer (2, 34, 60). This is likely due to the active expression of E6 
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from the integrated high-risk HPV genome (59). In the previous chapter, we 
showed that the large T antigen of human polyomaviruses, such as Merkel cell 
polyomavirus (MCPyV), is able to specifically and significantly upregulate 
APOBEC3B protein and activity. Merkel cell carcinoma is a rare skin cancer and 
approximately 80% of cases have copies of the MCPyV genome integrated into 
chromosomal DNA (155, 157). We performed RNA sequencing on the tumors of 
six Merkel cell carcinoma patients and whole genome sequencing (WGS) of 
three patients. 
Splitting the patients by detection of MCPyV transcripts initially revealed a 
striking difference in the abundance and context of mutations in virus-associated 
versus non-associated tumors. Tumors without MCPyV had abundant UV-
signature mutations and chromosomal translocations that interrupted genes 
associated with DNA damage recognition and repair. MCPyV-associated tumors 
had ~20-fold fewer mutations that were primarily T-to-C with a transcriptional 
strand bias consistent with a previously defined mutation signature. When further 
investigating the integration site of the virus in the WGS data, we identified that 
these sites overlap focal amplifications of the host genome. These amplifications 
are very similar to those observed in HPV-associated cancers and support a 
looping model where integration of the viral genome forms transiently circular 
DNA that facilitates the firing of the viral origin to amplify the viral genome as well 
as flanking host chromosomal DNA. In conclusion, we identified that MCPyV 
drives carcinogenesis in Merkel cell carcinoma in the absence of abundant point 
 151 
mutations and copy number alterations observed in most tumor types and 
integration of the virus seeds focal amplifications in the tumor genome. 
 
DISCUSSION 
The antiviral enzyme APOBEC3H-I contributes to cancer mutagenesis 
Through carefully controlled bioinformatic and biochemical experiments, 
we identified in the absence of APOBEC3B that APOBEC3H-I is a significant 
contributor of APOBEC signature mutations in breast and lung cancers. These 
results advance multiple models in which APOBEC3H-I causes a continuous 
smoldering mutator phenotype that is eclipsed upon activation of the highly active 
mutator APOBEC3B by a tumor-initiating event. This explains why it the effect 
could only be observed in the absence of APOBEC3B. Collectively expression 
and activity of APOBEC3B and APOBEC3H-I can now account for all APOBEC-
signature mutations in cancer, apart from some possibly coming from 
APOBEC3A in some myeloid lineage cancers (90). However, many questions 
still remain in regards to APOBEC-mediated mutagenesis in cancer. Specifically, 
known upregulation of APOBEC3H by HIV-1 infection opens the potential for 
flares of cancer mutagenesis initiated by viral infection (288). 
One of the more interesting phenotypes that doesn’t have a complete 
mechanistic explanation is the cellular localization of APBOEC3H-I vs 
APOBEC3H-II (48). This is a fundamental difference between the two haplotypes 
that facilitates APOBEC3H-I to act as a genomic DNA mutator. Differential 
localization may be due to a yet-to-be discovered cytoplasmic retention factor 
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that requires the R105 amino acid to bind to APOBEC3H. Despite the number of 
new studies on APOBEC3s and their roles in cancer, we still understand very 
little about the initiation and early stages of tumor development with or without 
APOBEC3B. Continued mechanistic studies in APOBEC3B-null primary tumors 
will facilitate these insights.  
The cancer mutagenic enzyme APOBEC3B is induced by polyomavirus infection 
and contributes to virus evolution 
Studies into the mutation signatures in cancer gave the first indications of 
a connection between tumor viruses and APOBEC-mediated cancer 
mutagenesis. Continued studies into the oncoproteins of HPV confirmed that 
these viruses manipulate the expression of APOBEC family members through 
direct binding of the APOBEC3B promoter and activation of transcription factors 
such as TEADs (59, 137, 138). Other studies into the regulation of APOBEC3B in 
cancer has further revealed the complexity of its regulatory mechanisms and the 
need for novel molecular methods to interrogate it (74, 166, 195, 197). Tumor 
viruses continue to act as valuable molecular probes to understand the regulation 
of oncogenes and tumor suppressors, highlighting the value of studying small 
DNA viruses such as BK polyomavirus. Our study has revealed that T-antigen, 
which shares some overlapping function with high-risk HPV E6, is able to 
specifically upregulate APOBEC3B at the transcript, protein and enzymatic 
activity levels. 
Human papillomaviruses were the first to be shown to be depleted for 
APOBEC-target motifs and enriched for product motifs and this corresponded to 
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the ability of that virus to upregulate APOBEC3B (143). We were able to show 
that the BKPyV genome has similar motif distributions while also showing a 
strong replication-based strand biased depletion not observed in HPV. Additional 
studies into the structure of small DNA viruses may also provide valuable insights 
into how APOBEC3B is able to mutate host genomic DNA. 
Copy number variants in polyomavirus-mediated Merkel cell carcinoma are 
induced by viral integration 
Although the previous chapter showed that transduction of MCPyV LTAg 
in primary RPTEs is able to upregulate APOBEC3B, there is no evidence of 
elevated expression of any APOBEC3 family member in our study of Merkel cell 
carcinoma (MCC) and others (159, 160, 251). Additionally, virus-positive MCC 
tumors lacked any significant observable APOBEC-signature mutations, which is 
in stark contrast to HPV-associated tumors, which have some of the highest 
APOBEC-mediated mutation loads (34). Additional studies in other cell lines, 
such as the novel primary cell line for MCPyV replication (289), will be required to 
determine if this is cell type specific phenomenon. It is also possible that MCPyV 
has additional mechanisms to prevent or counteract the expression and activities 
of APOBEC3 enzymes since we know that they can act on polyomavirus 
genomes. 
However, like HPV-associated tumors, we identified that MCPyV 
integration sites are able to seed focal amplifications in the tumor genome (261). 
Additional WGS studies on MCC will determine the degree of complexity that 
these rearrangements can take and what initiates the integration. A recent study 
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showed that increased expression of APOBEC3A corresponds with integrated 
HPV in tumors (290). It could be that MCPyV initially upregulates APOBEC3B 
and this increases DNA damage in the host and viral genomes. This damage 
then promotes double-strand breaks and facilitates the integration of the viral 
genome. After integration, large sections of the viral T antigen are frequently 
deleted (155, 226). This could be an explanation as to why MCPyV-positive 
tumors don’t show APOBEC3B expression or mutation signature. 
 
CLOSING REMARKS 
Historically, the study of viruses has proven to be integral in regards to 
understanding oncoproteins, tumor suppressors, and the biology of DNA 
replication. Additionally both viruses and cancers are similar in the characteristic 
that they require constant new genetic diversity to survive and outpace the host 
immune system, but are also susceptible to hypermutation and genome 
instability. The primary goal of my thesis has been to better understand how the 
antiviral APOBEC3 family contributes to the genetic diversity of cancer and 
tumor-associated viruses and how in turn tumors and viruses affect the 
regulation of APOBEC3 enzymes. Here I have shown by investigating tumors 
with a homozygous germline deletion of APOBEC3B, a specific haplotype of the 
normally virus-associated APOBEC, APOBEC3H, can contribute to the APOBEC 
signature mutations observed in breast and lung cancers (Chapter 2). The 
normally cancer associated enzyme, APOBEC3B, is induced by the Large T 
antigen of human polyomaviruses, much like what is observed in HPV infections 
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and HPV-associated cancers (Chapter 3). Paradoxically when investigating 
Merkel cell carcinoma, which is caused by Merkel cell polyomavirus, we found 
that these tumors do not have a significant proportion of APOBEC-signature 
mutations. Rather integration of the virus seeds focal amplifications of the host 
genome, in which Large T antigen expression is lost (Chapter 4). These studies 
combine to provide novel insights into the complex interplay between 
oncoviruses and APOBEC regulation and activity across multiple tissue types 
and cancers. 
 156 
REFERENCES  
1.  Burns MB, Lackey L, Carpenter M a, Rathore A, Land AM, Leonard B, 
Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz N a, 
Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. 2013. 
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 
494:366–70. 
2.  Roberts S a, Lawrence MS, Klimczak LJ, Grimm S a, Fargo D, Stojanov P, 
Kiezun A, Kryukov G V, Carter SL, Saksena G, Harris S, Shah RR, 
Resnick M a, Getz G, Gordenin D a. 2013. An APOBEC cytidine 
deaminase mutagenesis pattern is widespread in human cancers. Nat 
Genet 45:970–6. 
3.  Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau 
KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, 
Hinton J, Menzies A, Stebbings L a, Leroy C, Jia M, Rance R, Mudie LJ, 
Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, 
Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague 
JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, 
Langerød A, Aparicio S a JR, Tutt A, Sieuwerts AM, Borg Å, Thomas G, 
Salomon AV, Richardson AL, Børresen-Dale A-L, Futreal PA, Stratton MR, 
Campbell PJ. 2012. The life history of 21 breast cancers. Cell 149:994–
1007. 
4.  Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio S a JR, Behjati S, 
Biankin A V, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L, Boyault S, 
 157 
Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd 
JE, Foekens J a, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, 
Imielinski M, Imielinsk M, Jäger N, Jones DTW, Jones D, Knappskog S, 
Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, 
Northcott P a, Pajic M, Papaemmanuil E, Paradiso A, Pearson J V, Puente 
XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, 
Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt ANJ, 
Valdés-Mas R, van Buuren MM, van ’t Veer L, Vincent-Salomon A, 
Waddell N, Yates LR, Zucman-Rossi J, Futreal PA, McDermott U, Lichter 
P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister 
SM, Campbell PJ, Stratton MR. 2013. Signatures of mutational processes 
in human cancer. Nature 500:415–21. 
5.  Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, Gan A, 
Myint SS, Siew EY, Ler LD, Ng LG, Weng W-H, Chuang C-K, Yuen JS, 
Pang S-T, Tan P, Teh BT, Rozen SG. 2015. Mutation signatures implicate 
aristolochic acid in bladder cancer development. Genome Med 7:38. 
6.  Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, 
Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud 
A-L, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc J-F, Mazzaferro V, 
Calvo F, Villanueva A, Nault J-C, Bioulac-Sage P, Stratton MR, Llovet JM, 
Zucman-Rossi J. 2015. Exome sequencing of hepatocellular carcinomas 
identifies new mutational signatures and potential therapeutic targets. Nat 
Genet 47:505–511. 
 158 
7.  Pleasance ED, Stephens PJ, O’Meara S, McBride DJ, Meynert A, Jones D, 
Lin M-L, Beare D, Lau KW, Greenman C, Varela I, Nik-Zainal S, Davies 
HR, Ordoñez GR, Mudie LJ, Latimer C, Edkins S, Stebbings L, Chen L, Jia 
M, Leroy C, Marshall J, Menzies A, Butler A, Teague JW, Mangion J, Sun 
Y a., McLaughlin SF, Peckham HE, Tsung EF, Costa GL, Lee CC, Minna 
JD, Gazdar A, Birney E, Rhodes MD, McKernan KJ, Stratton MR, Futreal 
PA, Campbell PJ. 2010. A small-cell lung cancer genome with complex 
signatures of tobacco exposure. Nature 463:184–190. 
8.  Brash DE, Haseltine WA. 1982. UV-induced mutation hotspots occur at 
DNA damage hotspots. Nature 298:189–92. 
9.  Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang 
L-E, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M. 2003. Repair of UV light-
induced DNA damage and risk of cutaneous malignant melanoma. J Natl 
Cancer Inst 95:308–315. 
10.  De Gruijl FR, Van Kranen HJ, Mullenders LHF. 2001. UV-induced DNA 
damage, repair, mutations and oncogenic pathways in skin cancer. J 
Photochem Photobiol B Biol 63:19–27. 
11.  Franklin A, Milburn PJ, Blanden R V, Steele EJ. 2004. Human DNA 
polymerase-eta, an A-T mutator in somatic hypermutation of rearranged 
immunoglobulin genes, is a reverse transcriptase. Immunol Cell Biol 
82:219–25. 
12.  Wang Y, Woodgate R, McManus TP, Mead S, McCormick JJ, Maher VM. 
2007. Evidence that in xeroderma pigmentosum variant cells, which lack 
 159 
DNA polymerase eta, DNA polymerase iota causes the very high 
frequency and unique spectrum of UV-induced mutations. Cancer Res 
67:3018–26. 
13.  Hemnani T, Parihar MS. 1998. Reactive oxygen species and oxidative 
DNA damage. Indian J Physiol Pharmacol 42:440–452. 
14.  Jena NR. 2012. DNA damage by reactive species: Mechanisms, mutation 
and repair. J Biosci 37:503–507. 
15.  Haradhvala NJ, Polak P, Stojanov P, Covington KR, Shinbrot E, Hess JM, 
Rheinbay E, Kim J, Maruvka YE, Braunstein LZ, Kamburov A, Hanawalt 
PC, Wheeler DA, Koren A, Lawrence MS, Getz G. 2016. Mutational strand 
asymmetries in cancer genomes reveal mechanisms of DNA damage and 
repair. Cell 1–12. 
16.  Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. 2013. 
Deciphering signatures of mutational processes operative in human 
cancer. Cell Rep 3:246–259. 
17.  Spivak G. 2016. Transcription-coupled repair: an update. Arch Toxicol 
90:2583–2594. 
18.  Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, 
Church DN. 2016. A panoply of errors: polymerase proofreading domain 
mutations in cancer. Nat Rev Cancer 16:71–81. 
19.  Strauss B, Rabkin S, Sagher D, Moore P. 1982. The role of DNA 
polymerase in base substitution mutagenesis on non-instructional 
templates. Biochimie 64:829–838. 
 160 
20.  Duffy S, Shackelton LA, Holmes EC. 2008. Rates of evolutionary change in 
viruses : patterns and determinants 9. 
21.  Harris RS, Liddament MT. 2004. Retroviral restriction by APOBEC 
proteins. Nat Rev Immunol 4:868–77. 
22.  Münk C, Willemsen A, Bravo IG. 2012. An ancient history of gene 
duplications, fusions and losses in the evolution of APOBEC3 mutators in 
mammals. BMC Evol Biol 12:71. 
23.  LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, Emerman 
M, Greene WC, Jónsson SR, Landau NR, Löchelt M, Malik HS, Malim MH, 
Münk C, O’Brien SJ, Pathak VK, Strebel K, Wain-Hobson S, Yu X-F, Yuhki 
N, Harris RS. 2009. Guidelines for naming nonprimate APOBEC3 genes 
and proteins. J Virol 83:494–7. 
24.  Conticello SG. 2008. The AID/APOBEC family of nucleic acid mutators. 
Genome Biol 9:229. 
25.  Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, Brown WL, 
Harris RS. 2011. Human and rhesus APOBEC3D, APOBEC3F, 
APOBEC3G, and APOBEC3H demonstrate a conserved capacity to 
restrict Vif-deficient HIV-1. J Virol 85:11220–34. 
26.  Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, 
Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNA-
editing enzymes on chromosome 22. Genomics 79:285–296. 
27.  Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin E V. 2005. APOBEC4, 
a new member of the AID/APOBEC family of polynucleotide 
 161 
(deoxy)cytidine deaminases predicted by computational analysis. Cell 
Cycle 4:1281–1285. 
28.  Liao W, Hong S-H, Chan BH-J, Rudolph FB, Clark SC, Chan L. 1999. 
APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine 
deaminase supergene family. Biochem Biophys Res Commun 260:398–
404. 
29.  Greeve J, Navaratnam N, Scott J. 1991. Characterization of the 
apolipoprotein B mRNA editing enzyme: no similarity to the proposed 
mechanism of RNA editing in kinetoplastid protozoa. Nucleic Acids Res 
19:3569–76. 
30.  Teng B, Burant CF, Davidson NO. 1993. Molecular cloning of an 
apolipoprotein B messenger RNA editing protein. Science 260:1816–9. 
31.  Navaratnam N, Morrison JR, Bhattacharya S, Patel D, Funahashi T, 
Giannoni F, Teng BB, Davidson NO, Scott J. 1993. The p27 catalytic 
subunit of the apolipoprotein B mRNA editing enzyme is a cytidine 
deaminase. J Biol Chem 268:20709–12. 
32.  Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS. 2007. The 
APOBEC-2 crystal structure and functional implications for the deaminase 
AID 445:447–451. 
33.  Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 
2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in 
lymphocytes and tissues: Implications for HIV-1 restriction. Nucleic Acids 
Res 38:4274–4284. 
 162 
34.  Burns MB, Temiz N a, Harris RS. 2013. Evidence for APOBEC3B 
mutagenesis in multiple human cancers. Nat Genet 45:977–83. 
35.  Schumann GG. 2007. APOBEC3 proteins: major players in intracellular 
defence against LINE-1-mediated retrotransposition. Biochem Soc Trans 
35:637–42. 
36.  Horn A V., Klawitter S, Held U, Berger A, Jaguva Vasudevan AA, Bock A, 
Hofmann H, Hanschmann KMO, Trösemeier JH, Flory E, Jabulowsky R a., 
Han JS, Löwer J, Löwer R, Münk C, Schumann GG. 2014. Human LINE-1 
restriction by APOBEC3C is deaminase independent and mediated by an 
ORF1p interaction that affects LINE reverse transcriptase activity. Nucleic 
Acids Res 42:396–416. 
37.  Muckenfuss H, Hamdorf M, Held U, Perkovic M, Löwer J, Cichutek K, Flory 
E, Schumann GG, Münk C. 2006. APOBEC3 proteins inhibit human LINE-
1 retrotransposition. J Biol Chem 281:22161–72. 
38.  Heidmann O. 2005. APOBEC3G cytidine deaminase inhibits 
retrotransposition of endogenous retroviruses 433:1–4. 
39.  Wissing S, Montano M, Garcia-Perez JL, Moran J V., Greene WC. 2011. 
Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed 
cells and human embryonic stem cells. J Biol Chem 286:36427–36437. 
40.  Dutko J a, Schäfer A, Kenny AE, Cullen BR, Curcio MJ. 2005. Inhibition of 
a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. 
Curr Biol 15:661–6. 
41.  Kinomoto M, Kanno T, Shimura M, Ishizaka Y, Kojima A, Kurata T, Sata T, 
 163 
Tokunaga K. 2007. All APOBEC3 family proteins differentially inhibit LINE-
1 retrotransposition. Nucleic Acids Res 35:2955–64. 
42.  Stenglein MD, Harris RS. 2006. APOBEC3B and APOBEC3F inhibit L1 
retrotransposition by a DNA deamination-independent mechanism. J Biol 
Chem 281:16837–41. 
43.  Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. 2006. 
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon 
function in human cells. Nucleic Acids Res 34:89–95. 
44.  Seplyarskiy VB, Soldatov RA, Popadin KY, Antonarakis SE, Bazykin GA, 
Nikolaev SI. 2016. APOBEC-induced mutations in human cancers are 
strongly enriched on the lagging DNA strand during replication 1–9. 
45.  Knisbacher BA, Levanon EY. 2015. DNA editing of LTR retrotransposons 
reveals the impact of APOBECs on vertebrate genomes. Mol Biol Evol 
33:msv239. 
46.  Koning F a, Newman ENC, Kim E-Y, Kunstman KJ, Wolinsky SM, Malim 
MH. 2009. Defining APOBEC3 expression patterns in human tissues and 
hematopoietic cell subsets. J Virol 83:9474–85. 
47.  Lackey L, Law EK, Brown WL, Harris RS. 2013. Subcellular localization of 
the APOBEC3 proteins during mitosis and implications for genomic DNA 
deamination 12:762–772. 
48.  Li MMH, Emerman M. 2011. Polymorphism in human APOBEC3H affects a 
phenotype dominant for subcellular localization and antiviral activity. J Virol 
85:8197–207. 
 164 
49.  Lackey L, Demorest ZL, Land AM, Hultquist JF, Brown WL, Harris RS. 
2012. APOBEC3B and AID have similar nuclear import mechanisms. J Mol 
Biol 419:301–14. 
50.  Chen J, MacCarthy T, Smith M, Zhang B, Pan X, Ferguson-Smith A. 2017. 
The preferred nucleotide contexts of the AID/APOBEC cytidine 
deaminases have differential effects when mutating retrotransposon and 
virus sequences compared to host genesPLOS Computational Biology. 
51.  Carpenter MA, Li M, Rathore A, Lackey L, Law EK, Land AM, Leonard B, 
Shandilya SMD, Bohn M-F, Schiffer CA, Brown WL, Harris RS. 2012. 
Methylcytosine and normal cytosine deamination by the foreign DNA 
restriction enzyme APOBEC3A. J Biol Chem 287:34801–34808. 
52.  Nabel C. 2013. Nucleic acid determinants of cytosine deamination by AID / 
APOBEC enzymes in immunity and epigenetics. 
53.  Kohli RM, Maul RW, Guminski AF, McClure RL, Gajula KS, Saribasak H, 
McMahon MA, Siliciano RF, Gearhart PJ, Stivers JT. 2010. Local 
sequence targeting in the AID/APOBEC family differentially impacts 
retroviral restriction and antibody diversification. J Biol Chem 285:40956–
64. 
54.  Prasad R, Poltoratsky V, Hou EW, Wilson SH. 2016. Rev1 is a base 
excision repair enzyme with 5′-deoxyribose phosphate lyase activity. 
Nucleic Acids Res gkw869. 
55.  Chan K, Resnick MA, Gordenin DA. 2013. The choice of nucleotide 
inserted opposite abasic sites formed within chromosomal DNA reveals the 
 165 
polymerase activities participating in translesion DNA synthesis. DNA 
Repair (Amst) 12:878–889. 
56.  Kim N, Mudrak S V., Jinks-Robertson S. 2011. The dCMP transferase 
activity of yeast Rev1 is biologically relevant during the bypass of 
endogenously generated AP sites. DNA Repair (Amst) 10:1262–1271. 
57.  Doseth B, Ekre C, Slupphaug G, Krokan HE, Kavli B. 2012. Strikingly 
different properties of uracil-DNA glycosylases UNG2 and SMUG1 may 
explain divergent roles in processing of genomic uracilDNA Repair. 
58.  Pulukuri SMK, Knost JA, Estes N, Rao JS. 2009. Small interfering RNA-
directed knockdown of uracil DNA glycosylase induces apoptosis and 
sensitizes human prostate cancer cells to genotoxic stress. Mol Cancer 
Res 7:1285–1293. 
59.  Vieira VC, Leonard B, White EA, Starrett GJ, Temiz N a, Lorenz LD, Lee D, 
Soares MA, Lambert PF, Howley PM, Harris RS, Harris S. 2014. Human 
papillomavirus E6 triggers upregulation of the antiviral and cancer genomic 
DNA deaminase APOBEC3B. MBio 5:1–8. 
60.  Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. 2014. 
APOBEC-mediated cytosine deamination links PIK3CA helical domain 
mutations to human papillomavirus-driven tumor development. Cell Rep 
7:1833–1841. 
61.  Papadimitriou JC, Randhawa P, Rinaldo CH, Drachenberg CB, Alexiev B, 
Hirsch HH. 2016. BK polyomavirus infection and renourinary 
tumorigenesis. Am J Transplant 16:398–406. 
 166 
62.  Pino L, Rijo E, Nohales G, Frances A, Ubre A, Arango O. 2013. Bladder 
transitional cell carcinoma and BK virus in a young kidney transplant 
recipient. Transpl Infect Dis 15:E25-7. 
63.  Cancer T, Atlas G, Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak 
RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, 
Cherniack AD, Kim J, Pedamallu CS, Noble MS, Al-Ahmadie HA, Reuter 
VE, Rosenberg JE, F.Bajorin D, Bochner BH, Solit DB, Koppie T, Robinson 
B, Gordenin DA, Fargo D, Klimczak LJ, Roberts SA, Au J, Laird PW, 
Hinoue T, Schultz N, Ramirez R, Hansel D, Hoadley KA, Kim WY, 
Damrauer JS, Baylin SB, Mungall AJ, Robertson AG, Chu A, Kwiatkowski 
DJ, Sougnez C, Cibulskis K, Lichtenstein L, Sivachenko A, Stewart C, 
Lawrence MS, Getz G, Lander E, Gabrie SB, Donehower L, Carter SL, 
Saksena G, Schumacher SE, Freeman SS, Jung J, Bhatt AS, Pugh T, 
Beroukhim R, Meyerson M, Ally A, Balasundaram M, Butterfield YSN, 
Dhalla N, Hirst C, Holt RA, Jones SJM, Lee D, Li HI, Marra MA, Mayo M, 
Moore RA, Schein JE, Sipahimalani P, Tam A, Thiessen N, Wong T, Wye 
N, Bowlby R, Chuah E, Guin R, Shen H, Bootwalla MS, Triche Jr T, Lai 
PH, Van Den Berg DJ, Weisenberger DJ, Balu S, Bodenheimer T, Hoyle 
AP, Jefferys SR, Meng S, Mose LE, Simons J V, Soloway MG, Wu J, 
Parker JS, Hayes DN, Roach J, Buda E, Jones CD, Mieczkowski PA, Tan 
D, Veluvolu U, Waring S, Auman JT, Perou CM, Wilkerson MD, Santoso N, 
Parfenov M, Ren X, Pantazi A, Hadjipanayis A, Seidman J, Kucherlapati R, 
Lee S, Yang L, Park PJ, Xu AW, Protopopov A, Zhang J, Bristow C, 
 167 
Mahadeshwar HS, Seth S, Song X, Tang J, Zeng D, Chin L, Guo C, 
Casasent TD, Liu W, Ju Z, Motter T, Peng B, Ryan M, Su X, Yang JY, 
Lorenzi PL, Yao H, Zhang N, Mills GB, Cho J, DiCara D, Frazer S, 
Gehlenborg N, Heiman DI, Lin P, Liu Y, Stojanov P, Voet D, Zhang H, Zou 
L, Bernard B, Kreisberg D, Reynolds S, Rovira H, Shmulevich I, Gao J, 
Jacobsen A, Aksoy BA, Antipin Y, Ciriello G, Dresdner G, Gross B, Lee W, 
Reva B, Shen R, Sinha R, Sumer SO, Weinhold N, Ladanyi M, Sander C, 
Benz C, Carlin D, Haussler D, Ng S, Paull E, Stuart J, Zhu J, Zhang W, 
Taylor BS, Lichtenberg TM, Zmuda E, Barr T, Black AD, George M, Hanf 
B, Helsel C, McAllister C, Ramirez NC, Tabler TR, Weaver S, Wise L, 
Bowen J, Gastier-Foster JM, Jian W, Tello S, Ittman M, Castro P, 
McClenden WD, Gibbs R, Saller C, Tarvin K, DiPiero JM, Owens J, Bollag 
R, Li Q, Weinberger P, Czerwinski C, Huelsenbeck-Dill L, Iacocca M, 
Petrelli N, Rabeno B, Swanson P, Shelton T, Curley E, Gardner J, Mallery 
D, Penny R, Van Bang N, Hanh PT, Kohl B, Van Le X, Phu BD, Thorp R, 
Tien N V, Vinh LQ, Sandusky G, Burks E, Christ K, Gee J, Holway A, 
Moinzadeh A, Sorcini A, Sullivan T, Garcia-Grossman IR, Regazzi AM, 
Boice L, Rathmell WK, Thorne L, Bastacky S, Davies B, Dhir R, Gingrich J, 
Hrebinko R, Maranchie J, Nelson J, Parwani A, Bshara W, Gaudioso C, 
Morrison C, Alexopoulou V, Bartlett J, Engel J, Kodeeswaran S, Antic T, 
O’Donnell PH, Smith ND, Steinberg GD, Egea S, Gomez-Fernandez C, 
Herbert L, Jorda M, Soloway MG, Beaver A, Carter SL, Kapur P, Lewis C, 
Lotan Y, Bondaruk J, Czerniak B, Skinner E, Aldape K, Jensen MA, Kahn 
 168 
AB, Pihl TD, Pot DA, Srinivasan D, Wan Y, Ferguson ML, Zenklusen JC, 
Davidsen T, Demchok JA, Shaw KRM, Sheth M, Tarnuzzer R, Wang Z, 
Hutter C, Ozenberger BA, Sofia HJ, Eley G. 2014. Comprehensive 
molecular characterization of urothelial bladder carcinoma. Nature 
507:315–22. 
64.  Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, 
Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Høyer S, 
Borre M, Reinert T, Fristrup N, Dyrskjøt L, Shah S, Pedersen JS, Orntoft 
TF, Ørntoft TF. 2014. Mutational context and diverse clonal development in 
early and late bladder cancer. Cell Rep 7:1649–63. 
65.  Liu S, Chaudhry MR, Berrebi AA, Papadimitriou JC, Drachenberg CB, 
Haririan A, Alexiev BA. 2016. Polyomavirus replication and smoking are 
independent risk factors for bladder cancer after renal transplantation. 
Transplantation 0:1. 
66.  Hoopes JI, Cortez LM, Mertz TM, Malc EP, Mieczkowski PA, Roberts SA. 
2016. APOBEC3A and APOBEC3B preferentially deaminate the lagging 
strand template during DNA replication. Cell Rep 1–10. 
67.  Bhagwat AS, Hao W, Townes JP, Lee H, Tang H, Foster PL. 2016. Strand-
biased cytosine deamination at the replication fork causes cytosine to 
thymine mutations in Escherichia coli. Proc Natl Acad Sci U S A 113:2176–
81. 
68.  Green AM, Landry S, Budagyan K, Avgousti DC, Shalhout S, Bhagwat AS, 
Weitzman MD. 2016. APOBEC3A damages the cellular genome during 
 169 
DNA replication. Cell Cycle 15:998–1008. 
69.  Seplyarskiy VB, Andrianova MA, Bazykin GA. 2016. APOBEC3A / B-
induced mutagenesis is responsible for 20 % of heritable mutations in the 
TpCpW context. 
70.  Yan S, He F, Gao B, Wu H, Li M, Huang L, Liang J. 2016. Increased 
APOBEC3B predicts worse outcomes in lung cancer: a comprehensive 
retrospective study. J Cancer 7:618–625. 
71.  Tsuboi M, Yamane A, Horiguchi J, Yokobori T, Kawabata-Iwakawa R, 
Yoshiyama S, Rokudai S, Odawara H, Tokiniwa H, Oyama T, Takeyoshi I, 
Nishiyama M. 2015. APOBEC3B high expression status is associated with 
aggressive phenotype in Japanese breast cancers. Breast Cancer. 
72.  Xu L, Chang Y, An H, Zhu Y, Yang Y, Xu J. 2015. High APOBEC3B 
expression is a predictor of recurrence in patients with low-risk clear cell 
renal cell carcinoma. Urol Oncol 33:1–8. 
73.  Pim D, Massimi P, Dilworth SM, Banks L. 2005. Activation of the protein 
kinase B pathway by the HPV-16 E7 oncoprotein occurs through a 
mechanism involving interaction with PP2A. Oncogene 24:7830–8. 
74.  Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan 
AM, Burns MB, McDougle RM, Parker PJ, Brown WL, Harris RS. 2015. 
The PKC/NF-kB signaling pathway induces APOBEC3B expression in 
multiple human cancers. Cancer Res 75:4538–4547. 
75.  Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, 
Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou W-M, 
 170 
Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning 
JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. 2014. 
Specific and nonhepatotoxic degradation of nuclear hepatitis B virus 
cccDNA. Science 343:1221–8. 
76.  Siriwardena SU, Guruge TA, Bhagwat AS. 2015. Characterization of the 
catalytic domain of human APOBEC3B and the critical structural role for a 
conserved methionine. J Mol Biol 427:3042–55. 
77.  Shi K, Carpenter M a., Kurahashi K, Harris RS, Aihara H. 2015. Crystal 
structure of the DNA deaminase APOBEC3B catalytic domain. J Biol Chem 
290:28120–28130. 
78.  Shi K, Carpenter MA, Banerjee S, Shaban NM, Kurahashi K, Salamango 
DJ, McCann JL, Starrett GJ, Duffy J V, Demir Ö, Amaro RE, Harki DA, 
Harris RS, Aihara H. 2016. Structural basis for targeted DNA cytosine 
deamination and mutagenesis by APOBEC3A and APOBEC3B. Nat Struct 
Mol Biol 24:131–139. 
79.  Byeon I-JL, Byeon C-H, Wu T, Mitra M, Singer D, Levin JG, Gronenborn 
AM. 2016. Nuclear magnetic resonance structure of the APOBEC3B 
catalytic domain: structural basis for substrate binding and DNA deaminase 
activity. Biochemistry 55:2944–59. 
80.  Kouno T, Silvas T V, Hilbert BJ, Shandilya SMD, Bohn MF, Kelch BA, 
Royer WE, Somasundaran M, Kurt Yilmaz N, Matsuo H, Schiffer CA. 2017. 
Crystal structure of APOBEC3A bound to single-stranded DNA reveals 
structural basis for cytidine deamination and specificity. Nat Commun 
 171 
8:15024. 
81.  Chan K, Roberts S a, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, 
Kwiatkowski DJ, Fargo DC, Mieczkowski P a, Getz G, Gordenin D a. 2015. 
An APOBEC3A hypermutation signature is distinguishable from the 
signature of background mutagenesis by APOBEC3B in human cancers. 
Nat Genet. 
82.  Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. 2007. Population 
stratification of a common APOBEC gene deletion polymorphism. PLoS 
Genet 3:e63. 
83.  Xuan D, Li G, Cai Q, Deming-Halverson S, Shrubsole MJ, Shu X-O, Kelley 
MC, Zheng W, Long J. 2013. APOBEC3 deletion polymorphism is 
associated with breast cancer risk among women of European ancestry. 
Carcinogenesis 34:2240–3. 
84.  Wen WX, Soo JS-S, Kwan PY, Hong E, Khang TF, Mariapun S, Lee CS-M, 
Hasan SN, Rajadurai P, Yip CH, Mohd Taib NA, Teo SH. 2016. Germline 
APOBEC3B deletion is associated with breast cancer risk in an Asian 
multi-ethnic cohort and with immune cell presentation. Breast Cancer Res 
18:56. 
85.  Revathidevi S, Manikandan M, Rao AKDM, Vinothkumar V, Arunkumar G, 
Rajkumar KS, Ramani R, Rajaraman R, Ajay C, Munirajan AK. 2016. 
Analysis of APOBEC3A/3B germline deletion polymorphism in breast, 
cervical and oral cancers from South India and its impact on miRNA 
regulation. Tumor Biol. 
 172 
86.  Long J, Delahanty RJ, Li G, Gao Y-T, Lu W, Cai Q, Xiang Y-BY-B, Li C, Ji 
B-T, Zheng Y, Ali S, Shu X-OX-O, Zheng W. 2013. A Common Deletion in 
the APOBEC3 Genes and Breast Cancer Risk. JNCI J Natl Cancer Inst 
105:573–579. 
87.  Qi G, Xiong H, Zhou C. 2014. APOBEC3 deletion polymorphism is 
associated with epithelial ovarian cancer risk among Chinese women. 
Tumour Biol 35:5723–6. 
88.  Rezaei M, Hashemi M, Hashemi SM, Mashhadi MA, Taheri M. 2015. 
APOBEC3 deletion is associated with breast cancer risk in a sample of 
Southeast Iranian population. Int J Mol Cell Med 4:4–9. 
89.  Caval V, Suspène R, Shapira M, Vartanian J-P, Wain-Hobson S. 2014. A 
prevalent cancer susceptibility APOBEC3A hybrid allele bearing 
APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat Commun 
5:5129. 
90.  Starrett GJ, Luengas EM, McCann JL, Ebrahimi D, Temiz NA, Love RP, 
Feng Y, Adolph MB, Chelico L, Law EK, Carpenter MA, Harris RS. 2016. 
The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to 
breast and lung cancer mutagenesis. Nat Commun 7:12918. 
91.  Ezzikouri S, Kitab B, Rebbani K, Marchio  a, Wain-Hobson S, Dejean  a, 
Vartanian J-P, Pineau P, Benjelloun S. 2013. Polymorphic APOBEC3 
modulates chronic hepatitis B in Moroccan population. J Viral Hepat 
20:678–86. 
92.  Prasetyo AA, Sariyatun R, Sari Y, Haryati S, Adnan ZA, Kageyama S. 
 173 
2015. The APOBEC3B deletion polymorphism is associated with 
prevalence of hepatitis B virus, hepatitis C virus, Torque Teno virus, and 
Toxoplasma gondii co-infection among HIV-infected individuals. J Clin Virol 
70:67–71. 
93.  He X, Xu H, Wang X, He X, Gao P, Niu J. 2016. Association between 
APOBEC3B deletion polymorphism and susceptibility to chronic hepatitis B 
infection and outcomes of hepatocellular carcinoma in Chinese Han 
population. Int J Clin Exp Pathol 9:9520–9528. 
94.  Abe H, Ochi H, Maekawa T, Hatakeyama T, Tsuge M, Kitamura S, Kimura 
T, Miki D, Mitsui F, Hiraga N, Imamura M, Fujimoto Y, Takahashi S, 
Nakamura Y, Kumada H, Chayama K. 2009. Effects of structural variations 
of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. 
Hepatol Res 39:1159–1168. 
95.  Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guétard D, 
Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, 
Wain-Hobson S. 2010. Massive APOBEC3 editing of hepatitis B viral DNA 
in cirrhosis. PLoS Pathog 6:1–9. 
96.  Xu R, Zhang X, Zhang W, Fang Y, Zheng S, Yu XF. 2007. Association of 
human APOBEC3 cytidine deaminases with the generation of hepatitis 
virus B x antigen mutants and hepatocellular carcinoma. Hepatology 
46:1810–1820. 
97.  Jha P, Sinha S, Kanchan K, Qidwai T, Narang A, Singh PK, Pati SS, 
Mohanty S, Mishra SK, Sharma SK, Awasthi S, Venkatesh V, Jain S, Basu 
 174 
A, Xu S, Mukerji M, Habib S. 2012. Deletion of the APOBEC3B gene 
strongly impacts susceptibility to falciparum malaria. Infect Genet Evol 
12:142–148. 
98.  Middlebrooks CD, Banday AR, Matsuda K, Udquim K-I, Onabajo OO, 
Paquin A, Figueroa JD, Zhu B, Koutros S, Kubo M, Shuin T, Freedman 
ND, Kogevinas M, Malats N, Chanock SJ, Garcia-Closas M, Silverman DT, 
Rothman N, Prokunina-Olsson L. 2016. Association of germline variants in 
the APOBEC3 region with cancer risk and enrichment with APOBEC-
signature mutations in tumors. Nat Genet. 
99.  Wittkopp CJ, Adolph MB, Wu LI, Chelico L, Emerman M. 2016. A single 
nucleotide polymorphism in human APOBEC3C enhances restriction of 
lentiviruses. PLoS Pathog 12:e1005865. 
100.  An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, 
Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O’Brien 
SJ, Telenti A, Winkler CA. 2004. APOBEC3G genetic variants and their 
influence on the progression to AIDS. J Virol 78:11070–6. 
101.  An P, An P, Bleiber G, Bleiber G, Duggal P, Duggal P, Nelson G, Nelson 
G, May M, May M, Mangeat B, Mangeat B, Winkler CA, Winkler CA, 
Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, 
Buchbinder S, O’Brien SJ, Telenti A, Winkler CA. 2004. APOBEC3G 
genetic variants and their infuence on the progression to AIDS. J Virol 
78:11070–11076. 
102.  Singh KK, Wang Y, Gray KP, Farhad M, Brummel S, Fenton T, Trout R, 
 175 
Spector SA. 2013. Genetic variants in the host restriction factor 
APOBEC3G are associated with HIV-1-related disease progression and 
central nervous system impairment in children. J Acquir Immune Defic 
Syndr 62:197–203. 
103.  Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley 
DR, Chakravarti A, Clark AG, Donnelly P, Eichler EE, Flicek P, Gabriel SB, 
Gibbs RA, Green ED, Hurles ME, Knoppers BM, Korbel JO, Lander ES, 
Lee C, Lehrach H, Mardis ER, Marth GT, McVean GA, Nickerson DA, 
Schmidt JP, Sherry ST, Wang J, Wilson RK, Gibbs RA, Boerwinkle E, 
Doddapaneni H, Han Y, Korchina V, Kovar C, Lee S, Muzny D, Reid JG, 
Zhu Y, Wang J, Chang Y, Feng Q, Fang X, Guo X, Jian M, Jiang H, Jin X, 
Lan T, Li G, Li J, Li Y, Liu S, Liu X, Lu Y, Ma X, Tang M, Wang B, Wang G, 
Wu H, Wu R, Xu X, Yin Y, Zhang D, Zhang W, Zhao J, Zhao M, Zheng X, 
Lander ES, Altshuler DM, Gabriel SB, Gupta N, Gharani N, Toji LH, Gerry 
NP, Resch AM, Flicek P, Barker J, Clarke L, Gil L, Hunt SE, Kelman G, 
Kulesha E, Leinonen R, McLaren WM, Radhakrishnan R, Roa A, Smirnov 
D, Smith RE, Streeter I, Thormann A, Toneva I, Vaughan B, Zheng-Bradley 
X, Bentley DR, Grocock R, Humphray S, James T, Kingsbury Z, Lehrach 
H, Sudbrak R, Albrecht MW, Amstislavskiy VS, Borodina TA, Lienhard M, 
Mertes F, Sultan M, Timmermann B, Yaspo M-L, Mardis ER, Wilson RK, 
Fulton L, Fulton R, Sherry ST, Ananiev V, Belaia Z, Beloslyudtsev D, Bouk 
N, Chen C, Church D, Cohen R, Cook C, Garner J, Hefferon T, Kimelman 
M, Liu C, Lopez J, Meric P, O’Sullivan C, Ostapchuk Y, Phan L, 
 176 
Ponomarov S, Schneider V, Shekhtman E, Sirotkin K, Slotta D, Zhang H, 
McVean GA, Durbin RM, Balasubramaniam S, Burton J, Danecek P, 
Keane TM, Kolb-Kokocinski A, McCarthy S, Stalker J, Quail M, Schmidt 
JP, Davies CJ, Gollub J, Webster T, Wong B, Zhan Y, Auton A, Campbell 
CL, Kong Y, Marcketta A, Gibbs RA, Yu F, Antunes L, Bainbridge M, 
Muzny D, Sabo A, Huang Z, Wang J, Coin LJM, Fang L, Guo X, Jin X, Li 
G, Li Q, Li Y, Li Z, Lin H, Liu B, Luo R, Shao H, Xie Y, Ye C, Yu C, Zhang 
F, Zheng H, Zhu H, Alkan C, Dal E, Kahveci F, Marth GT, Garrison EP, 
Kural D, Lee W-P, Fung Leong W, Stromberg M, Ward AN, Wu J, Zhang 
M, Daly MJ, DePristo MA, Handsaker RE, Altshuler DM, Banks E, Bhatia 
G, del Angel G, Gabriel SB, Genovese G, Gupta N, Li H, Kashin S, Lander 
ES, McCarroll SA, Nemesh JC, Poplin RE, Yoon SC, Lihm J, Makarov V, 
Clark AG, Gottipati S, Keinan A, Rodriguez-Flores JL, Korbel JO, Rausch 
T, Fritz MH, Stütz AM, Flicek P, Beal K, Clarke L, Datta A, Herrero J, 
McLaren WM, Ritchie GRS, Smith RE, Zerbino D, Zheng-Bradley X, Sabeti 
PC, Shlyakhter I, Schaffner SF, Vitti J, Cooper DN, Ball E V., Stenson PD, 
Bentley DR, Barnes B, Bauer M, Keira Cheetham R, Cox A, Eberle M, 
Humphray S, Kahn S, Murray L, Peden J, Shaw R, Kenny EE, Batzer MA, 
Konkel MK, Walker JA, MacArthur DG, Lek M, Sudbrak R, Amstislavskiy 
VS, Herwig R, Mardis ER, Ding L, Koboldt DC, Larson D, Ye K, Gravel S, 
Swaroop A, Chew E, Lappalainen T, Erlich Y, Gymrek M, Frederick 
Willems T, Simpson JT, Shriver MD, Rosenfeld JA, Bustamante CD, 
Montgomery SB, De La Vega FM, Byrnes JK, Carroll AW, DeGorter MK, 
 177 
Lacroute P, Maples BK, Martin AR, Moreno-Estrada A, Shringarpure SS, 
Zakharia F, Halperin E, Baran Y, Lee C, Cerveira E, Hwang J, Malhotra A, 
Plewczynski D, Radew K, Romanovitch M, Zhang C, Hyland FCL, Craig 
DW, Christoforides A, Homer N, Izatt T, Kurdoglu AA, Sinari SA, Squire K, 
Sherry ST, Xiao C, Sebat J, Antaki D, Gujral M, Noor A, Ye K, Burchard 
EG, Hernandez RD, Gignoux CR, Haussler D, Katzman SJ, James Kent 
W, Howie B, Ruiz-Linares A, Dermitzakis ET, Devine SE, Abecasis GR, 
Min Kang H, Kidd JM, Blackwell T, Caron S, Chen W, Emery S, Fritsche L, 
Fuchsberger C, Jun G, Li B, Lyons R, Scheller C, Sidore C, Song S, 
Sliwerska E, Taliun D, Tan A, Welch R, Kate Wing M, Zhan X, Awadalla P, 
Hodgkinson A, Li Y, Shi X, Quitadamo A, Lunter G, McVean GA, Marchini 
JL, Myers S, Churchhouse C, Delaneau O, Gupta-Hinch A, Kretzschmar 
W, Iqbal Z, Mathieson I, Menelaou A, Rimmer A, Xifara DK, Oleksyk TK, 
Fu Y, Liu X, Xiong M, Jorde L, Witherspoon D, Xing J, Eichler EE, 
Browning BL, Browning SR, Hormozdiari F, Sudmant PH, Khurana E, 
Durbin RM, Hurles ME, Tyler-Smith C, Albers CA, Ayub Q, 
Balasubramaniam S, Chen Y, Colonna V, Danecek P, Jostins L, Keane 
TM, McCarthy S, Walter K, Xue Y, Gerstein MB, Abyzov A, 
Balasubramanian S, Chen J, Clarke D, Fu Y, Harmanci AO, Jin M, Lee D, 
Liu J, Jasmine Mu X, Zhang J, Zhang Y, Li Y, Luo R, Zhu H, Alkan C, Dal 
E, Kahveci F, Marth GT, Garrison EP, Kural D, Lee W-P, Ward AN, Wu J, 
Zhang M, McCarroll SA, Handsaker RE, Altshuler DM, Banks E, del Angel 
G, Genovese G, Hartl C, Li H, Kashin S, Nemesh JC, Shakir K, Yoon SC, 
 178 
Lihm J, Makarov V, Degenhardt J, Korbel JO, Fritz MH, Meiers S, Raeder 
B, Rausch T, Stütz AM, Flicek P, Paolo Casale F, Clarke L, Smith RE, 
Stegle O, Zheng-Bradley X, Bentley DR, Barnes B, Keira Cheetham R, 
Eberle M, Humphray S, Kahn S, Murray L, Shaw R, Lameijer E-W, Batzer 
MA, Konkel MK, Walker JA, Ding L, Hall I, Ye K, Lacroute P, Lee C, 
Cerveira E, Malhotra A, Hwang J, Plewczynski D, Radew K, Romanovitch 
M, Zhang C, Craig DW, Homer N, Church D, Xiao C, Sebat J, Antaki D, 
Bafna V, Michaelson J, Ye K, Devine SE, Gardner EJ, Abecasis GR, Kidd 
JM, Mills RE, Dayama G, Emery S, Jun G, Shi X, Quitadamo A, Lunter G, 
McVean GA, Chen K, Fan X, Chong Z, Chen T, Witherspoon D, Xing J, 
Eichler EE, Chaisson MJ, Hormozdiari F, Huddleston J, Malig M, Nelson 
BJ, Sudmant PH, Parrish NF, Khurana E, Hurles ME, Blackburne B, 
Lindsay SJ, Ning Z, Walter K, Zhang Y, Gerstein MB, Abyzov A, Chen J, 
Clarke D, Lam H, Jasmine Mu X, Sisu C, Zhang J, Zhang Y, Gibbs RA, Yu 
F, Bainbridge M, Challis D, Evani US, Kovar C, Lu J, Muzny D, 
Nagaswamy U, Reid JG, Sabo A, Yu J, Guo X, Li W, Li Y, Wu R, Marth 
GT, Garrison EP, Fung Leong W, Ward AN, del Angel G, DePristo MA, 
Gabriel SB, Gupta N, Hartl C, Poplin RE, Clark AG, Rodriguez-Flores JL, 
Flicek P, Clarke L, Smith RE, Zheng-Bradley X, MacArthur DG, Mardis ER, 
Fulton R, Koboldt DC, Gravel S, Bustamante CD, Craig DW, Christoforides 
A, Homer N, Izatt T, Sherry ST, Xiao C, Dermitzakis ET, Abecasis GR, Min 
Kang H, McVean GA, Gerstein MB, Balasubramanian S, Habegger L, Yu 
H, Flicek P, Clarke L, Cunningham F, Dunham I, Zerbino D, Zheng-Bradley 
 179 
X, Lage K, Berg Jespersen J, Horn H, Montgomery SB, DeGorter MK, 
Khurana E, Tyler-Smith C, Chen Y, Colonna V, Xue Y, Gerstein MB, 
Balasubramanian S, Fu Y, Kim D, Auton A, Marcketta A, Desalle R, 
Narechania A, Wilson Sayres MA, Garrison EP, Handsaker RE, Kashin S, 
McCarroll SA, Rodriguez-Flores JL, Flicek P, Clarke L, Zheng-Bradley X, 
Erlich Y, Gymrek M, Frederick Willems T, Bustamante CD, Mendez FL, 
David Poznik G, Underhill PA, Lee C, Cerveira E, Malhotra A, Romanovitch 
M, Zhang C, Abecasis GR, Coin L, Shao H, Mittelman D, Tyler-Smith C, 
Ayub Q, Banerjee R, Cerezo M, Chen Y, Fitzgerald TW, Louzada S, 
Massaia A, McCarthy S, Ritchie GR, Xue Y, Yang F, Gibbs RA, Kovar C, 
Kalra D, Hale W, Muzny D, Reid JG, Wang J, Dan X, Guo X, Li G, Li Y, Ye 
C, Zheng X, Altshuler DM, Flicek P, Clarke L, Zheng-Bradley X, Bentley 
DR, Cox A, Humphray S, Kahn S, Sudbrak R, Albrecht MW, Lienhard M, 
Larson D, Craig DW, Izatt T, Kurdoglu AA, Sherry ST, Xiao C, Haussler D, 
Abecasis GR, McVean GA, Durbin RM, Balasubramaniam S, Keane TM, 
McCarthy S, Stalker J, Chakravarti A, Knoppers BM, Abecasis GR, Barnes 
KC, Beiswanger C, Burchard EG, Bustamante CD, Cai H, Cao H, Durbin 
RM, Gerry NP, Gharani N, Gibbs RA, Gignoux CR, Gravel S, Henn B, 
Jones D, Jorde L, Kaye JS, Keinan A, Kent A, Kerasidou A, Li Y, Mathias 
R, McVean GA, Moreno-Estrada A, Ossorio PN, Parker M, Resch AM, 
Rotimi CN, Royal CD, Sandoval K, Su Y, Sudbrak R, Tian Z, Tishkoff S, 
Toji LH, Tyler-Smith C, Via M, Wang Y, Yang H, Yang L, Zhu J, Bodmer W, 
Bedoya G, Ruiz-Linares A, Cai Z, Gao Y, Chu J, Peltonen L, Garcia-
 180 
Montero A, Orfao A, Dutil J, Martinez-Cruzado JC, Oleksyk TK, Barnes KC, 
Mathias RA, Hennis A, Watson H, McKenzie C, Qadri F, LaRocque R, 
Sabeti PC, Zhu J, Deng X, Sabeti PC, Asogun D, Folarin O, Happi C, 
Omoniwa O, Stremlau M, Tariyal R, Jallow M, Sisay Joof F, Corrah T, 
Rockett K, Kwiatkowski D, Kooner J, Tịnh Hiê`n T, Dunstan SJ, Thuy Hang 
N, Fonnie R, Garry R, Kanneh L, Moses L, Sabeti PC, Schieffelin J, Grant 
DS, Gallo C, Poletti G, Saleheen D, Rasheed A, Brooks LD, Felsenfeld AL, 
McEwen JE, Vaydylevich Y, Green ED, Duncanson A, Dunn M, Schloss 
JA, Wang J, Yang H, Auton A, Brooks LD, Durbin RM, Garrison EP, Min 
Kang H, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. 
2015. A global reference for human genetic variation. Nature 526:68–74. 
104.  Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. 2006. 
Population level analysis of human immunodeficiency virus type 1 
hypermutation and its relationship with APOBEC3G and vif genetic 
variation. J Virol 80:9259–69. 
105.  Compaore TR, Soubeiga ST, Ouattara AK, Obiri-Yeboah D, Tchelougou D, 
Maiga M, Assih M, Bisseye C, Bakouan D, Compaore IP, Dembele A, 
Martinson J, Simpore J. 2016. APOBEC3G variants and protection against 
HIV-1 infection in Burkina Faso. PLoS One 11:e0146386. 
106.  Harari A, Ooms M, Mulder LCF, Simon V. 2009. Polymorphisms and splice 
variants influence the antiretroviral activity of human APOBEC3H. J Virol 
83:295–303. 
107.  Wang X, Abudu A, Son S, Dang Y, Venta PJ, Zheng Y-H. 2011. Analysis of 
 181 
human APOBEC3H haplotypes and anti-human immunodeficiency virus 
type 1 activity. J Virol 85:3142–3152. 
108.  OhAinle M, Kerns J a., Li MMH, Malik HS, Emerman M. 2008. 
Antiretroelement activity of APOBEC3H was lost twice in recent human 
evolution. Cell Host Microbe 4:249–259. 
109.  Zhen A, Du J, Zhou X, Xiong Y, Yu X-F. 2012. Reduced APOBEC3H 
variant anti-viral activities are associated with altered RNA binding 
activities. PLoS One 7:e38771. 
110.  Zhu M, Wang Y, Wang C, Shen W, Liu J, Geng L, Cheng Y, Dai J, Jin G, 
Ma H, Hu Z, Shen H. 2015. The eQTL-missense polymorphisms of 
APOBEC3H are associated with lung cancer risk in a Han Chinese 
population. Sci Rep 5:14969. 
111.  Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng Y-H. 2008. Human 
cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 
283:11606–14. 
112.  Kim E-Y, Lorenzo-Redondo R, Little SJ, Chung Y-S, Phalora PK, Maljkovic 
Berry I, Archer J, Penugonda S, Fischer W, Richman DD, Bhattacharya T, 
Malim MH, Wolinsky SM. 2014. Human APOBEC3 induced mutation of 
human immunodeficiency virus type-1 contributes to adaptation and 
evolution in natural infection. PLoS Pathog 10:e1004281. 
113.  Beral V, Peterman TA, Berkelman RL, Jaffe HW. 1990. Kaposi’s sarcoma 
among persons with AIDS: a sexually transmitted infection? Lancet 
335:123–128. 
 182 
114.  Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, 
Moore PS. 1994. Identification of herpesvirus-like DNA sequences in AIDS-
associated Kaposi’s sarcoma. Science 266:1865–9. 
115.  Thel E, Esarman C, Uan Y, Hang C, Oore ASM, Onathan J, Aid WS, 
Nowles AMK. 1995. Kaposi’s sarcoma–associated herpesvirus-like dna 
sequences in aids-related body-cavity–based lymphomas. N Engl J Med 
332:1186–91. 
116.  Cuevas JM, Geller R, Garijo R, López-Aldeguer J, Sanjuán R. 2015. 
Extremely High Mutation Rate of HIV-1 In Vivo. PLOS Biol 13:e1002251. 
117.  Rawson JMO, Landman SR, Reilly CS, Mansky LM. 2015. HIV-1 and HIV-
2 exhibit similar mutation frequencies and spectra in the absence of G-to-A 
hypermutation. Retrovirology 12:60. 
118.  Koning FA, Goujon C, Bauby H, Malim MH. 2011. Target cell-mediated 
editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J 
Virol 85:13448–13452. 
119.  Ebrahimi D, Anwar F, Davenport MP. 2011. APOBEC3 has not left an 
evolutionary footprint on the HIV-1 genome. J Virol 85:9139–9146. 
120.  Delviks-Frankenberry KA, Nikolaitchik OA, Burdick RC, Gorelick RJ, Keele 
BF, Hu W-S, Pathak VK. 2016. Minimal contribution of APOBEC3-induced 
G-to-A hypermutation to HIV-1 recombination and genetic variation. PLOS 
Pathog 12:e1005646. 
121.  Gonçalves DU, Proietti FA, Ribas JGR, Araújo MG, Pinheiro SR, Guedes 
AC, Carneiro-Proietti ABF. 2010. Epidemiology, treatment, and prevention 
 183 
of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol 
Rev 23:577–89. 
122.  Ooms M, Krikoni A, Kress AK, Simon V, Münk C. 2012. APOBEC3A, 
APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic 
virus type 1. J Virol 86:6097–108. 
123.  Mahieux R, Suspène R, Delebecque F, Henry M, Schwartz O, Wain-
Hobson S, Vartanian J-P. 2005. Extensive editing of a small fraction of 
human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine 
deaminases. J Gen Virol 86:2489–2494. 
124.  Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, 
Vartanian J-P, Matsuoka M. 2010. APOBEC3G generates nonsense 
mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J 
Virol 84:7278–87. 
125.  Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. 2007. Resistance of 
human T cell leukemia virus type 1 to APOBEC3G restriction is mediated 
by elements in nucleocapsid. Proc Natl Acad Sci U S A 104:2915–20. 
126.  Jern P, Coffin JM. 2008. Effects of Retroviruses on Host Genome Function. 
Annu Rev Genet 42:709–732. 
127.  Maksakova IA, Romanish MT, Gagnier L, Dunn CA, van de Lagemaat LN, 
Mager DL. 2006. Retroviral elements and their hosts: insertional 
mutagenesis in the mouse germ line. PLoS Genet 2:e2. 
128.  Chen H, Lilley CE, Yu Q, Lee D V., Chou J, Narvaiza I, Landau NR, 
Weitzman MD. 2006. APOBEC3A is a potent inhibitor of adeno-associated 
 184 
virus and retrotransposons. Curr Biol 16:480–485. 
129.  Speek M. 2001. Antisense promoter of human L1 retrotransposon drives 
transcription of adjacent cellular genes. Mol Cell Biol 21:1973–85. 
130.  Duggal NK, Fu W, Akey JM, Emerman M. 2013. Identification and antiviral 
activity of common polymorphisms in the APOBEC3 locus in human 
populations. Virology 443:329–37. 
131.  D’Souza G, Dempsey A. 2011. The role of HPV in head and neck cancer 
and review of the HPV vaccine. Prev Med (Baltim) 53 Suppl 1:S5–S11. 
132.  zur Hausen H. 2009. Papillomaviruses in the causation of human cancers - 
a brief historical account. Virology 384:260–265. 
133.  zur Hausen H. 1996. Papillomavirus infections--a major cause of human 
cancers. Biochim Biophys Acta 1288:F55-78. 
134.  Kessis TD, Connolly DC, Hedrick L, Cho KR. 1996. Expression of HPV16 
E6 or E7 increases integration of foreign DNA. Oncogene 13:427–31. 
135.  Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH. 
1990. The region of the HPV E7 oncoprotein homologous to adenovirus 
E1a and Sv40 large T antigen contains separate domains for Rb binding 
and casein kinase II phosphorylation. EMBO J 9:153–60. 
136.  Crook T, Tidy JA, Vousden KH. 1991. Degradation of p53 can be targeted 
by HPV E6 sequences distinct from those required. Cell 67:547–556. 
137.  Mori S, Takeuchi T, Ishii Y, Yugawa T, Kiyono T, Nishina H, Kukimoto I. 
2017. Human papillomavirus 16 E6 up-regulates APOBEC3B via the TEAD 
transcription factor. J Virol JVI.02413-16. 
 185 
138.  Mori S, Takeuchi T, Ishii Y, Kukimoto I. 2015. Identification of APOBEC3B 
promoter elements responsible for activation by human papillomavirus type 
16 E6. Biochem Biophys Res Commun 460:555–560. 
139.  den Boon J a., Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, 
Zuna RE, Wang Z, Hewitt SM, Pearson R, Schott M, Chung L, He Q, 
Lambert P, Walker J, Newton M a., Wentzensen N, Ahlquist P. 2015. 
Molecular transitions from papillomavirus infection to cervical precancer 
and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad 
Sci 112:E3255–E3264. 
140.  Warren CJ, Xu T, Guo K, Griffin LM, Westrich J a, Lee D, Lambert PF, 
Santiago ML, Pyeon D. 2014. APOBEC3A functions as a restriction factor 
of human papillomavirus. J Virol 89:688–702. 
141.  Ahasan MM, Wakae K, Wang Z, Kitamura K, Liu G, Koura M, Imayasu M, 
Sakamoto N, Hanaoka K, Nakamura M, Kyo S, Kondo S, Fujiwara H, 
Yoshizaki T, Mori S, Kukimoto I, Muramatsu M. 2015. APOBEC3A and 3C 
decrease human papillomavirus 16 pseudovirion infectivity. Biochem 
Biophys Res Commun 457:295–9. 
142.  Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M, Monjurul  a. M, 
Kukimoto I, Muramatsu M. 2013. APOBEC3 Deaminases induce 
hypermutation in human papillomavirus 16 DNA upon beta interferon 
stimulation. J Virol 88:1308–1317. 
143.  Warren CJ, Van Doorslaer K, Pandey A, Espinosa JM, Pyeon D. 2015. 
Role of the host restriction factor APOBEC3 on papillomavirus evolution. 
 186 
Virus Evol 1:vev015. 
144.  Gosert R, Kardas P, Major EO, Hirsch HH. 2010. Rearranged JC virus 
noncoding control regions found in progressive multifocal 
leukoencephalopathy patient samples increase virus early gene expression 
and replication rate. J Virol 84:10448–10456. 
145.  Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, 
Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, 
Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P. 2011. 
Progressive multifocal leukoencephalopathy (PML) development is 
associated with mutations in JC Virus capsid protein VP1 that change its 
receptor specificity. J Infect Dis 204:103–114. 
146.  Padgett BL, Rogers CM. 1977. JC virus , a human polyomavirus 
associated with progressive multifocal leukoencephalopathy: Additional 
biological characteristics and antigenic relationships. Microbiology 15:656–
662. 
147.  Saundh BK, Tibble S, Baker R, Sasnauskas K, Harris M, Hale A. 2010. 
Different patterns of BK and JC polyomavirus reactivation following renal 
transplantation. 
148.  Gosert R, Rinaldo CH, Funk GA, Egli A, Ramos E, Drachenberg CB, 
Hirsch HH. 2008. Polyomavirus BK with rearranged noncoding control 
region emerge in vivo in renal transplant patients and increase viral 
replication and cytopathology. J Exp Med 205:841–52. 
149.  Sullivan CS, Tremblay JD, Fewell SW, Lewis JA, Brodsky JL, Pipas JM. 
 187 
2000. Species-specific elements in the large T-antigen J domain are 
required for cellular transformation and DNA replication by simian virus 40. 
Mol Cell Biol 20:5749–57. 
150.  Kwun HJ, Guastafierro A, Shuda M, Meinke G, Bohm A, Moore PS, Chang 
Y. 2009. The minimum replication origin of merkel cell polyomavirus has a 
unique large T-antigen loading architecture and requires small T-antigen 
expression for optimal replication. J Virol 83:12118–12128. 
151.  Gai D, Wang D, Li S-X, Chen XS. 2016. The structure of SV40 large T 
hexameric helicase in complex with AT-rich origin DNA. Elife 5:1–18. 
152.  Caracciolo V, Reiss K, Khalili K, De Falco G, Giordano  a. 2006. Role of 
the interaction between large T antigen and Rb family members in the 
oncogenicity of JC virus. Oncogene 25:5294–5301. 
153.  Abend JR, Joseph AE, Das D, Campbell-Cecen DB, Imperiale MJ. 2009. A 
truncated T antigen expressed from an alternatively spliced BK virus early 
mRNA. J Gen Virol 90:1238–1245. 
154.  Nguyen KD, Lee EE, Yue Y, Stork J, Pock L, North JP, Vandergriff T, 
Cockerell C, Hosler GA, Pastrana D V., Buck CB, Wang RC. 2016. Human 
polyomavirus 6 and 7 are associated with pruritic and dyskeratotic 
dermatoses. J Am Acad Dermatol 76:932–940.e3. 
155.  Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, Zur 
Hausen A. 2008. Frequent detection of merkel cell polyomavirus in human 
merkel cell carcinomas and identification of a unique deletion in the VP1 
gene. Cancer Res 68:5009–5013. 
 188 
156.  Bialasiewicz S, Whiley DM, Lambert SB, Nissen MD, Sloots TP. 2009. 
Detection of BK, JC, WU, or KI polyomaviruses in faecal, urine, blood, 
cerebrospinal fluid and respiratory samples. J Clin Virol 45:249–254. 
157.  Feng H, Shuda M, Chang Y, Moore PS. 2008. Clonal integration of a 
polyomavirus in human Merkel cell carcinoma. Science 319:1096–100. 
158.  Buck CB, Phan GQ, Raiji MT, Murphy PM, McDermott DH, McBride AA. 
2012. Complete genome sequence of a tenth human polyomavirus. J Virol 
86:10887. 
159.  Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu Y-M, Dhanasekaran 
SM, Palanisamy N, Siddiqui J, Cao X, Su F, Wang R, Xiao H, Kunju LP, 
Mehra R, Tomlins S a., Fullen DR, Bichakjian CK, Johnson TM, Dlugosz  
a. a., Chinnaiyan  a. M. 2015. The distinctive mutational spectra of 
polyomavirus-negative Merkel cell carcinoma. Cancer Res 75:3720–3728. 
160.  Goh G, Walradt T, Markarov V, Blom A, Doumani R, Stafstrom K, Moshiri 
A, Yelistratova L. 2015. Mutational landscape of MCPyV-positive and 
MCPyV-negative merkel cell carcinomas with implications for 
immunotherapy 7. 
161.  Starrett GJ, Marcelus C, Cantalupo PG, Katz JP, Cheng J, Akagi K, 
Thakuria M, Rabinowits G, Wang LC, Symer DE, Pipas JM, Harris RS, 
DeCaprio JA. 2017. Merkel cell polyomavirus exhibits dominant control of 
the tumor genome and transcriptome in virus-associated merkel cell 
carcinoma. MBio 8:1–14. 
162.  Wen Y-M, Wang Y-X. 2009. Biological features of hepatitis B virus isolates 
 189 
from patients based on full-length genomic analysis. Rev Med Virol 19:57–
64. 
163.  Turelli P, Mangeat B, Jost S, Vianin S, Trono D. 2004. Inhibition of hepatitis 
B virus replication by APOBEC3G. Science (80- ) 303:1829. 
164.  Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian J-
P. 2005. Extensive editing of both hepatitis B virus DNA strands by 
APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S 
A 102:8321–6. 
165.  Deng Y, Du Y, Zhang Q, Han X, Cao G. 2014. Human cytidine deaminases 
facilitate hepatitis B virus evolution and link inflammation and 
hepatocellular carcinoma. Cancer Lett 343:161–171. 
166.  Gao Y, Feng J, Guang Y, Zhang S, Liu Y, Bu Y, Xun M, Zhao M, Chen F, 
Zhang W, Ye L, Zhang X. 2017. HBx-elevated MSL2 modulates HBV 
cccDNA through inducing degradation of APOBEC3B to enhance 
hepatocarcinogenesis. Hepatology 10.1002/hep.29316. 
167.  Bouzidi MS, Caval V, Suspène R, Hallez C, Pineau P, Wain-Hobson S, 
Vartanian J-P. 2016. APOBEC3DE Antagonizes Hepatitis B Virus 
Restriction Factors APOBEC3F and APOBEC3G. J Mol Biol 428:3514–
3528. 
168.  Suspene R, Aynaud M-MM-M, Koch S, Pasdeloup D, Labetoulle M, 
Gaertner B, Vartanian J-PJ-P, Meyerhans A, Wain-Hobson S, Suspène R, 
Aynaud M-MM-M, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, 
Vartanian J-PJ-P, Meyerhans A, Wain-Hobson S. 2011. Genetic editing of 
 190 
herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human 
APOBEC3 cytidine deaminases in culture and in vivo. J Virol 85:7594–602. 
169.  Minkah N, Chavez K, Shah P, Maccarthy T, Chen H, Landau N, Krug LT. 
2014. Host restriction of murine gammaherpesvirus 68 replication by 
human APOBEC3 cytidine deaminases but not murine APOBEC3. Virology 
454–455:215–26. 
170.  Bekerman E, Jeon D, Ardolino M, Coscoy L. 2013. A role for host 
activation-induced cytidine deaminase in innate immune defense against 
KSHV. PLoS Pathog 9:e1003748. 
171.  Wagener R, Alexandrov LB, Montesinos-Rongen M, Schlesner M, Haake 
A, Drexler HG, Richter J, Bignell GR, McDermott U, Siebert R. 2015. 
Analysis of mutational signatures in exomes from B-cell lymphoma cell 
lines suggest APOBEC3 family members to be involved in the 
pathogenesis of primary effusion lymphoma. Leukemia 29:1612–1615. 
172.  Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, 
Hinoue T, Laird PW, Curtis C, Shen H, Weisenberger DJ, Schultz N, Shen 
R, Weinhold N, Kelsen DP, Bowlby R, Chu A, Kasaian K, Mungall AJ, 
Gordon Robertson A, Sipahimalani P, Cherniack A, Getz G, Liu Y, Noble 
MS, Pedamallu C, Sougnez C, Taylor-Weiner A, Akbani R, Lee J-S, Liu W, 
Mills GB, Yang D, Zhang W, Pantazi A, Parfenov M, Gulley M, Blanca 
Piazuelo M, Schneider BG, Kim J, Boussioutas A, Sheth M, Demchok JA, 
Rabkin CS, Willis JE, Ng S, Garman K, Beer DG, Pennathur A, Raphael 
BJ, Wu H-T, Odze R, Kim HK, Bowen J, Leraas KM, Lichtenberg TM, 
 191 
Weaver S, McLellan M, Wiznerowicz M, Sakai R, Getz G, Sougnez C, 
Lawrence MS, Cibulskis K, Lichtenstein L, Fisher S, Gabriel SB, Lander 
ES, Ding L, Niu B, Ally A, Balasundaram M, Birol I, Bowlby R, Brooks D, 
Butterfield YSN, Carlsen R, Chu A, Chu J, Chuah E, Chun H-JE, Clarke A, 
Dhalla N, Guin R, Holt RA, Jones SJM, Kasaian K, Lee D, Li HA, Lim E, 
Ma Y, Marra MA, Mayo M, Moore RA, Mungall AJ, Mungall KL, Ming Nip K, 
Gordon Robertson A, Schein JE, Sipahimalani P, Tam A, Thiessen N, 
Beroukhim R, Carter SL, Cherniack AD, Cho J, Cibulskis K, DiCara D, 
Frazer S, Fisher S, Gabriel SB, Gehlenborg N, Heiman DI, Jung J, Kim J, 
Lander ES, Lawrence MS, Lichtenstein L, Lin P, Meyerson M, Ojesina AI, 
Sekhar Pedamallu C, Saksena G, Schumacher SE, Sougnez C, Stojanov 
P, Tabak B, Taylor-Weiner A, Voet D, Rosenberg M, Zack TI, Zhang H, 
Zou L, Protopopov A, Santoso N, Parfenov M, Lee S, Zhang J, 
Mahadeshwar HS, Tang J, Ren X, Seth S, Yang L, Xu AW, Song X, 
Pantazi A, Xi R, Bristow CA, Hadjipanayis A, Seidman J, Chin L, Park PJ, 
Kucherlapati R, Akbani R, Ling S, Liu W, Rao A, Weinstein JN, Kim S-B, 
Lee J-S, Lu Y, Mills G, Laird PW, Hinoue T, Weisenberger DJ, Bootwalla 
MS, Lai PH, Shen H, Triche Jr T, Van Den Berg DJ, Baylin SB, Herman 
JG, Getz G, Chin L, Liu Y, Murray BA, Noble MS, Arman Askoy  r B, 
Ciriello G, Dresdner G, Gao J, Gross B, Jacobsen A, Lee W, Ramirez R, 
Sander C, Schultz N, Senbabaoglu Y, Sinha R, Onur Sumer S, Sun Y, 
Weinhold N, Thorsson V, Bernard B, Iype L, Kramer RW, Kreisberg R, 
Miller M, Reynolds SM, Rovira H, Tasman N, Shmulevich I, Ng S, Haussler 
 192 
D, Stuart JM, Akbani R, Ling S, Liu W, Rao A, Weinstein JN, Verhaak 
RGW, Mills GB, Leiserson MDM, Raphael BJ, Wu H-T, Taylor BS, Black 
AD, Bowen J, Ann Carney J, Gastier-Foster JM, Helsel C, Leraas KM, 
Lichtenberg TM, McAllister C, Ramirez NC, Tabler TR, Wise L, Zmuda E, 
Penny R, Crain D, Gardner J, Lau K, Curely E, Mallery D, Morris S, 
Paulauskis J, Shelton T, Shelton C, Sherman M, Benz C, Lee J-H, 
Fedosenko K, Manikhas G, Potapova O, Voronina O, Belyaev D, 
Dolzhansky O, Kimryn Rathmell W, Brzezinski J, Ibbs M, Korski K, Kycler 
W, Łaźniak R, Leporowska E, Mackiewicz A, Murawa D, Murawa P, 
Spychała A, Suchorska WM, Tatka H, Teresiak M, Wiznerowicz M, Abdel-
Misih R, Bennett J, Brown J, Iacocca M, Rabeno B, Kwon S-Y, Penny R, 
Gardner J, Kemkes A, Mallery D, Morris S, Shelton T, Shelton C, Curley E, 
Alexopoulou I, Engel J, Bartlett J, Albert M, Park D-Y, Dhir R, Luketich J, 
Landreneau R, Janjigian YY, Kelsen DP, Cho E, Ladanyi M, Tang L, 
McCall SJ, Park YS, Cheong J-H, Ajani J, Constanza Camargo M, Alonso 
S, Ayala B, Jensen MA, Pihl T, Raman R, Walton J, Wan Y, Demchok JA, 
Eley G, Mills Shaw KR, Sheth M, Tarnuzzer R, Wang Z, Yang L, Claude 
Zenklusen J, Davidsen T, Hutter CM, Sofia HJ, Burton R, Chudamani S, 
Liu J. 2014. Comprehensive molecular characterization of gastric 
adenocarcinoma. Nature 513:202–209. 
173.  Zhang J, Wei W, Jin H, Ying R, Zhu A, Zhang F. 2015. The roles of 
APOBEC3B in gastric cancer. Int J Clin Exp Pathol 8:5089–5096. 
174.  Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, Leong MML, 
 193 
Deng M, Kwok TCT, Chan JY-W, Kwong DL-W, Lee AW-M, Ng WT, Ngan 
RKC, Yau CC, Tung S, Lee VH-F, Lam K-O, Kwan CK, Li WS, Yau S, 
Chan K-W, Lung ML. 2016. Whole-exome sequencing identifies multiple 
loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal 
carcinoma. Proc Natl Acad Sci U S A 113:11283–11288. 
175.  Kuong KJ, Loeb LA. 2013. APOBEC3B mutagenesis in cancer. Nat Genet 
45:964–5. 
176.  Helleday T, Eshtad S, Nik-Zainal S. 2014. Mechanisms underlying 
mutational signatures in human cancers. Nat Rev Genet 1–14. 
177.  McGranahan N, Swanton C. 2015. Biological and Therapeutic Impact of 
Intratumor Heterogeneity in Cancer Evolution. Cancer Cell 27:15–26. 
178.  Roberts SA, Gordenin DA. 2014. Hypermutation in human cancer 
genomes: footprints and mechanisms. Nat Rev Cancer 14:786–800. 
179.  Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, 
Raine K, Jones D, Hinton J, Marshall J, Stebbings L a, Menzies A, Martin 
S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie 
LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, 
Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E, 
Stephens PJ, McLaren S, Butler AP, Teague JW, Jönsson G, Garber JE, 
Silver D, Miron P, Fatima A, Boyault S, Langerød A, Tutt A, Martens JWM, 
Aparicio S a JR, Borg Å, Salomon AV, Thomas G, Børresen-Dale A-L, 
Richardson AL, Neuberger MS, Futreal PA, Campbell PJ, Stratton MR. 
2012. Mutational processes molding the genomes of 21 breast cancers. 
 194 
Cell 149:979–93. 
180.  de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, 
Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Gronroos E, 
Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, 
Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee S-M, Forster M, 
Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom 
W, Teefe E, Chen S-C, Begum S, Rabinowitz A, Phillimore B, Spencer-
Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, 
Swanton C. 2014. Spatial and temporal diversity in genomic instability 
processes defines lung cancer evolution. Science (80- ) 346:251–256. 
181.  Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, 
Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, 
Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød 
A, Ringnér M, Ahn S-M, Boyault S, Brock JE, Broeks A, Butler A, Desmedt 
C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, 
Jang SJ, Jones DR, Kim H-Y, King TA, Krishnamurthy S, Lee HJ, Lee J-Y, 
Li Y, McLaren S, Menzies A, Mustonen V, O’Meara S, Pauporté I, Pivot X, 
Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu 
G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, 
Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, 
Vincent-Salomon A, Yates L, Caldas C, Veer L van’t, Tutt A, Knappskog S, 
Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, 
Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson 
 195 
AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, 
Børresen-Dale A-L, Richardson AL, Kong G, Thomas G, Stratton MR. 
2016. Landscape of somatic mutations in 560 breast cancer whole-genome 
sequences. Nature 1–20. 
182.  Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, 
Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim H-Y, 
Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, 
Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver 
MJ, Martens JWM, Børresen-Dale A-L, Richardson AL, Kong G, Thomas 
G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S. 2016. The 
topography of mutational processes in breast cancer genomes. Nat 
Commun 7:11383. 
183.  Harris RS, Dudley JP. 2015. APOBECs and virus restriction. Virology 479–
480:1–15. 
184.  Simon V, Bloch N, Landau NR. 2015. Intrinsic host restrictions to HIV-1 
and mechanisms of viral escape. Nat Immunol 16:546–553. 
185.  Landry S, Narvaiza I, Linfesty DC, Weitzman MD. 2011. APOBEC3A can 
activate the DNA damage response and cause cell-cycle arrest. EMBO 
Rep 12:444–50. 
186.  Suspène R, Aynaud M-M, Guétard D, Henry M, Eckhoff G, Marchio A, 
Pineau P, Dejean A, Vartanian J-P, Wain-Hobson S. 2011. Somatic 
hypermutation of human mitochondrial and nuclear DNA by APOBEC3 
cytidine deaminases, a pathway for DNA catabolism. Proc Natl Acad Sci U 
 196 
S A 108:4858–63. 
187.  Caval V, Bouzidi MS, Suspène R, Laude H, Dumargne M-C, Bashamboo 
A, Krey T, Vartanian J-P, Wain-Hobson S. 2015. Molecular basis of the 
attenuated phenotype of human APOBEC3B DNA mutator enzyme. 
Nucleic Acids Res 43:9340–9. 
188.  Shee C, Cox BD, Gu F, Luengas EM, Joshi MC, Chiu L-Y, Magnan D, 
Halliday JA, Frisch RL, Gibson JL, Nehring RB, Do HG, Hernandez M, Li L, 
Herman C, Hastings PJ, Bates D, Harris RS, Miller KM, Rosenberg SM. 
2013. Engineered proteins detect spontaneous DNA breakage in human 
and bacterial cells. Elife 2:e01222. 
189.  Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. 2010. APOBEC3 
proteins mediate the clearance of foreign DNA from human cells. Nat 
Struct Mol Biol 17:222–9. 
190.  Land AM, Law EK, Carpenter M a, Lackey L, Brown WL, Harris RS. 2013. 
Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and 
nongenotoxic. J Biol Chem 288:17253–60. 
191.  Thielen BK, McNevin JP, McElrath MJ, Hunt BVS, Klein KC, Lingappa JR. 
2010. Innate immune signaling induces high levels of TC-specific 
deaminase activity in primary monocyte-derived cells through expression of 
APOBEC3A isoforms. J Biol Chem 285:27753–27766. 
192.  Verhalen B, Starrett GJ, Harris RS, Jiang M. 2016. Functional Upregulation 
of the DNA Cytosine Deaminase APOBEC3B by Polyomaviruses. J Virol 
90:6379–6386. 
 197 
193.  Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O’Shea KS, Moran 
J V, Cullen BR. 2006. Cellular inhibitors of long interspersed element 1 and 
Alu retrotransposition. Proc Natl Acad Sci U S A 103:8780–5. 
194.  Leonard B, Hart SN, Burns MB, Carpenter M a., Temiz N a., Rathore A, 
Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg  
a. L, Cunningham JM, Shridhar V, Bell D a., April C, Bentley D, Bibikova M, 
Cheetham RK, Fan J-B, Grocock R, Humphray S, Kingsbury Z, Peden J, 
Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, 
Kaufmann SH, Harris RS. 2013. APOBEC3B upregulation and genomic 
mutation patterns in serous ovarian carcinoma. Cancer Res 73:7222–7231. 
195.  Cescon DW, Haibe-Kains B, Mak TW. 2015. APOBEC3B              
expression in breast cancer reflects cellular proliferation, while a deletion 
polymorphism is associated with immune activation. Proc Natl Acad Sci 
201424869. 
196.  Sieuwerts AM, Willis S, Burns MB, Look MP, Gelder MEM Van, Schlicker 
A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, Gray KP, 
Foekens J a., Harris RS, Martens JWM. 2014. Elevated APOBEC3B 
correlates with poor outcomes for estrogen-receptor-positive breast 
cancers. Horm Cancer 5:405–413. 
197.  Periyasamy M, Patel H, Lai C-F, Nguyen VTM, Nevedomskaya E, Harrod 
A, Russell R, Remenyi J, Ochocka AM, Thomas RS, Fuller-Pace F, Győrffy 
B, Caldas C, Navaratnam N, Carroll JS, Zwart W, Coombes RC, Magnani 
L, Buluwela L, Ali S. 2015. APOBEC3B-mediated cytidine deamination is 
 198 
required for estrogen receptor action in breast cancer. Cell Rep 13:1–14. 
198.  Walker B a., Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, 
Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang Y-W, 
Jones JR, Cairns D a., Gregory WM, Owen RG, Cook G, Drayson MT, 
Jackson GH, Davies FE, Morgan GJ. 2015. APOBEC family mutational 
signatures are associated with poor prognosis translocations in multiple 
myeloma. Nat Commun 6:6997. 
199.  Burns MB, Leonard B, Harris RS. 2015. APOBEC3B: Pathological 
consequences of an innate immune DNA mutator. Biomed J 38:102. 
200.  Harris RS. 2015. Molecular mechanism and clinical impact of APOBEC3B-
catalyzed mutagenesis in breast cancer. Breast Cancer Res 17:8. 
201.  Swanton C, McGranahan N, Starrett GJ, Harris RS. 2015. APOBEC 
enzymes: Mutagenic fuel for cancer evolution and heterogeneity. Cancer 
Discov 5:704–12. 
202.  Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, 
Davies HR, Knappskog S, Martin S, Papaemmanuil E, Ramakrishna M, 
Shlien A, Simonic I, Xue Y, Tyler-Smith C, Campbell PJ, Stratton MR. 
2014. Association of a germline copy number polymorphism of APOBEC3A 
and APOBEC3B with burden of putative APOBEC-dependent mutations in 
breast cancer. Nat Genet 46:487–91. 
203.  Refsland EW, Hultquist JF, Luengas EM, Ikeda T, Shaban NM, Law EK, 
Brown WL, Reilly C, Emerman M, Harris RS. 2014. Natural polymorphisms 
in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to 
 199 
affect viral G-to-A mutation levels and infectivity. PLoS Genet 
10:e1004761. 
204.  Ooms M, Majdak S, Seibert CW, Harari A, Simon V. 2010. The localization 
of APOBEC3H variants in HIV-1 virions determines their antiviral activity. J 
Virol 84:7961–9. 
205.  Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-mahrt SK, Watt 
IN, Neuberger MS, Malim MH. 2003. DNA Deamination Mediates Innate 
Immunity to Retroviral Infection. Cell 113:803–809. 
206.  Yu Q, K?nig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin 
JM, Landau NR. 2004. Single-strand specificity of APOBEC3G accounts 
for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 
11:435–442. 
207.  Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, 
Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA. 2015. 
An APOBEC3A hypermutation signature is distinguishable from the 
signature of background mutagenesis by APOBEC3B in human cancers. 
Nat Genet 47:1067–1072. 
208.  Lawrence MS, Stojanov P, Polak P, Kryukov G V, Cibulskis K, Sivachenko 
A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman 
PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman 
E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, 
Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, 
Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak 
 200 
AM, Lohr J, Landau D-A, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, 
Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, 
Winckler W, Ardlie K, Gabriel SB, Roberts CWM, Biegel JA, Stegmaier K, 
Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, 
Lander ES, Getz G. 2013. Mutational heterogeneity in cancer and the 
search for new cancer-associated genes. Nature 499:214–8. 
209.  Rathore A, Carpenter MA, Demir Ö, Ikeda T, Li M, Shaban NM, Law EK, 
Anokhin D, Brown WL, Amaro RE, Harris RS. 2013. The local dinucleotide 
preference of APOBEC3G can be altered from 5’-CC to 5’-TC by a single 
amino acid substitution. J Mol Biol 425:4442–54. 
210.  Eftedal I, Guddal PH, Slupphaug G, Volden G, Krokan HE. 1993. 
Consensus sequences for good and poor removal of uracil from double 
stranded DNA by uracil-DNA glycosylase. Nucleic Acids Res 21:2095–101. 
211.  Makridakis NM, Reichardt JK V. 2012. Translesion DNA Polymerases and 
Cancer. Front Genet 3:174. 
212.  Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, Zhang Y, 
Kohli RM. 2012. AID/APOBEC deaminases disfavor modified cytosines 
implicated in DNA demethylation. Nat Chem Biol 8:751–8. 
213.  Ehrlich M, Norris KF, Wang RY, Kuo KC, Gehrke CW. 1986. DNA cytosine 
methylation and heat-induced deamination. Biosci Rep 6. 
214.  Leonard B, Starrett GJ, Maurer MJ, Oberg A, Van Bockstal M, Van Dorpe 
J, De Wever O, Helleman J, Sieuwerts AM, Berns EMJJ, Martens JWM, 
Anderson B, Brown WL, Kalli KR, Kaufmann SH, Harris RS. 2016. 
 201 
APOBEC3G expression correlates with T cell infiltration and improved 
clinical outcomes in high-grade serous ovarian carcinoma. Clin Cancer Res 
1078-0432.CCR-15-2910-. 
215.  McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. 
2015. Clonal status of actionable driver events and the timing of mutational 
processes in cancer evolution. Sci Transl Med 7:283ra54-283ra54. 
216.  Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-
Garcia W, Treviño V, Shen H, Laird PW, Levine D a, Carter SL, Getz G, 
Stemke-Hale K, Mills GB, Verhaak RGW. 2013. Inferring tumour purity and 
stromal and immune cell admixture from expression data. Nat Commun 
4:2612. 
217.  Larue RS, Lengyel J, Jónsson SR, Andrésdóttir V, Harris RS. 2010. 
Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its 
mammalian host and is capable of cross-species activity. J Virol 84:8193–
201. 
218.  Chelico L, Prochnow C, Erie DA, Chen XS, Goodman MF. 2010. Structural 
model for deoxycytidine deamination mechanisms of the HIV-1 inactivation 
enzyme APOBEC3G. J Biol Chem 285:16195–205. 
219.  Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA 
deaminase acts processively 3′ → 5′ on single-stranded DNA. Nat Struct 
Mol Biol 13:392–399. 
220.  Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, 
Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and 
 202 
SAMtools. Bioinformatics 25:2078–9. 
221.  Doerries K. 2006. Human polyomavirus JC and BK persistent infection. 
Adv Exp Med Biol. Springer New York, New York, NY. 
222.  DeCaprio JA, Garcea RL. 2013. A cornucopia of human polyomaviruses. 
Nat Rev Microbiol 11:264–76. 
223.  Bennett SM, Broekema NM, Imperiale MJ. 2012. BK polyomavirus: 
Emerging pathogen. Microbes Infect 14:672–683. 
224.  Wollebo HS, White MK, Gordon J, Berger JR, Khalili K. 2015. Persistence 
and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560–
70. 
225.  Chang Y, Moore PS. 2012. Merkel cell carcinoma: a virus-induced human 
cancer. Annu Rev Pathol 7:123–44. 
226.  Cheng J, Rozenblatt-Rosen O, Paulson KG, Nghiem P, DeCaprio JA. 
2013. Merkel cell polyomavirus large T antigen has growth-promoting and 
inhibitory activities. J Virol 87:6118–26. 
227.  Giacobbi NS, Gupta T, Coxon AT, Pipas JM. 2015. Polyomavirus T 
antigens activate an antiviral state. Virology 476:377–385. 
228.  Abend JR, Low JA, Imperiale MJ. 2010. Global effects of BKV infection on 
gene expression in human primary kidney epithelial cells. Virology 397:73–
9. 
229.  Yogo Y, Sugimoto C, Zhong S, Homma Y. 2009. Evolution of the BK 
polyomavirus: epidemiological, anthropological and clinical implications. 
Rev Med Virol 19:185–199. 
 203 
230.  Gjoerup O, Chang Y. 2010. Update on human polyomaviruses and cancer. 
Adv Cancer Res 106:1–51. 
231.  Wendzicki JA, Moore PS, Chang Y. 2015. Large T and small T antigens of 
Merkel cell polyomavirus. Curr Opin Virol 11:38–43. 
232.  Vieira VC, Soares M a. 2013. The role of cytidine deaminases on innate 
immune responses against human viral infections. Biomed Res Int 2013. 
233.  Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi 
M, Kadowaki N, Takaori-Kondo A. 2012. APOBEC3B can impair genomic 
stability by inducing base substitutions in genomic DNA in human cells. Sci 
Rep 2:806. 
234.  Jiang M, Zhao L, Gamez M, Imperiale MJ. 2012. Roles of ATM and ATR-
mediated DNA damage responses during lytic BK polyomavirus infection. 
PLoS Pathog 8. 
235.  Low J, Humes HD, Szczypka M, Imperiale M. 2004. BKV and SV40 
infection of human kidney tubular epithelial cells in vitro. Virology 323:182–
188. 
236.  Jiang M, Abend JR, Tsai B, Imperiale MJ. 2009. Early events during BK 
virus entry and disassembly. J Virol 83:1350–8. 
237.  Verhalen B, Justice JL, Imperiale MJ, Jiang M. 2015. Viral DNA replication-
dependent DNA damage response activation during BK polyomavirus 
infection. J Virol 89:JVI.03650-14. 
238.  Bollag B, Mackeen PC, Frisque RJ. 1996. Purified JC virus T antigen 
derived from insect cells preferentially interacts with binding site II of the 
 204 
viral core origin under replication conditions. Virology 218:81–93. 
239.  Jiang M, Entezami P, Gamez M. 2011. Functional Reorganization of 
Promyelocytic Leukemia Nuclear Bodies during BK Virus Infection. MBio 
2:e00281-10. 
240.  Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, 
McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. 2011. 
Fast, scalable generation of high-quality protein multiple sequence 
alignments using Clustal Omega. Mol Syst Biol 7:539. 
241.  Moens U, Rasheed K, Abdulsalam I, Sveinbjørnsson B. 2015. The role of 
Merkel cell polyomavirus and other human polyomaviruses in emerging 
hallmarks of cancer. Viruses 7:1871–901. 
242.  Hoelzer K, Shackelton LA, Parrish CR. 2008. Presence and role of 
cytosine methylation in DNA viruses of animals. Nucleic Acids Res 
36:2825–37. 
243.  Monajemi M, Woodworth CF, Benkaroun J, Grant M, Larijani M. 2012. 
Emerging complexities of APOBEC3G action on immunity and viral fitness 
during HIV infection and treatment. Retrovirology 9:35. 
244.  Haché G, Mansky LM, Harris RS. Human APOBEC3 proteins, retrovirus 
restriction, and HIV drug resistance. AIDS Rev 8:148–57. 
245.  Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Peñas PF, Nghiem 
P. 2008. Clinical characteristics of Merkel cell carcinoma at diagnosis in 
195 patients: the AEIOU features. J Am Acad Dermatol 58:375–81. 
246.  Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore 
 205 
PS, Becker JC. 2010. Merkel cell polyomavirus-infected Merkel cell 
carcinoma cells require expression of viral T antigens. J Virol 84:7064–
7072. 
247.  Andres C, Belloni B, Puchta U, Sander C a, Flaig MJ. 2010. Prevalence of 
MCPyV in Merkel cell carcinoma and non-MCC tumors. J Cutan Pathol 
37:28–34. 
248.  Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, Chang Y. 
2008. T antigen mutations are a human tumor-specific signature for Merkel 
cell polyomavirus. Proc Natl Acad Sci U S A 105:16272–16277. 
249.  Li J, Wang X, Diaz J, Tsang SH, Buck CB, You J. 2013. Merkel cell 
polyomavirus large T antigen disrupts host genomic integrity and inhibits 
cellular proliferation. J Virol 87:9173–88. 
250.  Ohba K, Ichiyama K, Yajima M, Gemma N, Nikaido M, Wu Q, Chong P, 
Mori S, Yamamoto R, Wong JEL, Yamamoto N. 2014. In vivo and in vitro 
studies suggest a possible involvement of HPV infection in the early stage 
of breast carcinogenesis via APOBEC3B induction. PLoS One 9:e97787. 
251.  Wong SQ, Waldeck K, Vergara IA, Schroder J, Madore J, Wilmott JS, 
Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, 
Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, 
Johnston M, Shackleton M, Sandhu S, Bowtell DDL, Johnstone RW, Fox 
SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill 
RW. 2015. UV-Associated mutations underlie the etiology of MCV-negative 
Merkel cell carcinomas. Cancer Res 75:5228–5234. 
 206 
252.  Cohen PR, Tomson BN, Elkin SK, Marchlik E, Jennifer L, Kurzrock R. 
2016. Genomic portfolio of Merkel cell carcinoma as determined by 
comprehensive genomic profiling: implications for targeted therapeutics. 
Oncotarget 7. 
253.  Alexandrov LB, Stratton MR. 2014. Mutational signatures: The patterns of 
somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 
24:52–60. 
254.  Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. 2014. Mutational 
landscape of basal cell carcinomas by whole-exome sequencing. J Invest 
Dermatol 134:213–20. 
255.  Boukamp P. 2005. Non-melanoma skin cancer: what drives tumor 
development and progression? Carcinogenesis 26:1657–1667. 
256.  Rass K, Reichrath J. 2008. UV damage and DNA repair in malignant 
melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 624:162–
178. 
257.  Harms PW, Patel RM, Verhaegen ME, Giordano TJ, Nash KT, Johnson 
CN, Daignault S, Thomas DG, Gudjonsson JE, Elder JT, Dlugosz A a, 
Johnson TM, Fullen DR, Bichakjian CK. 2013. Distinct gene expression 
profiles of viral- and nonviral-associated merkel cell carcinoma revealed by 
transcriptome analysis. J Invest Dermatol 133:936–45. 
258.  Pardo L a, Stühmer W. 2014. The roles of K(+) channels in cancer. Nat 
Rev Cancer 14:39–48. 
259.  Schuller HM, Al-Wadei HAN, Majidi M. 2008. GABAB receptor is a novel 
 207 
drug target for pancreatic cancer. Cancer 112:767–778. 
260.  Miao Y, Zhang Y, Wan H, Chen L, Wang F. 2010. GABA-receptor agonist, 
propofol inhibits invasion of colon carcinoma cells. Biomed Pharmacother 
64:583–588. 
261.  Akagi K, Li J, Broutian TR, Padilla-Nash H, Xiao W, Jiang B, Rocco JW, 
Teknos TN, Kumar B, Wangsa D, He D, Ried T, Symer DE, Gillison ML. 
2014. Genome-wide analysis of HPV integration in human cancers reveals 
recurrent, focal genomic instability. Genome Res 24:185–99. 
262.  Katz JP, Pipas JM. 2014. SummonChimera infers integrated viral genomes 
with nucleotide precision from NGS data 15:1–6. 
263.  Agelli M, Clegg LX. 2003. Epidemiology of primary Merkel cell carcinoma in 
the United States. J Am Acad Dermatol 49:832–841. 
264.  Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler 
I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-
Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright A a, 
Rosenberg MW, Duke F, Kaplan B, Wang R, Nickerson E, Walline HM, 
Lawrence MS, Stewart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, 
Espinosa-Castilla M, Woie K, Bjorge L, Wik E, Halle MK, Hoivik E a, 
Krakstad C, Gabiño NB, Gómez-Macías GS, Valdez-Chapa LD, Garza-
Rodríguez ML, Maytorena G, Vazquez J, Rodea C, Cravioto A, Cortes ML, 
Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, 
Akslen L a, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldaña H a, 
Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M. 2014. Landscape 
 208 
of genomic alterations in cervical carcinomas. Nature 506:371–5. 
265.  Schowalter RM, Pastrana D V., Pumphrey KA, Moyer AL, Buck CB. 2010. 
Merkel cell polyomavirus and two previously unknown polyomaviruses are 
chronically shed from human skin. Cell Host Microbe 7:509–515. 
266.  Toh ST, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, Ronaghi M, 
Toh HC, Chow PKH, Chung AYF, Ooi LLPJ, Lee CGL. 2013. Deep 
sequencing of the hepatitis B virus in hepatocellular carcinoma patients 
reveals enriched integration events, structural alterations and sequence 
variations. Carcinogenesis 34:787–798. 
267.  Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, Guan Y, Lee 
W, Carnevali P, Stinson J, Johnson S, Diao J, Yeung S, Jubb A, Ye W, Wu 
TD, Kapadia SB, Sauvage FJ De, Gentleman RC, Stern HM, Seshagiri S, 
Pant KP, Modrusan Z, Ballinger DG, Zhang Z, de Sauvage FJ, Gentleman 
RC, Stern HM, Seshagiri S, Pant KP, Modrusan Z, Ballinger DG, Zhang Z. 
2012. The effects of hepatitis B virus integration into the genomes of 
hepatocellular carcinoma patients. Genome Res 22:593–601. 
268.  Sung W-K, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, 
Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, 
Fan ST, Chan KL, Gong Z, Hu Y, Lin Z, Wang G, Zhang Q, Barber TD, 
Chou W-C, Aggarwal A, Hao K, Zhou W, Zhang C, Hardwick J, Buser C, 
Xu J, Kan Z, Dai H, Mao M, Reinhard C, Wang J, Luk JM. 2012. Genome-
wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat 
Genet 44:765–9. 
 209 
269.  Martel-Jantin C, Filippone C, Cassar O, Peter M, Tomasic G, Vielh P, 
Brière J, Petrella T, Aubriot-Lorton MH, Mortier L, Jouvion G, Sastre-Garau 
X, Robert C, Gessain A. 2012. Genetic variability and integration of Merkel 
cell polyomavirus in Merkel cell carcinoma. Virology 426:134–142. 
270.  Cohen PR, Kurzrock R. 2015. Merkel cell carcinoma with a suppressor of 
fused (SUFU) mutation: Case report and potential therapeutic implications. 
Dermatol Ther (Heidelb) 129–143. 
271.  Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, 
Carnevali P, Nazarenko I, Nilsen GB, Yeung G, Dahl F, Fernandez A, 
Staker B, Pant KP, Baccash J, Borcherding AP, Brownley A, Cedeno R, 
Chen L, Chernikoff D, Cheung A, Chirita R, Curson B, Ebert JC, Hacker 
CR, Hartlage R, Hauser B, Huang S, Jiang Y, Karpinchyk V, Koenig M, 
Kong C, Landers T, Le C, Liu J, McBride CE, Morenzoni M, Morey RE, 
Mutch K, Perazich H, Perry K, Peters BA, Peterson J, Pethiyagoda CL, 
Pothuraju K, Richter C, Rosenbaum AM, Roy S, Shafto J, Sharanhovich U, 
Shannon KW, Sheppy CG, Sun M, Thakuria J V, Tran A, Vu D, Zaranek 
AW, Wu X, Drmanac S, Oliphant AR, Banyai WC, Martin B, Ballinger DG, 
Church GM, Reid CA. 2010. Human genome sequencing using unchained 
base reads on self-assembling DNA nanoarrays. Science (80- ) 327:78–81. 
272.  Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman 
N, Stratton MR. 2004. A census of human cancer genes. Nat Rev Cancer 
4:177–183. 
273.  Choi Y, Chan AP. 2015. PROVEAN web server: a tool to predict the 
 210 
functional effect of amino acid substitutions and indels. Bioinformatics 
31:2745–2747. 
274.  Choi Y. 2012. A fast computation of pairwise sequence alignment scores 
between a protein and a set of single-locus variants of another protein, p. 
414–417. In Proceedings of the ACM Conference on Bioinformatics, 
Computational Biology and Biomedicine - BCB ’12. 
275.  Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. 2012. Predicting the 
functional effect of amino acid substitutions and indels. PLoS One 
7:e46688. 
276.  Ng PC. 2003. SIFT: predicting amino acid changes that affect protein 
function. Nucleic Acids Res 31:3812–3814. 
277.  Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, 
Salzberg SL, Rinn JL, Pachter L. 2012. Differential gene and transcript 
expression analysis of RNA-seq experiments with TopHat and Cufflinks. 
Nat Protoc 7:562–78. 
278.  Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change 
and dispersion for RNA-seq data with DESeq2. Genome Biol 15:1–21. 
279.  Gehring JS, Fischer B, Lawrence M, Huber W. 2015. SomaticSignatures: 
inferring mutational signatures from single-nucleotide variants. 
Bioinformatics 31:3673–5. 
280.  Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 
2. Nat Methods 9:357–9. 
281.  Zerbino DR, Birney E. 2008. Velvet: Algorithms for de novo short read 
 211 
assembly using de Bruijn graphs. Genome Res 18:821–829. 
282.  Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, 
Madden TL. 2009. BLAST+: architecture and applications. BMC 
Bioinformatics 10:1–9. 
283.  Cantalupo PG, Calgua B, Zhao G. 2011. Raw sewage harbors diverse viral 
populations. MBio 2:e00180-11. 
284.  Dalianis T, Hirsch HH. 2013. Human polyomaviruses in disease and 
cancer. Virology 437:63–72. 
285.  Jiang M, Abend JR, Johnson SF, Imperiale MJ. 2009. The role of 
polyomaviruses in human disease. Virology 384:266–273. 
286.  Harris KF, Christensen JB, Imperiale MJ. 1996. BK virus large T antigen: 
interactions with the retinoblastoma family of tumor suppressor proteins 
and effects on cellular growth control. J Virol 70:2378–86. 
287.  Pipas JM, Levine AJ. 2001. Role of T antigen interactions with p53 in 
tumorigenesis. Semin Cancer Biol 11:23–30. 
288.  Mehta H V, Jones PH, Weiss JP, Okeoma CM. 2012. IFN-α and 
lipopolysaccharide upregulate APOBEC3 mRNA through different signaling 
pathways. J Immunol 189:4088–103. 
289.  Liu W, Yang R, Payne AS, Schowalter RM, Spurgeon ME, Lambert PF, Xu 
X, Buck CB, You J. 2016. Identifying the Target Cells and Mechanisms of 
Merkel Cell Polyomavirus Infection. Cell Host Microbe 1–13. 
290.  Kondo S, Wakae K, Wakisaka N, Nakanishi Y, Ishikawa K, Komori T, 
Moriyama-Kita M, Endo K, Murono S, Wang Z, Kitamura K, Nishiyama T, 
 212 
Yamaguchi K, Shigenobu S, Muramatsu M, Yoshizaki T. 2016. 
APOBEC3A associates with human papillomavirus genome integration in 
oropharyngeal cancers. Oncogene 36:1–11. 
 
 
 
